UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS

Abstract: Urea derivatives of formula (I), wherein R<1> is a group of formula (1) (in which R<4> is aryl which may have suitable substituent(s), or heterocyclic group which may have suitable substituent(s), and Y is bond, lower alkylene, -S-, -O-, (a), =CH-, -CONH-, (b), (in which R<7> is lower alkyl), -NHSO2-, -SO2NH-, -SO2NHCO- or -CONHSO2-); or thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent(s); R<2> is lower alkyl, lower alkoxy(lower)alkyl, cycloalkyl, ar(lower)alkyl which may have suitable substituent(s), heterocyclic group or heterocyclic(lower)alkyl, R<3> is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), and n is 0 or 1, and a pharmaceutically acceptable salt thereof which are useful as a medicament in the treatment of hypercholesterolemia, hyperlipidemia and atherosclerosis.

Description: DESCRIPTION UREA DERIVATIVES AND THEIR USEAS ACAT-INHIBITORS TECHNICAL FIELD This invention relates to new urea derivatives and pharmaceutically acceptable salts thereof which are useful as a medicament. BACKGROUND ART Some urea derivatives have been known as acyl-CoA : cholesterol acyltransferase enzyme (hereinafter, ACAT) inhibitors, for example, in U.S. Patent Nos. 4,473,579 and 4,623,662, EP Patent Application Publication Nos. 0354994, 0399422 and 0512570 and PCT International Publication Nos. WO 91/13871, WO 93/24458 and WO 94/26738. DISCLOSURE OF INVENTION This invention relates to new urea derivatives and pharmaceutically acceptable sales thereof which have an inhibitory activity against ACAT and an advantage of good absorption into blood on oral administration, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby. One object of this invention is to provide new and useful urea derivatives and pharmaceutically acceptable salts which possess an inhibitory activity against ACAT. Another object of this invention is to provide processes for preparation of said urea derivatives and salts thereof. A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said urea derivatives and pharmaceutically acceptable salt thereof. Still further object of this invention is to provide a therapeutic method for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby in human beings or animals, using said urea derivatives and pharmaceutically acceptable salts thereof. High levels of blood cholesterol and blood lipids are conditions which are involved in the onset of atherosclerosis. It is well known that inhibition of ACAT-catalyzed cholesterol esterification could lead to diminish intestinal absorption of cholesterol as well as a decrease in the intracellular accumulation of cholesterol esters in the intima of the arterial wall. Therefore, ACAT inhibitors are useful for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis of diseases caused thereby such as cardiac insufficiency (e.g. angina pectoris, myocardial infarction, etc.), cerebrovascular disturbance (e.g. cerebral infarction, cerebral apoplexy, etc.), arterial aneurism, peripheral vascular disease, xantho as, restenosis after percutaneous transluminal coronary angioplasty, or the like. The object urea derivatives of this invention are new and can be represented by the following general formula (I) : wherein R 1 is a group of the formula (in which R 4 is aryl which may have suitable substituent (s) , or heterocyclic group which may have suitable substituent (s) , and 0 II Y is bond, lower alkylene, -S-, -0-, -C-, =C - , -CONH-, -N-CO-, (in which R 7 is lower R 7 alkyl), -NHS0 2 -, -S0 2 NH-, -S0 2 NKC0- or -CONHS0 2 -) ; or thiazolyl, imi azolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent (s) ; R 2 is lower alkyl, lower alkoxy(lower)alkyl, cycloalkyl, ar(lower)alkyl which may have suitable substituent (s) , heterocyclic group or heterocyclic(lower)alkyl, R 3 is aryl which may have suitable substituent (s) or heterocyclic group which may have suitable substituent (s) , and n is 0 or I. The object compound (I) of the present invention can be prepared by the following processes. - 4 - Process (1) (ii: or a salt thereo. ereof 0 I! R 1 - (CH L 2)n -N-C-NH-R" R" (I) or a salt thereof Process (2! R 1 -(CH 2 ) n -NH hXN-R 3 R- (II) (IV) or a salt thereof or a salt thereo: - -_> - f ormation of ureido group (I) or a salt thereof 15 (la) or a salt thereof 25 30 oxidation - o - ( lb ) or a salt thereof wherein R 1-, R9, R'-. and n are each as defined above, R^ is pyridyl having two lower alkylthio and lower alkyl, and Rg is pyridyl having two lower alkylsulfonyl and lower alkyl; pyridyl having two lower alkylsulfinyl and lower alkyl; or pyridyl having lower alkylsulfonyl, lower alkylsulfinyl and lower alkyl. The starting compound can be prepared by tne following processes . Process (Al (V) 10 15 (VII) or a salt thereof ereof 30 (IXa) 35 or a salt thereof - 8 - Process (B ) R 1 - CN (IX) or a salt thereo: reduction - CHO or a salt thereof Process fC. - 0H or a salt thereof or a salt thereo: (Xa) or a salt thereof Process (D) R- - B(OH) (XIII) or a salt thereof f (Xb) or a salt thereof - 10 - Process IE '. R 1 - CHO (X) or a salt thereof reof ( Ha ) or salt thereof wherein R , R , and R are each as defined above, R is lower alkoxy, R° is lower alkyl, R is aryl which may have suitable substituent (s) , and X is a leaving group. Suitable pharmaceutically acceptable salts of the .___ « _ . WO 96/10559 - 11 - object compound (I) are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, 5 etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine o salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maieate, tartrate, fumarate, 5 citrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc. ) . Q In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions which the present invention intends to include within the scope thereof are explained in detail as follows. 5 The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided. The term "higher" is used to intend a group having 0 to 20 carbon atoms, unless otherwise provided. Suitable "lower alkyl" and "lower alkyl moiety" m the terms "ar (lower) alkyl", "lower alkoxy(lower) alkyl" and "heterocyclic (lower) alkyl" may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, 5 propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyi, pentyl, tert-pentyl, hexyl, and the like, and in which more preferable example may be C^-C^ alkyl. Suitable "lower alkylene" may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethyiene, methvlmethylene, ethylethylene, propylene, and the like, in which more preferable example may be C -C 4 alkylene and the most preferable one may be methylene. Suitable "lower alkoxy" and "lower alkoxy oiety" in the term "lower alkoxy (lower) alkyl" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like. Suitable "cycloalkyl" may include cyclo (C3-C7) alkyl (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.) and the like. Suitable "aryl" and "aryl moiety" in the term "ar (lower) alkyl" may include phenyl, naphthyl and the like. Suitable "halogen" may include fluorine, bromine, chlorine and iodine. Suitable "leaving group" may include acid residue, and the like. Suitable "acid residue" may include halogen as exemplified above, and the like. Suitable "heterocylic group" and "heterocyclic moiety" in the term "heterocyclic (lower) alkyl" may include unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocvclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyi, i idazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidinyl, pyrazinyi, pyridazinyl, triazolyl (e.g., 1H-1, 2, -triazolyi, 4K-1,2,4- triazolyl, 1H-1, 2, 3-triazolyl, 2H-1, 2, 3-triazolyl, etc.), tetrazolyl (e.g., IH-tetrazolyl, 2H-tetrazolyl, etc.), etc. ; saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocvclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.; unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocvclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4- oxadiazolyl, 1,2, 5-oxadiazolyl, etc.), etc.; saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, etc.; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atcm(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3- thiadiazolyl, 1,2, 4-thiadiazolyl, 1, 3, 4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.; saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydroaithiinyl, dihydrodithionyl, etc.; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.; saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom, for example, 4H-2, 3, 5, 6-tetrahydropyranyl, etc.; unsaturated condensed heterocyclic group containing 1 to 3 oxygen atom(s), for example, chromanyl, isochromanyl, methylenedioxyphenyl, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc. ; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.; unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc.; and the like. Suitable "protected amino" may include acylamino or an a ino group substituted by a conventional protecting group such as mono (or di or tri i aryl (lower) alkyl, for example, mono (or di or tri) phenyl (lower) alkyl (e.g., benzyl, tπtyi, etc. ) or the like . Suitable "hydroxy protective group" in the term "protected hydroxy" may include acyl, mono (or di or tri) phenyl (lower) alkyl which may have one or more suitable substituent (s) (e.g., benzyl, 4-methoxybenzyl, trityi, etc.) , trisubstituted silyl [e.g., tri (lower) alkylsilyl (e.g., trimethylsilyl, t-butyldimethylsilyl, etc.), et: substituted (lower) alkyl (e.g., methoxymethyl, ethoxymethyl, etc.) , tetrahydropyranyl and the like. Suitable "acyl" and "acyl moiety" in the term "acylamino" may include Carbamoyl; Thiocarbamoyl; A.liphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyi, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyi, icosanoyl, etc. ) ; lower or higher alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbcnyl, t-butoxycarbonyi, t-pentyloxycarbonyl, heptyloxycarbonyl, etc. ) ; lower or higher alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.); lower or higher alkoxysulfonyl (e.g., methoxysulfonyl, ethoxysulfonyl, etc.); cyclo (lower) alkylcarbonyl (e.g., cyclopentylcarbonyl, cyclohexylcarbonyl, etc.); or the like. Aromatic acyl such as aroyl (e.g., benzoyl, toluoyl, naphthoyi, etc.); ar (lower) alkanoyl [e.g., phenyl (lower)alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl (lower)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.]; ar (lower)alkenoyl [e.g., phenyl (lower) alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyi, etc.), naphthyl (lower)alkenoyl (e.g., naphthylpropenoyl, naphthylbutenoyl, etc.), etc.]; ar(lower)alkoxycarbonyl [e.g., phenyl (lower) alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), etc.]; aryloxycarbonyl (e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc.); aryloxy(lower)alkanoyl (e.g., phenoxyacetyl, phenoxypropionyl, etc.); arylglyoxyloyl (e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc. ) ; arylsulfonyl (e.g., phenylsulfonyl, p-tolylsulfonyl, etc., ; or the like. Suitable "substituent" in the terms "aryl which may have suitable substituent (s) " and "ar (lower) lkyl which may have suitable substituent (s) " may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or di or tri) halo (lower) alkyl wherein halogen moiety and lower alkyl moiety are each as exemplified above, cyclo (lower) alkyl, cyclo (lower) alkenyl, halogen as exemplified above, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl as exemplified above, ar (lower) alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy (lower) alkyl wherein lower alkyl moiety as exemplified above, protected carboxy(lower) alkyl, nitro, ammo, protected ammo, di (lower) alkylam o wnere lower al yl moiety is as exemplified above, am o (lower) alkyl wnerem lower alkyl moiety is as exemplified above, protected ammo lower) alkyl, hydroxy (lower) alκyl wherein lower al yl moiety is as exemplified above, protected hydroxy (lower) alkyl, cyano, sulfc, sulfamoyl, carbamovloxv, m.ercapto, lower alkylthio wherein lower alkyl noiety is as exemplified above, immo, protected ammo as exemplified above, heterocyclic group which may have mono (or di or tr ) ar (lower) alkyl wherein heterocyclic group, aryl moiety and lower alkyl moiety are each as exemplifieα above, and the like. Suitable "substituent" the term "heterocyclic group whic may have suitable suostituent (s' " may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or αi or tri) halo (lower) alkyl wherein halogen moiety and lower alkyl moiety are each as exemplified above, cyclo (lower)alkyl, cyclo (lower) alkenyl, halogen as exemplified above, carboxy, protected carboxy, hydroxy, protected hydroxy, as exemplified above, aryl as exemplified above, mono;or di or tri) ar(lower) alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy(lower)alkyl wherein lower alkyl moiety as exemplified above, protected carboxy(lower) alkyl, nitro, amino, protected amino, di (lower)alkylamino wherein lower alkyl moiety is as exemplified above, amino(lower)alkyl wherein lower alkyl moiety is as exemplified above, protected amino (lower) - alkyl, hydroxy(lower)alkyl wherein lower alkyl moiety is as exemplified above, protected hydroxy(lower)alkyl, cyanc, sulfo, sulfamoyl, carbamoyloxy, ercapto, lower alkylthio wherein lower alkyl moiety is as exemplified above, lower alkylsulfinyl wherein lower alkyl moiety is as exemplified above, acyl as exemplified above, oxo, imino, and the like. Suitable "substituent" in the term "thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl or isoxazolyl, each of which may have suitable substituen (s) " may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or di or tri)halo (lower) alkyl wherein halogen moiety and lower alkyl moiety are each as exemplified above, cyclo(lower) alkyl, cyclo(lower)alkenyl, halogen as exemplified above, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl as exemplified above, haloaryl wherein halogen moiety and aryl moiety are each as exemplified above, arylthio wherein aryl moiety is as exemplified above, heterocyclic group as exemplified above, ar(lower)alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy(lower) alkyl wherein lower alkyl moiety as exemplified above, protected carboxy(lower)alkyl, nitro, amino, protected amino, di (lower) alkylamino wherein lower alkyl moiety is as exemplified above, amino (lower) alkyl wherein lower alkyl moiety is as exemplified above, protected amino (lower) alkyl, hydroxy (lower) alkyl wherein lower alkyl moiety is as exemplified above, protected hydroxy (lower) alkyl, cyano, sulfo, sulfamoyl, carbamoyloxv, m.ercapto, lower alkylthio wherein lower alkyl moiety is as exemplified above, imino, and the like. The processes for preparing the object and starting compounds of the present invention are explained in detail in the following. Process (1) The compound (I) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (III) or a salt thereof. This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.) , benzene, N, -dimethylformamide, tetrahydrofuran, toluene, methylene chloride, εthylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which do not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. When the starting compound is in liquid, it can be used also as a solvent. Process [_2_1 The compound (I) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof and the compound (IV) or a salt thereof to formation reaction of ureido group. This reaction is carried out in the presence of reagent which introduces carbonyl group such as phosgene [e.g. , triphosgene, etc.], haloformate compound [e.g. ethyl chloroformate, trichloromethyl chloroformate, phenyl chloroformate, etc.], N,N'-carbonyldiimidazole, metal carbonyl compounds [a.g. cobalt carbonyl, manganese carbonyl, etc.], a combination of carbon monoxide and catalysts such as palladium chloride, etc., or the like. This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which άo not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating. The reaction is usually carried out in the presence of an organic base such as tri (lower)alkylamine (e.g., trimethylamine, triethylamine, diisopropylethylamine, etc. ) , or the like. Process U The compound (lb) or a salt thereof can be prepared by subjecting the compound (la) or a salt thereof to oxidation reaction. Oxidation is carried out in a conventional manner, which is capable or oxidizing a sulfur atom to an oxidized sulfur atom, and suitable oxidizing reagent may be oxygen acid such as periodate (e.g. sodium periodate, potassium periodate, etc.), peroxy acid such as perbenzoic acid (e.g., perbenzoic acid, -chloroperbenzoic acid, etc.), and the like. The reaction is usually carried out in a conventional solvent such as water, alcohol, (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, dichloromethane, ethylene dichloride, chloroform, N,N- dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction . Among these solvents, hydrophilic solvents may be used in a mixture with water. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating. Process (A) - CO The compound (VII) or a salt thereof can be prepared by reacting the compound (V with the compound (VI; . The reaction can be carried out m the manner disclosed in Preparation 2 or similar manners thereto. Process (A)-Gj The compound (IXa) or a salt thereof can be prepared DV reacting the compound (VII) or a salt thereof with the compound (VIII) or a salt thereof. The reaction can oe carried out m the manner disclosed in Preparation 20 or similar manners thereto. Process (B) The compound (X) or a salt thereof can oe prepare:: r_. subjecting the compounα (IX) or a salt thereof to reduction reaction. Reduction is carried out m a conventional manner, including chemical reαuction and catalytic reduction. Suitable reducing reagents to be used m cneπucal reduction and hydrides (e.g., hydrogen iodide, hydrogen sαlfide, lithium aluminum nydride, sodium borohydπαe, sodium cyanoborohydπde, αiisooutylalummum hydride, etc.;, a metal (e.g., tin, zinc, iron, etc. ) or metallic compounc (e.g., chromium chloride, chromium acetate, etc.), ana t e like. Suitable catalysts to be used catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum blacκ, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like. The reduction is usually carried out in the conventional solvent such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), tetrahydrofuran, toluene, dichloromethane, dioxane, N,N-dimethylformamide, N,N-dimethylacetamide or any other solvents which do not adversely affect the reaction, or a mixture thereof. The reduction is usually carried out in the presence of an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc. ) . Additionally, in case that the above-mentioned acids to be used in chemical reduction are liquid, they car. also be used as a solvent. Process (C) The compound (Xa) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with the compound (XII) or a salt thereof. The reaction can be carried out in the manner disclosed in Preparation 48 or similar manners thereto. Process (D) The compound (Xb) or a salt thereof can be prepared by reacting the compound (XIII) or a salt thereof with the compound (XII) or a salt thereof. The reaction can be carried out in the manner - 22 - disclosed in Preparation 38 or similar manners thereto. Process (E) The compound (Ila) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XIV) or a salt thereof and then by subjecting the resultant compound to reduction reaction. Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction. Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.) or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc. ) . Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like. The reduction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), tetrahydrofuran, toluene, dioxane, N, N-dimethylformamide, N, -dimethylacetamide or any other solvents which do not adversely affect the reaction, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Suitable salts of the object and starting compounds i: Processes (l)-(3) and (A) - (E) can be referred to the ones as exemplified for the compound (I) . The compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like. It is to be noted that the compound (I) and the other compounds may include one or more stereoisomer(s) such as optical isomer(s) and geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s), and all of such isomers and mixture thereof are included within the scope of this invention. Preferred embodiments of the object compound (I) are as follows. R is a group of the formula (in which R 4 is phenyl which may have 1 to 3 suitable substituent(s) (more preferably substituent selected from the group consisting of halogen, lower alkyl, di (lower)alkylamino, protected amino (more preferably acylamino; most preferably lower alkylsulfonylamino) , cyano, heterocyclic group (more preferably tetrazolyl) which may have mono (or di or tri) ar (lower) lkyl (more preferably mono (or di or tri)phenyl (lower) alkyl; most preferably triphenyl (lower) alkyl) , hydroxy, protected hydroxy (more preferably lower alkoxy(lower) alkoxy; and mono (or di or tri)halo(lower)alkyl (more preferably trihalo(lower)alkyl) ) , [more preferably phenyl, halophenyl, lower alkylphenyl, di (lower)alkyla inophenyl, lower alkylsulfonylaminophenyl, cyanophenyl, tetrazolylphenyi, (triphenyl (lower)- alkyltetrazolyl) henyl, trihalo (lower)- alkylphenyl, phenyl having two lower alkyl and hydroxy, or phenyl having two lower alkyl and lower alkoxy(lower) alkoxy] ; or heterocyclic group (more preferably thienyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrrolyl, tetrazolyl, oxazolyl, thiazolyi, oxadiazolyl, piperazinyl, thiazolidinyl or methylenedioxyphenyl) which may have 1 to 3 (more preferably one or two) suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl, mono(or di or tri) ar (lower) alkyl (more preferably phenyl (lower) alkyl or triphenyl (lower alkyl) and oxo) [more preferably thienyl; pyrazolyl which may have lower alkyl or triphenyl (lower) lkyl; imidazolyl; triazolyl which may have one or two substituent (s) selected from the group consisting of lower alkyl and phenyl (lower) alkyl; pyridyl; pyrrolyl; tetrazolyl which may have lower alkyl or triphenyl (lower)alkyl; oxazolyl; lower alkylthiazolyi; lower alkyloxadiazolyl; lower alkylpiperazinyl; dioxothiazolidinyl; or - 25 - methylenedioxyphenyl j ; 0 Y is bond, lower alkylene, -S-, -0-, -C-, =CH-, -CONH-, -N-CO- (in which R 7 s lower alkyl), R 7 -NHS0 2 -, -SO ? NH-, -S0 2 NHCO- or -CONHS0 2 ~) ; or thiazolyi, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have 1 to 5 suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl, hydroxy, protected hydroxy (more preferably acyloxy) , phenyl, halophenyl, phenylthio and pyrrolyl) [more preferably halophenylthiazclyl, phenylimidazolyl, phenylpyrazolyl, phenylpyπdyl, phenylthiopyπdyl, pyrrolylpyridyl, phenylthienyl, phenylfuryl, phenylisoxazolyl or chromanyl having 4 lower alkyl and hydroxy] ; R^ is lower alkyl, lower alkoxy(lower)alkyl, cyclo (03-0*7) alkyl (more preferably cyclopentyl, cyclohexyl or cycloheptyl) , phenyl (lower)alkyl which may nave 1 to 3 (more preferably one or two; most preferably one) suitable substituent (s) (more preferably substituent (s) selected from the group consisting of halogen, lower alkoxy and d (lower alkyl)ammo) [more preferably phenyl (lower)alkyl, halophenyl (lower)alkyl, lower alkoxyphenyl (lower) alkyl or ci (lower alkyl) ammophenyl (lower)alkyl] , tetrahydropyranyl or furyl (lower) alkyl, and R 3 is phenyl which may have 1 to 3 (more preferably two or three) suitable substituent(s) (more preferably substituent selected from the group consisting of lower alkyl and halogen) [more preferably di (or tri) ower alkyDphenyl or trihalcphenyl] ; pyridyl or pyrimidmyl, each of whicn may nave 1 to 3 - 26 - (more preferably two or three) suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl, lower alkylthio, halogen, lower alkoxy, lower alkylsulfinyl and lower alkylsulfonyl) [more preferably pyridyl having two lower alkylthio and lower alkyl; pyridyl having halogen, lower alkyl and lower alkylthio; tri (lower alkyl) pyridyl; pyridyl having two (lower) alkoxy and lower alkyl; pyridyl having lower alkoxy, lower alkylthio and lower alkyl; pyridyl having two lower alkylsulfinyl and lower alkyl; pyridyl having two lower alkylsulfonyl and lower alkyl; pyridyl having lower alkylthio, lower alkoxy and lower alkyl; pyridyl having lower alkylsulfinyl, lower alkylsulfonyl and lower alkyl; pyridyl having lower alkylthio, lower alkylsulfonyl and lower alkyl; pyridyl having two halogen and lower alkyl; di (lower) alkoxypyrimidinyl; or pyrimidinyl having two lower alkylthio and lower alkyl], and n is 0 or 1. The object compounds (I) and pharmaceutically acceptable salts thereof possess a strong inhibitory activity against ACAT, and are useful for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby. In order to illustrate the usefulness of the object compound (I) , the pharmacological test data of the representative compound of the compound (I) are shown m the following. Test compound (a) : 1-Cycloheptyl-l- (4-phenoxyphenylmethyl) -3- (2,4,6- trifluoroohenvl) urea Test Acyl-CoA : cholesterol acyltransferase (ACAT) inhibitory activity Method : ACAT activity was measured by the method of Heider et al. described in Journal of Lipid Research, Vol. 24, page 1127 (1983) . The enzyme ACAT was prepared from the mucosal microsome fraction of the small intestine of male, 18-week old Japanese white rabbits which had been fed diet containing 2\ cholesterol for 8 weeks. The inhibitory activity of test compound was calculated by measuring the amount of the labeled cholesterol ester produced from [ C]oleoyl-CoA and endogenous cholesterol as follows. [ C]Oleoyl-CoA and microsome were incubated with test compound at 37°C for 5 minutes. The reaction was stopped by the addition of chloroform-methanol (2:1, V/V) . Cholesterol ester fraction in the chloroform-methanol extracts was isolated by thin-layer chromatographv and was counted their label. Result For therapeutic purpose, the compound (I) of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral or external (topical) administration, wherein more preferable one is oral administration. The pharmaceutical preparations may be capsules, tablets, dragees, granules, suppositories, solution, lotion, suspension, emulsion, ointment, gel, or the like. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives. While the dosage of the compound (I) will vary depending upon the age and condition of the patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the compound (I) may be effective for treating the above-mentioned diseases. Ir general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day. The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail . - to be continued en the next page - 29 - Preparation 1 To a solution of acetophenone (20 g) and dimethyl oxalate (23.6 g) in N,N-dimethylformamide (160 ml) was added sodium hydride (60 " * oil suspension, 8 g) at 0-5°C. The mixture was stirred for one hour at room temperature, then heated for 30 minutes at 50°C. After cooling, to the reaction mixture was added 2.4N-hydrochloric acid (70 ml) and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (700 g, n-hexane - ethyl acetate (4:1 to 1:1)) to give methyl 2, 4-dioxo-4-phenylbutyrate (20.32 g) . IR (KBr) : 1732, 1622, 1601, 1574, 1444, 1269 cm -1 NMR (CDC1 3 , δ) : 3.95 (3H, s), 7.10 (1H, s), 7.45- 7.68 (3H, m) , 7.95-8.06 (2H, m) , 15.0-15.5 (1H, br) APCI-MASS (m/z) : 207 (M+H + ) Preparation 2 The mixture of 3-acetylbenzonitrile (43.55 g) and N,N- dimethylformamide dimethyl acetal (107.2 g) was stirred at 90°C for 3 hours under nitrogen. The mixture was concentrated in vacuo and diisopropyl ether (400 ml) was added thereto. The red-brown precipitates were collected by filtration, washed with diisopropyl ether and dried to give 3- [ (E) -3-dimethylaminoρropenoyl]benzonitrile (48.62 g ) • IR (KBr) : 3070, 2900, 2225, 1645, 1600, 1550 cm -1 NMR (DMSO-d 6 , δ) : 2.96 (3H, s), 3.17 (3H, s), 5.93 (1H, d, J=12.1Hz), 7.65 (1H, dd, J=7.7, 7.7Hz), 7.72 (1H, d, J=12.1Hz), 7.95 (1H, d, J=7.7Hz), 8.20 (1H, d, J=7.7Hz), 8.34 (1H, s) APCI-MASS (m/z) : 201 (M+H + ) - 30 - Preparation 3 To a solution of N- (3-acetylbenzyl) -acetamide (9.56 g) in 1, 2-dimethoxyethane (150 mi) was added dropwise bromine (7.99 g) at room temperature and the mixture was stirred at the same temperature for 1.5 hours. The precipitates were dissolved by addition of ethanol (150 ml) and thioacetamide (4.51 g) was added to the solution. The mixture was refluxed for 2.5 hours and evaporated in vacuo. The residue was extracted by ethyl acetate and the organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-[(2- methylthiazol-4-yl) benzyl] -acetamide (8.24 g) . IR (KBr) : 3295, 3110, 3070, 2930, 1645, 1550 cm "1 NMR (DMSO-d 6 , δ) : 1.89 (3H, s), 2.72 (3K, s), 4.29 (2H, d, J=5.9Hz), 7.2-7.9 (4K, m) , 7.90 (1H, s), 8.40 (1H, t, J=5.9Hz) APCI-MASS (m/z) : 247 (M+H + ) Preparation 4 To a solution of N- [3- (2-methylthiazol-4-yi) benzyl - acetamide (8.23 g) in ethanol (100 ml) was added cone, hydrochloric acid (13.9 ml) and the mixture was refluxed for 12 hours. The mixture was cooled to 5°C and acetone (100 ml) was added thereto slowly. The precipitates were collected by filtration and washed with acetone, dπeα over phosphorus pentoxide to give 3- (2-methylthiazol-4-yl ) - benzylamine-hydrochloride (5.14 g) . IR (KBr) : 3090, 2915, 2840, 2635, 1605, 1575, 1510 cm -1 NMR (DMSO-d 6 , δ) : 2.73 (3H, s), 4.07 (2H, ABq, J=5.7Hz), 7.47 (2H, d, J=5.1Hz), 7.9-8.0 (1H, r.) , 7.97 (1H, s), 8.14 (1H, s) , 8.57 (2H, br s) APCI-MASS (m/z) : 205 (M of free compound +H + ) 0559 - 31 - Preparation 5 To a suspension of methyl 4-[ (E)-3-dimethyiamino- propenoyl]benzoate (5.0 g) in methanol (150 ml) was added acetic acid (1.84 ml) and hydrazine onohydrate (1.56 ml). A.fter stirring for 10 hours at room temperature, the solvent was evaporated in vacuo. The residue was dissolved in ethyl acetate, washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give methyl 4- (pyrazol-3-yl)benzoate (4.21 g) . IR (KBr) : 2800-3500 (br) , 1709, 1610, 1537, 1439, 1414 cm -1 NMR (DMSO-d δ , δ) : 3.86 (3H, s) , 6.85 (1H, d, J=2.2Hz), 7.84 (1H, br s) , 7.85-8.10 (4H, m) , 13.10 (1H, br) APCI-MASS (m/z) : 203 (M+H + ) Preparation 6 To a solution of methyl 4-[ (E)-3-dimethylamino- propenoyl)benzoate (5.23 g) in acetic acid (50 ml) was added methylhydrazine (1.31 ml). The mixture was stirred for 3 hours at room temperature. To the solution was added 5N-sodium hydroxide solution in order to basify under ice cooling and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate solution, water, brine, dried over magnesium sulfate, evaporated in vacuo. After chromatography on silica gel (eluting with dichloromethane-methanol (120:1)), methyl 4- (l-methylpyrazol-3-yl)benzoate (3.14 g) was isolated and methyl 4- (l-methylpyrazol-5-yl)benzoate (1.63 g) was obtained. Methyl 4- (l-methylpyrazol-3-yl)benzoate: IR (KBr) : 3134, 2949, 1705, 1612, 1439, 1344, 1281 cm -1 NMR (CDC1 3 , δ) : 3.92 (3H, s) , 3.97 (3H, s), 6.61 (1H, d, J=2.2Hz), 7.41 (1H, d, J=2.2Hz), 7.82- - 32 - 7.93 (2H, m) , 8.03-8.14 (2H, m) APCI-MASS (m/z) : 217 (M+H + ) Methyl 4- (l-methylpyrazol-5-yl)benzoate : IR (KBr) : 3035, 2960, 1718, 1614, 1464, 1425, 1286 cm -1 NMR (CDC1 3 , δ) : 3.93 (3H, s), 3.96 (3H, s), 6.38 (1H, d, J=2.0Hz), f .46-7.5 7 (2H, m) , 7.54 (1H, d, J=2.0Hz), 8.08-8.19 (2H, ) APCI-MASS (m/ z ) : 217 {M~-H + ) Preparation 7 To a solution of thiophenol (2.20 g) in methanol (10 ml) was added 28?. sodium methoxide-methanol solution (3.86 ml) and the mixture was stirred at room temperature for 15 minutes . To the mixture was added methyl 6- chloronicotinate (3.43 g) and the mixture was refluxed for 6.5 hours under nitrogen. The mixture was evaporated to dryness and the residue was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatographv on silica gel to give methyl 6- (phenylthio)nicotinate (5.13 g) as a crystal . IR (KBr) : 3070, 2950, 1720, 1585, 1550 cm -1 NMR (CDCI3, δ) : 3.91 (3H, s) , 6.86 (1H, dd, J=8.5, 0.8Hz), 7.4-7.5 (3H, m) , 7.55-7.7 {2H, m) , 8.00 (1H, dd, J=8.5, 2.2Hz), 9.00 (1H, dd, J=2.2, 0.8Hz) APCI-MASS (m/z) : 246 (M+H + ) Preparation 8 To a solution of aniline (8.20 g) in pyπdine (100 mi) was added portionwise 4-carboxybenzenesulfonyl chloride (17.65 g) at 5°C and the mixture was stirred at 9C°C for 6 0559 - 33 - hours under nitrogen. The mixture was poured into a mixture of ethyl acetate (300 ml), ice water (200 ml) and cone, hydrochloric acid (150 ml) . The precipitates were formed and collected by filtration and washed with ethyl acetate and diisopropyl ether and dried in vacuo over phosphorus pentoxide tb give 4- (phenylsuifamoyl)benzoic acid (6.87 g) as white crystal. The filtrate was separated and the organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. To the residue was added diisopropyl ether and the second crop (6.57 g) was obtained by filtration. IR (KBr) : 3265, 2840, 2675, 2560, 1680, 1600, 1575 cm "1 NMR (DMSO-d 6 , δ) : 7.0-7.2 (3K. m) , 7.2-7.35 (2H, m) , 7.85 (2H, d, J=8.4Hz), 8.07 (2H, d, J=8.4Hz), 10.45 (1H, s) Preparation 9 To a solution of ethyl 4-aminobenzoate (8.26 g) in pyπdine (25 ml) was added dropwise benzenesulfonyl chloride (8.83 g) at 5°C and the mixture was stirred at room temperature for 1 hour under nitrogen. The mixture was poured into a mixture of ethyl acetate (150 ml), ice water (100 ml) and cone, hydrochloric acid (30 ml) . The precipitates were formed and collected by filtration, washed with ethyl acetate and diisopropyl ether and dried in vacuo over phosphorus pentoxide to give ethyl 4 - (phenylsulfonylamino) enzoate (10.72 g) as a white crystal. The filtrate was separated and the organic layer was washed with brine, dried over magnesium sulfate and evaporated vacuo. To the residue was added diisopropyl ether and the second crop (3.83 g) was obtained by filtration. IR (KBr) : 3230, 3070, 2990, 2940, 2880, 1695, 1610, 1510 cm -1 NMR (DMSO-d 6 , δ) : 1.27 (3H, t, -=7.1Hz), 4.24 [2ή ' , - 34 - q, J=XlHz), 7 -22 (2H, d, J=8.8Hz), 7.5-7.7 (3H, m) , 7.8-7.9 (4H, m) , 10.86 (IH, s) APCI-MASS (m/z) : 306 (M-rH " ) Preparation 10 To a stirred mixture of bromine (50.2 ml) in dichlorometha.ne (1 (} and anhydrous sodium carbonate (206.8 g) was added a solution of 1-methylpyrazole (80 g) in dichloromethane 00 ml) at 0-5°C. After stirring for one hour under ice-cooling, the mixture was stirred for further one hour at room temperature, then cooled. To the reaction mixture water (1 .) was added thereto. The dichloromethane layer was separated and aqueous layer was extracted twice with dichloromethane. The combined organic layer was washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was distilled in vacuo to afford 4-bromo-l-methylpyrazole (150.6 g) . bp : 82°C (20 mmHg) IR (Neat) : 3100, 2930 cm -1 NMR (CDC1 3 , δ) : 3.89 (3H, s), 7.38 (IH, s) , 7.44 (IH, si APCI-MASS (m/z) : 161, 163 (M+H "*" ) Preparation 11 To a solution of methyl 4-formylbenzoate (4.0 g and tosylmethyl isocyanide (5.0 g) methanol (40 ml) was added potassium carbonate (3.54 g) . The mixture was refluxed for 3.5 hours. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water and brme, dried over magnesium sulfate, evaporated m vacuo. The residue was chromatograpneα or. silica gel (100 g, elutmg with n-hexane - ethyl acetate (2:1 to 1:1) to give methyl 4- (oxazol-5-yl) benzoate (4.04 g) . - 35 - IR (KEr) : 1726, 1614, 1275, 1109 cm "1 NMR (CDC1 3 , δ) : 3.94 (3H, s), 7.48 (IH, s) , 7.68-7.78 (2H, m) , X 97 (IH, s), 8.06-8.16 (2H, m) APCI-MASS (m/z) : 204 (M+K + > Preparation 12 A solution of methyl 2, 4-dioxo-4-phenylbutyrate (6 g) and hydroxylamine-hydrochloride (6.07 g) in methanol (120 ml) was refluxed for 4 hours. The solvent was removed in vacuo. To the residue was added chloroform. The organic solution was washed with water, brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (150 g, n-hexane - ethyl acetate (3:1)) to give 3-methoxycarbonyl-5-phenylisoxa∑ole (5.25 g) . IR (KBr) : 1728, 1570, 1448, 1250 cm -1 NMR (CDC1 3. δ) : 4.01 (3H, s), 6.94 (IH, s), 7.45-7.55 (3H, m) , 7.75-7.88 (2H, m) APCI-MASS (m/z) : 204 (M^H + ) Preparation 13 A solution of methyl 2, 4-dioxo-4-phenylbutyrate (ό g) and hydrazine, mo.nohydrate (1.42 ml) in ethanol (48 ml; was refluxed for 5 hours. The solvent was removed in vacuo. The resulting solid was collected by filtration, washed with diisopropyl ether to give 5-methoxyIcarbonyl-3- pyenylpyrazole (3.0 g) . IR (KBr) : 2500-3400 (br) , 1 7 30, 1491, 1244 cm -1 NMR (DMSO-d 6 , δ) : 3.83, 3.88 (total 3H, each s) , 7.18-7.53 (4H, m) , 7 .78-7.94 (2H, m) , 13.90-14.15 (IH, ) APCI-MASS (m/z) : 203 (M- » -H + . - 36 - Preparation 14 A mixture of methyl 3-cyanobenzoate (8.0 g) , sodium a∑ide (19.38 g) and ammonium chloride (15.95 g) in N,N- dimethylformamide (32 ml) was heated for 2.5 hours at 120°C. The mixture was poured into ice water (300 ml) - ethyl acetate (100 ml) . Under ice cooling, to the solution was added sodium nitrite (20.5 g) then 6N-hydrochloric acid until pH was adjusted to 1-2. After stirring for 30 minutes at room temperature, the mixture was extracted with ethyl acetate - tetrahydrofuran, washed with water and brine, dried over magnesium sulfate, evaporated* in vacuo to give methyl 3- (lH-tetrazol-5- yDbenzoate (10.01 g) . IR (KBr) : 2300-3500 (br) , 1705, 1684, 1618, 1562 cm "1 NMR (DMSO-d 6 ,δ) : 3.93 (3H, s), 7.78 (IH, dd, J=7.9, 7.9Hz), 8.10-8.20 (IH, m) , 8.25-8.38 (IH, m) , 8.60-8.70 (IK, m) APCI-MASS (m/z) : 205 (M+H + ) Preparation 15 To the solution of 4-bromobenzyl alcohol (4.85 g) and 3-tri-n-butylstannylthiophene (11.6 g) was added tεtrakis (triphenylphosphine)palladium(O) (0.9 g) , then the mixture was heated for one hour at 140°C. After cooling, the resulting precipitate was collected by filtration and washed with n-hexane to give 4- (3-thienyl)benzyl alcohol (2.67 g) . IR (KBr) : 3300 (br) , 1425, 1200, 1045, 1014, 777 cm "1 NMR (CDC1 3 , δ) : 1.72 (IH, t, J=5.9Kz) , 4.72 (2H, d, J=5.9Hz), 7.30-7.50 (5H, m) , 7.60 (2H, dd, J=6.4, 1.8Hz) Preparation 16 The following compound was obtained according to a similar manner to that of Preparation 15. 4- (2-Thienyl)benzyl alcohol IR (KBr) : 3300 (br) , 1427, 1213, 1047, 806 cm "1 NMR (CDC1 3 , δ) : 1.70 (IH, t, J=5.9Hz), 4.71 (2H, d, J=5.9Hz), 7.08 (IH, dd, J=5.I, 3.6Hz), 7.22- 7.42 (4H, m) , 7.52-7.68 (2H, m) Preparation 17 A mixture of ethyl 4-acetylbenzoate (10 g) and N,N- dimethylformamide dimethyl acetal (41.8 ml) was heated for 18 hours at 85°C. After cooling, the resulting solid was collected by filtration, washed with diisopropyl ether to give methyl 4- [ (E) -3-dimethylaminopropenoyl]benzoate (10.44 g) . IR (KBr) : 1718, 1637, 1578, 1541, 1425 cm -1 NMR (DMSO-d 6 , δ) : 2.94 (3H, s) , 3.17 (3H, s), 3.88 (3H, s), 5.85 (IH, d, J=12.2Hz), 7.77 (IH, d, J=12.2Hz), 7.90-8.05 (4H, m; APCI-MASS (m/z) : 234 (M+H ÷ ) Preparation 18 To a suspension of lithium aluminum hydride (569 mg) in tetrahydrofuran (120 ml) was added dropwise a solution of 2-methoxycarbonyl-4- (pyrrol-1-yl)pyridine (3.03 g) at 5°C and the mixture was stirred at room temperature for 3 hours. To the mixture were added sodium fluoride (2.52 g) and water (811 mg) and the mixture was stirred at room temperature for 30 minutes. The insoluble materials were removed by filtration and washed with tetrahydrofuran. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give [4- (pyrrol-l-yl)pyridin-2-yl]methanol (1.14 g) . - 38 - IR (KBr) : 3190, 2955, 2845, 1595, 1575, 1500 cm -1 NMR (DMSO-d 6 , δ) : 4.58 (2H, d, J=5.8Hz), 5.48 (IH, t, J=5.8Hz), 6.35-6.4 (2K, m) , 7.52 (IH, dd, J=5.6, 2.4Hz), 6.55-6.6 (2H, m) , 7.62 (IH, d, J=1.9Hz), 8.47 (IH, d, J=5.6Hz) APCI-MASS (m/z) : 175 (M+H + ) Preparation 19 The following compounds were obtained according to a similar manner to that of Preparation 18. (1) 3- (Pyrazol-3-yl) benzyl alcohol IR (Film) : 3245, 2930, 2880 cm "1 NMR (DMSO-d 6 , δ) : 4.52 (2H, d, J=5.6Hz) , 5.29 (IH, t, J=5.6Hz) , 6.68 (IH, d, J=2.2Hz) , 7.2-7.7 (4H, m) , 7.76 (IH, d, J=2.2Hz) , 12.9 (IH, br s) APCI-MASS (m/z) : 175 (M+H + ) (2 ) ( 6-Phenylpyridin-3-yl) methanol IR (Film) : 3325, 2865, 1600, 1565, 1475 cm "1 NMR (CDC1 3 , δ) : 4.74 (2H, s) , 7.4-7.55 (3H, m; , 7.7-7.85 (2H, m) , 7.9-8.05 (2H, m) , 8.62 (IH, d, J=1.3Hz) APCI-MASS (m/z) : 186 (M+H + ) (3) 4- (Benzoylamino) benzyl alcohol IR (KBr) : 3320, 2840, 1655, 1595, 1545 cm "1 NMR (DMSO-d 6 , δ) : 4.50 (2H, d, J=5.7Hz) , 5.22 (IH, t, J=5.7Hz) , 7.05 (IH, d, J= 7 .6Hz) , 7.29 (IH, d, J=7.6Hz) , 7.5-7.7 (4H, m) , 7.77 (IH, s) , 7.96 (2H, dd, J=7.6, 1.5Hz) , 10.23 (IH, s) APCI-MASS (m/z) : 228 (M+H~) (4) 4- (Phenylsulfonylamino) benzyl alcohol IR (Film) : 3515, 3265, 3060, 2935, 2875, 1705, - 39 - 1650, 1615, 1515 cm "1 NMR (DMSO-d 6 , δ) : 4.36 (2H, d, J=5.8Hz), 5.07 (IH, t, J=5.8Hz), 7.02 (2H, d, J=8.6Hz), 7.15 (2H, d, J=8.6Hz), 7.5-7.65 (2H, m) , 7.7-7.8 (2H, m) , 10.21 (IH, s) APCI-MASS (m/z) : 264 (M+H + ) (5) (6-Phenylthiopyridin-3-yl)methanol IR (Film) : 3320, 2865, 1590, 1560 cm "1 NMR (CDC1 3 , δ) : 2.46 and 2.71 (total IH, t, J=5.6Hz), 4.64 and 4.72 (total 2H, d, J=5.6Hz), 6.88 and 7.31 (total IH, d, J=8.3Hz), 7.4-7.75 (6H, m) , 8.3-8.4 (IH, m) APCI-MASS (m/z) : 218 (M+K + ) (6) 4- (0xazol-5-yl)benzyl alcohol IR (KBr) : 3330 (br) , 1510, 1491, 1041, 818 cm "1 NMR (CDCI3, δ) : 4.74 (2H, s), 7.34 (IH, s), 7.35-7.5C (2H, m) , 7.59-7.72 (2H, ) , 7.91 (IH, s) APCI-MASS (m/z) : 176 (M+H + * (7) (3-Phenylpyrazol-5-yl)methanol IR (KBr) : 2500-3500 (br) , 1471, 1360, 1030, 1001, 766 cm "1 NMR (DMSO-d 6 , δ) : 4.38-4.58 (2H, m) , 4.95-5.37 (IH, ) , 6.52-6.66 (IH, ) , 7.20-7.53 (3K, π) , 7.68-7.90 (2K, ) , 12.68-13.10 (IK, ) APCI-MASS (m/z) : 175 (M+H + ) (8) 4- (Pyrazol-3-yl)benzyl alcohol IR (KBr) : 2500-3600 (br) , 1522, 1456, 1419, 1032, 841, 762 cm "1 NMR (DMSO-d β , δ) : 4.51 (2K, d, J=5.7Hz) , 5.07-5.2 " (IH, m) , 6.60-6.74 (IH, br s) , 7.20-7.85 (5H, mi , - 40 - 12.82, 13.24 (total IH, each br s) APCI-MASS (m/z) : 175 (M+H + ) (9) 4- (l-Methylpyrazol-5-yl)benzyl alcohol IR (KBr) : 2500-3600 (br) , 1495, 1460, 1425, 1385, 1273 cm "1 NMR (CDC1 3 , δ) : 2.12 (IH, t, J=5.7Hz), 3.88 (3H, s), 4.77 (2H, d, J=5.7Hz), 6.30 (IH, d, J=1.9Hz), 7.35-7.52 (4H, m) , 7.51 (IH, d, J=1.9Hz) APCI-MASS (m/z) : 189 (M+I-T) (10) 3- (lH-Tetrazol-5-yl)benzoyl alcohol IR (KBr) : 2100-3600 (br) , 1562, 1485, 1419, 1219 cm "1 NMR (DMSO-d 6 , δ) : 4.61 (2H, s), 5.20-5.60 (IH, br), 7.48-7.65 (2H, m) , 7.85-7.98 (IH, m) , 8.05 (IH, s) APCI-MASS (m/z) : 177 (M÷H + ) Preparation 20 To a solution of 3- [ (E) -3-dimethylaminopropenoyl] - benzonitrile (48.5 g) in methanol (500 ml) was added acetic acid (21.82 g) followed by slow addition of hydrazine monohvdrate (18.17 g) at room temperature and the mixture was stirred at 17.5 hours at the same temperature. The mixture was evaporated to dryness and the residue was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized and the crystal was collected by filtration, washed with diisopropyl ether and dried to give 3- (pyrazcl-3- yl ) benzonitrile (37.71 g) . IR (KBr) : 3190, 3075, 2840, 2760, 2230, 1560 cm -1 NMR (DMSO-d 6 , δ) : 6.88 (IH, d, J=2.1Hz), 7.62 (IH, dd, 3=1 . 1 , 7.7Hz), 7.75 (IH, d, J=7.7Hz), 7.83 - 41 - ( IH, br s ) , 8 . 1 6 ( IH, d, J=7 . 7Hz ) , 8 . 24 ( IH, s ) , 13 . 08 ( IH, br ) Preparation 21 To a suspension of sodium hydride (2.0 g) in N,N- dimethylformamide (100 ml) was added thiophenol (5.51 g) , and the mixture was stirred at room temperature for 15 minutes. To the mixture was added 4-fluorobenzonitrile ( 6 . 66 g) , and the mixture was stirred at 130°C for 16 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (phenylthio)benzonitrile (12.24 g) as an oil. IR (Film) : 3070, 2235, 1595, 1505 cm "1 NMR (CDC1 3 , δ) : 7.15-7.3 (2H, m) , 7.65-7.8 (2H, m) , 7.4-7.6 (5H, ) APCI-MASS (m/z) 212 (M ^ H + ) Preparation 22 To a suspension of 4- (phenylsulfamoyl)benzole acid (13.43 g) in 1,2-dichloroethane (130 ml) were added thionyl chloride (11.52 g) and N,N-dimethylformamide (2 drops) and the mixture was stirred at 100°C for 2 hours, under nitrogen. The resulting solution was evaporated in vacuo and the residue was dissolved in dichloromethane (150 ml). To this solution was added N,O-dimethylhydroxylamine-hydro- chloride (5.19 g) , followed by dropwise addition of triethylamine (9.80 g) at 5°C. The mixture was stirred at room temperature for 4 hours. Water was added thereto and the separated organic layer was washed with brine, dried over magnesium sulfate and evaported in vacuo. The residue was purified by column chromatography on silica gel to give N-methyl-N-methoxy-4- (phenylsulfamoyl)benzamide (11.31 g) _ 42 - as an oil. IR (KBr) : 3150, 2950, 2905, 2890, 1625, 1600, 1570, 1495 cm "1 NMR (DMSO-d 6 , δ) : 3.24 (3H, s), 3.48 (3H, s), 7.0- 7.2 (3H, m), 7.2-7.3 (2H, m) , 7.7-7.9 (4H, m) , 10.38 (IH, s) Preparation 23 To the solution of 4-fluorobenzonitrile (10 g) and pyrazole (6.74 g) in N,N-dimethylformamide (100 ml) was added potassium carbonate (13.7 g) . Then the mixture was heated for 4 hours at 120°C. After cooling, the reaction mixture was diluted with ethyl acetate (1 .), washed with water, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel (400 g, eluting with n-hexane - ethyl acetate (3:1) ) to give 4- (pyrazol-1-yl) benzonitrile (10.54 g) . IR (KBr) : 2226, 1608, 1529, 1394 cm "1 NMR (CDC1 3 , δ) : 6.54 (IH, dd, J=2.5, I.8Hz), 7.70- 7.90 (5H, m) , 8.00 (IH, d, J=2.5Hz) APCI-MASS (m/z) : 170 (M*H + ) Preparation 24 To the solution of 4-fluorobenzonitrile (10 g) and imidazole (6.74 g) in N,N-dimethylformamide (200 ml) was added potassium carbonate (13.7 g) . Then the mixture was heated for 2 hours at 120°C. After cooling, the reaction mixture was diluted with ethyl acetate (2 .) , washed with water, brine, dried over magnesium sulfate and evaporated in vacuo to give 4- (imidazol-1-yl) benzonitrile (10.34 gj . IR (KBr) : 2225, 1608, 1520 cm "1 NMR (CDC1 3 , δ) : 7.27 (IH, s), 7.34 (IH, t, J=1.2Hz), 7.46-7.60 (2H, m) , 7.75-7.89 (2H, ) , 7.95 (IH, s) APCI-MASS (m/z) : 170 (M+H ÷ ) Preparation 25 To a solution of methyl 4- (l-methylpyrazol-3- yl)benzoate (2.5 g) in dichloromethane (80 ml) was added dropwise diisobutylaluminum hydride (1.02M toluene solution, 25.0 ml) at -60 - -50°C. After stirring for 30 minutes at the same temperature, sodium fluoride (4.28 g) and water (1.38 ml) was added thereto. The mixture was warmed to room temperature over 15 minutes and stirred for one hour. Insoluble materials were removed by filtration. The filtrate was evaporated in vacuo to give 4-(l- methylpyrazol-3-yl)benzyl alcohol (1.74 g) . IR (KBr) : 2500-3650 (br) , 1508, 1462, 1431, 1360, 1302 cm -1 NMR (CDC1 3 , δ) : 1.90 (IH, t, J=5.7Hz), 3.95 (3H, s), 4.70 (2H, d, J=5.7Hz), 6.54 (IH, d, J=2.2Hz), 7.33-7.43 (3H, m) , 7.74-7.84 (2H, m) APCI-MASS (m/z) : 189 (M÷H + ) Preparation 26 To a solution of 4-bromo-l-methylpyrazole (1 g) in ether (15 ml) was added dropwise n-butyliith um (1.63M in hexane, 4.2 ml) keeping the temperature below -60°C. After stirring for 30 minutes, a solution of tri-n-butyltin chloride (1.85 ml) in ether (1.85 ml) was added thereto. After stirring for one hour, the mixture was warmed to room temperature over 30 minutes and stirred for one hour. The reaction mixture was diluted with ether, washed with water and brine, dried over magnesium sulfate. and evaporated under reduced pressure to give l-methyl-4-tri- (n- butyl) stannylpyrazole (2.3 g) . IR (Neat) : 2930, 1504, 1460, 1120 cm "1 NMR (CDC1 3 , δ) : 0.75-1.70 (27H, m) , 3.93 (3H, s), 7.23 (IH, s), 7.42 (IH, s) Preparation 27 To a suspension of 5-bromc-2-furancarboxylιc acid (10 g) , N, O-dimethylhydroxylamme-hydrochloride (5.1 g) and 1- hydroxybenzotriazole (7.07 g) m dichloromethane (300 ml) 5 was added dropwise a solution of 1- (3-dιmethylammopropyl) - 3-ethylcarbodιιmιde (6.37 g) dichloromethane (60 ml) at room temperature. The resulting mixture was stirred at room temperature for 18 hours. Water (180 ml) was added thereto and the insoluble materials were removed by 10 filtration. The organic layer was separated and washed with brme, dried over magnesium sulfate, evaporated m vacuo. The residue was chromatographed on silica gel (350 g, elutmg with ethyl acetate - n-hexane (1:1) ) to give 5- bromo-2- (N-methyl-N-methoxycarbamoyl) furan (7.60 g) . 15 IR (Neat) : 2974, 2937, 1649, 1566, 1477 cm "1 NMR (CDC1 3 , δ) : 3.34 (3H, s), 3.77 (3H, s), 6.45 (IH, d, J=3.5Hz), 7.09 (IH, d, J=3.5Hz) APCI-MASS (m/z) : 234, 236 (M+H + ) 20 Preparation 28 To a mixture of 3-methylbιphenyl (5.0 g. and N-bromosuccmimide (5.29 gi m tetrachlorometnane (150 irX was added benzoyl peroxide (144 mg) and the mixture was refluxed for 6 hours. The mixture was cooled, and the 25 insoluble materials were filtered off. The filtrate was evaporated m vacuo and the residue was purified by column chromatography on silica gel to give crude 3-bromomethyl bipnenyl (6.59 g) as a yellow oil. IR (Film) : 3030, 1600, 1575 en "1 30 NMR (CDCI3, δ) : 4.56 (2H, s), 7.35-7.7 (9H, ml Preparation 29 The following compounds were obtained according to a similar manner to that of Preparation 28. -3 5 (1) 4-Bromomethylbenzophenone IR (KBr) : 3050, 1650, 1605 cm "1 NMR (CDC1 3 , δ) : 4.54 (2H, s), 7.4-7.85 (9H, m) (2) 4- (Pyridin-3-yl)benzyl bromide NMR (DMSO-d 6 , δ) : 6.10 (2H, s), 7.4-8.4 (6H, m) , 8.9-9.3 (2H, m) (3) 4- (Pyridin-2-yl)benzyl bromide IR (Film) : 3050, 3010, 2985, 1735, 1585, 1565 cm -1 NMR (CDCI3, δ) : 4.58 (2H, s) , 7.2-8.1 (7H, m) , 8.7-8.8 (IH, m) Preparation 30 To a solution of 4-ethoxycarbonyl-2- (4- chlorophenyl) thiazole (2.68 g) in a mixture of tetrahydrofuran (40 ml) and ethanol (10 ml) was added lithium borohydride (218 mg) at room temperature and the mixture was stired at 50°C for 1.5 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue crystalline solid was collected by filtration to give [2- (4-chlorophenyl) thiazol-4-yl]methanoI (1.43 g) . IR (KBr) : 3270, 3080, 2920, 2865, 1595, 1525, 1505 cm "1 NMR (DMSO-d 6 , δ) : 4.63 (2H, d, J=5.8Hz), 5.40 (IH, t, J=5.8Hz), 7.51 (IH, s), 7.5-7.6 (2H, m) , 7.9- 8.0 (2H, ) APCI-MASS (m/z) : 226 (M^H + ) Preparation 31 To a solution of methyl 6-chloronicotinate (6.86 g) and dihvdroxyphenyl borane (5.85 g) in 1,2-dimethoxyethane (150 ml) was added 2M sodium carbonate aσueous solution (48 ml), followed by tetrakis (triphenylphosphine)palladium(O) (2.31 g) and the mixture was refluxed for 16 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give methyl 6- phenylnicotinate (7.75 g) as a white crystal. IR (KBr) : 3070, 3030, 2995, 2945, 2845, 1725, 1595, 1560 cm -1 NMR (CDC1 3 , δ) : 3.98 (3H, s), 7.4-7.6 (3H, m) , 7.82 (IH, dd, J=8.3, 0.9Hz), 8.0-8.1 (2H, m) , 8.35 (IH, dd, J=8.3, 2.2Hz), 9.28 (IH, dd, J=2.2, 0.9Hz) Preparation 32 The following compound was obtained according to a similar manner to that of Preparation 31. N-Methyi-N-methoxy-4- [4- (dimethylamino) phenyl] - benzamide IR (KBr) : 3255, 3000, 2815, 1605, 1540, 1505 cm "1 NMR (CDCI3, δ) : 3.01 (6H, s), 3.38 (3H, s , 3.60 (3H, s), 6.80 (2H, d, J=8.9Hz), 7.5-7.65 (4H, m) , 7.74 (2H, dd, J=6.5, 1.9Hz) APCI-MASS (m/z) : 285 (M+H + ) Preparation 33 To a suspension of 4- (pyrrol-1-yl) enzoic acid (3.74 g) and N, O-dimethylhydroxylamine-hydrochloride (1.95 a ' in dichloromethane (100 ml) was added dropwise a solution of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (2.43 g) in dichloromethane (15 ml) at room temperature. The resulting solution was stirred at the same temperature for 18 hours. Water (60 ml) was addeα to tne mixture, and the insoluble materials were removed by filtration. The filtrate was separated, and the organic layer was washed with brine, dried over magnesium sulfate and evaporated vacuo. The residue was purified by column chromatography on silica gel to give 4- (pyrrol-1-yl) -N-methyl-N-metnoxybenzamide (2.12 g) as a white crystal. IR (KBr) : 3130, 3045, 2975, 2935, 1640, 1610, 1580, 1525 cm "1 NMP (CDC1 3 , δ) : 3.39 (3K, s) , 3.58 (3H, s), 6.4-6.45 (2H, m) , 7.15-7.2 (2H, m) , 7.4-7.5 (2H, ) , 7.8-7.9 (2H, m) APCI-MASS (m/z) : 231 (M-h " X Preparation 34 To a suspension of 3- (pyrrol-1-yl)benzoic acid (5.62 g) , N, O-dimethylhydroxylamine-hydrochloride (2.93 g) and 1- hydroxybenzotriazole (4.05 g) m dichloromethane (150 ml) was added dropwise a solution of 1- (3-dιmethylamιnopropyl) - 3-etnylcaroodιιmιde (3.65 g) m αichloromethane (30 ml) at room temperature. The resulting solution was stirred at roc 1, temperature for 20 nours . Water (100 ml) was aαdeα thereto and tne insoluble materials were removed by filtration. The filtrate was separated and the organic layer was washed with br e, dried over magnesium sulfate and evaporated in vacuo. The resiαue was purified oy column chromatography on silica gel to give 3- (pyrrol-1- yl) -N-methyl-N-methoxybenzamide (5.19 g) as a yellow oi . IR (Film) : 3130, 2935, 1645, 1610, 1585, 1500 cm "1 NMR (CDCI3, δ) : 3.39 (3H, s), 3.57 (3H, s), 6.35-6.4 (2H, m) , 7.1-7.15 (2H, m) , 7.45-7.6 XF, m) , 8.7-8.75 (IH, m) APCI-MASS (m/z) : 231 (M^H + ) Preparation 35 The following compound was obtained according to a similar manner to that of Preparation 34. [4- (N-Methyl-N-methoxy) carbamoylphenyl] - dihydroxyborane IR (KBr) : 3380, 1610, 1545, 1510 cm "1 NMR (DMSO-d 6 , δ) : 3.25 (3H, s) , 3.53 (3H, s), 7.5-7.8 (4H, ml APCI-MASS (m/z) : 210 (MX Preparation 36 To a suspension of lithium aluminum hydride (348 mg) in tetrahydrofuran (30 ml) was added dropwise a solution of 4- (pyrrol-1-yl) -N-methyl-N-methoxybenzamide (2.11 g) in tetrahydrofuran (40 ml) at 5°C and the mixture was stirred at 5°C for 1.5 hours. To the mixture were added sodium fluoride (1.54 g) and water (495 mg) , and the mixture was stirred at room temperature for 30 minutes. The insoluble materials were filtered off and washed with tetrahydrofuran. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 4- (pyrrol-1-yl) benzaldehyde (1.65 g) . IR (KBr) : 3130, 2800, 2745, 1690, 1605, 1520 cm "1 NMR (CDC1 3 , δ) : 6.35-6.45 (2H, m) , 7.15-7.25 (2H, ) , 7.5-7.6 (2K, m) , 7.9-8.0 (2K, ) , 9.99 π s) APCI-MASS (m/z) : 172 (M+H + ) Preparation 37 The following compounds were obtained according to a similar manner to that of Preparation 36. (I) 3- (Pyrrol-l-yl)benzaldehyde IR (Film) : 3220, 1700, 1650, 1590, 1540, 1500 cm "1 - 49 - NMR (CDCI3, δ) : 6.4-6.45 (2H, m) , 7.15-7.20 (2H, m) , 7.55-7.8 (3H, m) , 8.9-8.95 (IH, m) , 10.06 (IH, s) APCI-MASS (m/z) : 172 (M+H + ) (2) 4- (4-Dimethylaminophenyl)benzaldehyde IR (KBr) : 2895, 2810, 2725, 1695, 1680, 1595, 1540 cm -1 NMR (CDC1 3 , δ) : 3.03 (6H, s), 6.8-6.9 (2H, m) , 7.55-7.65 (2H, m) , 7.65-7.75 (2H, ) , 7.85-7.95 (2H, m) , 10.01 (IH, s) APCI-MASS (m/z) : 226 (M+H + ) (3) 4- (Phenylsulfamoyl)benzaldehyde IR (KBr) : 3260, 3055, 2860, 1695, 1595 cm -1 NMR (DMSO-d 6 , δ) : 7.0-7.15 (3H, m) , 7.2-7.3 (2H, ) , 7.93 (2H, d, J=8.1Hz), 8.05 (2H, d, J=8.IHz), 10.04 (IH, s), 10.48 (IH, br s) APCI-MASS (m/z) : 262 (M+H + ) 2-Bromo-5-furaldehyde IR (KBr) : 1670, 1464, 1377, 1271 cm "1 NMR (CDC1 3 , δ) : 6.57 (IK, d, J=3.6Hz), 7.19 (IH, d, J=3.6Hz), 9.54 (IH, s) Preparation 38 To a suspension of 4-bromobenzaldehyde (1.85 g) and [4-flurophenyl]dihydroxyborane (1.40 g) in toluene (50 mil was added powdered potassium carbonate (2.07 g) , followed by addition of tetrakis (triphenylphosphine)palladiu (0) (578 mg) and the mixture was refluxed for 24 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by - 50 - column chromatography on silica gel to give 4- (4- fluorophenyl) benzaldehyde (1.67 g) as a white crystal. IR (KBr) : 3055, 2855, 2755, 1705, 1600, 1565, 1520 cm "1 NMR (CDC1 3 , δ) : 7.1-7.25 (2K, m) , 7.55-7.7 (2H, m) , 7.71 (2H, d, J=8.2Hz), 7.95 (2H, d, J=8.2Hz), 10.06 (IH, s) APCI-MASS (m/z) : 201 (M+H + ) Preparation 39 To a solution of 2-bromo-5-thiophenecarbaldehyde (2 g) and dihydroxyphenylborane (1.66 g) was added 2M sodium carbonate solution (13.6 ml) and tetrakis (triphenylphosphine) palladium(0) (605 mg) . The mixture was heated for 5 hours at 80°C. The reaction mixture was poured into water, extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (100 g, eluting with n-hexane - ethyl acetate (5:1) ) to give 2- phenyl-5-thiophenecarbaldehyde (1.80 g) . IR (KBr) : 1647, 1441, 1232, 754 cm "1 NMR (CDC1 3 , δ) : 7.33-7.50 (4H, m) , 7.60-7.80 (3H, m) , 9.90 (IH, s) APCI-MASS (m/z) : 189 (M->-H + ) Preparation 40 The following compounds were obtained according to a similar manner to that of Preparation 39. (1) 2-Phenyl-5-furaldehyde IR (Neat) : 1674, 1522, 1475, 1257 cm "1 NMR (CDCI3, δ) : 6.85 (IH, d, J=3.7Hz), 7.33 (IH, d, J=3.7Hz), 7.37-7.53 (3H, m) , 7.80-7.92 (2H, m) , 9.66 (IH, s) APCI-MASS (m/z) : 173 (M+H + ) (2) 4-Phenyl-2-thiophenecarbaIdehyde IR (KBr) : 1676, 1539, 1429, 1173, 7go cm "1 NMR (CDC1 3 , δ) : 7.30-7.66 (5H, m) , 7.82-7.90 (IH, m) , 8.00-8.08 (IH, m) , 9.93 (IH, d, J=1.2Hz) FAB-MASS (m/z) : 189 (M÷ϊT) (3) 4- (4-Methylphenyl)benzaldehyde IR (KBr) : 3095, 3060, 2860, 2765, 1690, 1600, 1575, 1505 cm "1 NMR (CDC1 3 , δ) : 2.42 (3H, s), 7.29 (2H, d, J=10.4Hz), 7.55 (2H, dd, J=6.3, 1.8Hz), 7.74 (2H, dd, J=6.6, 1.8Hz), 7.94 (2H, dd, J=6.6, 1.8Hz), 10.05 (IH, s) APCI-MASS (m/z) : 197 (M+H + l 4- (4-Chlorophenyl) benzaldehyde IR (KBr) : 3055, 2820, 2720, 1695, 1605 cm "1 NMR (CDC1 3 , δ) : 7.4-7.5 (2H, ) , 7.55-7.65 (2H, m) , 7.7-7.8 (2H, m) , 7.9-8.0 (2H, m) , 10.06 s) APCI-MASS (m/z) : 217 (M+H + ) (5) 4- (4-Bromophenyl) benzaldehyde IR (KBr) : 3050, 2820, 2725, 1705, 1605, 1575, 1555 cm "1 NMR (CDCI3, δ) : 7.45-7.55 (2K, ) , 7.55-7.65 (2H, m) , 7.65-7.75 (2H, m) , 7.95-8.05 (2H, m) , 10.06 (IH, s) APCI-MASS (m/z) : 263, 261 (M+H + ) Preparation 41 To a solution of 4-carboxybenzaldehyde (3.00 g) and triethvlamine (2.23 g) in dichloromethane (50 ml) was added - 52 - dropwise isobutyl chloroformate (3.01 g) at 5°C and the mixture was stirred at 5°C for 40 minutes. To this solution was added aniline (2.05 g) and the mixture was stirred at room temperature for 16 hours. Water was added to the mixture, and the separated organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. To the residue was added hexane: ethyl acetate (1:1) and the powder was collected by filtration to give 4- (phenylcarbamoyl) benzaldehyde (2.24 g) . The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give the second crop (1.12 g ) • IR (KBr) : 3340, 3055, 2820, 2725, 1705, 1650, 1575, 1535 cm "1 NMR (DMSO-d 6 , δ) : 7.13 (IH, t, J=7.3Hz), 7.3-7.45 (2H, m) , 7.79 (2H, d, J=7.5Hz), 8.0-8.2 (4H, m) , 10.12 (IH, s), 10.46 (IH, ε) APCI-MASS ιm/z) : 226 (M^H T ) Preparation 42 To a solution of ethyl 4-ammooenzoate (3.30 g) m pyr d e (10 ml) was added αropwise benzoyl chloride (3.09 g) at 5°C, and the mixture was stirred at room temperature for 1.6 hours. The mixture was poured into a mixture of ethyl acetate, ice water and 6N hydrocnlor c acid (40 ml), and the separated organic layer was washed witn water and brme, dried over magnesium sulfate and evaporated in vacuo. The resicue was crystallized from hexane and ethyl acetate (5:1), and the crystal was collected by filtration to give ethyl 4- (benzoylammo - benzoate (5.14 g) . IR (KBr) : 3300, 3050, 2980, 1720, 1650, 1530 cm "1 NMR (DMSO-d 6 , δ) : 1.34 (3H, t, J=7.1Hz), 4.34 (2H, q, J=7.1Hz), 7.5-7.7 (5H, ) , 7.95-8.2 (3H, m) , 8.45-8.5 (IH, m) , 10.48 (IH, s) APCI-MASS (m/z) : 270 (M+H + ) Preparation 43 The following compound was obtained according to a similar manner to that of Preparation 41. 4- (2-Pyridylcarbamoyl)benzaldehyde IR (KBr) : 3230, 3180, 3115, 3035, 2810, 2725, 1710, 1675, 1585, 1540 cm "1 NMR (DMSO-d 6 , δ) : 7.20 (IH, dd, J=6.8, 1.5Hz), 7.8-7.9 (IH, ) , 8.03 (2H, d, J=8.4Hz), 8.20 (2H, d, J=8.4Hz), 8.15-8.25 (IH, ) , 8.4-8.45 (IH, m) , 10.12 (IH, s), 11.06 (IH, s) APCI-MASS (m/z) : 227 (M+H + ) Preparation 44 To a solution of [2- (4-chlorophenyl)thiazol-4- yl]methanol (1.42 g) in chloroform (80 ml) was added activated manganese dioxide (5.48 g) and the mixture was refluxed for 1.8 hours. The mixture was filtered and the filtrate was evaporated in vacuo to give 4-formyl-2- (4- chlorophenyl) thiazole (1.28 g) . IR (KBr) : 3110, 2840, 1695, 1595, 1575, 1500 cm -1 NMR (DMSO-d 6 , δ) : 7.55-7.65 (2H, m) , 8.0-8.I (2H, m), 8.80 (IH, s), 9.99 (IH, s) APCI-MASS (m/z) : 224 (M+H + ) Preparation 45 To a solution of (3-phenylpyrazol-5-yl)methanol (1.30 g) in acetone (130 ml) was added activated manganese dioxide (6.5 g) and the mixture was refluxed 1.5 hours. The mixture was filtered and the filtrate was evaporated vacuo to give 3-phenyl-5-formylpyrazole (1.16 g) . IR (KBr) : 2400-3500 (br) , 1676, 1473, 1282, 1192 cm "1 - 54 - NMR (DMSO-d. 7.20-7.56 (4H, m) 7.75-7.95 (2H, m) , 9.93 (IH, s), 14.05-14.30 (IK, br APCI-MASS (m/z) 173 (M+H + \ Preparation 46 The following compounds were obtained according to similar manners to those of Preparations 44 and 45. (1) 3- (Pyrazol-3-yl) benzaldehyde IR (Film) : 3325, 2975, 2920, 2840, 2745, 1700, 1610, 1585 cm " - 1 - NMR (DMSO-d 6 , δ) : 6.84 (IH, d, J=2.0Hz) , 7.6-8.25 (4H, m) , 8.36 (IH, s) , 10.07 (IH, s), 13.05 (IH, br s) APCI-MASS (m/z) : 173 (M+H + ) (2) 6-Phenyl-3-formylpyridine IR (KBr) : 3060, 2835, 2785, 2740, 1695, 1590, 1560 cm "1 NMR (CDC1 3 δ) : 7.25-7.4 (4H, m) , 7.92 (IH, d, J=8.3Hz), 8.05-8.15 (2H, m) , 8.24 (IH, dd, J=8.3, 2.2Hz) , 9.14 (IH, dd, J=2.2, 0.7Hz) , 10.14 (IH, s) APCI-MASS (m/z) : 184 (M+H + ) (3) 2-Formyl-4- (pyrrol-i-yl) pyridine IR (KBr) : 3110, 2845, 1705, 1595 cm "1 NMR (DMSO-d 6 , δ) : 6.35-6.4 (2H, m) , 7.75-7.8 (2H m) , 7.98 (IH, dd, J=5.2, 2.5Hz) , 3.12 (IH, d, J=2.2Hz), 8.80 (IH, d, J=5.5Hz) , 10.0 (IH, si APCI-MASS (m/z) : 173 (M+H + ) (4) 6-Phenylthio-3-formylpyridine IR (Film) : 3055, 2840, 2780, 1700, 1585, 1550 cm "1 NMR (CDCI3, δ) : 6.94 and 7.49 (total IH, d, J=8.4Hz), 7.45-7.65 (6H, m) , 7.89 and 8.14 (total IH, dd, J=8.4, 2.2Hz), 8.82 and 8.87 (total IH, d, J=2.2Hz), 9.98 and 10.10 (total IH, s) APCI-MASS (m/z) : 216 (M+H + ) (5) 4- (Benzoylamino)benzaldehyde IR (KBr) : 3305, 3055, 2840, 2735, 1715, 1660, 1645, 1540 cm "1 NMR (DMSO-d 6 , δ) : 7.5-7.7 (5H, m) , 7.95-8.15 (3H, m) , 8.40 (IH, s), 10.02 (IH, s), 10.54 (IH, s) APCI-MASS (m/z) : 226 (M+H + ) (6) 4- (Phenylsulfonylamino)benzaldehyde IR (KBr) : 3240, 3060, 2935, 2850, 2765, 1690, 1680, 1580, 1510 cm "1 NMR (DMSO-d 6 , δ) : 7.29 (2H, d, J=8.6Hz), 7.55-7.7 (3H, m) , 7.75-7.9 (4H, ) , 9.81 (IH, s) , 11.01 (IH, s) APCI-MASS (m/z) : 262 (M+HX (7) 4- (3-Thienyl)benzaldehyde IR (KBr) : 1689, 1601, 1211, 1167 cm "1 NMR (CDC1 3 , δ) : 7.41-7.47 (2K, m) , 7.62 (IH, t, J=2.1H∑), 7.70-7.83 (2H, m) , 7.85-7.98 (2H, m) , 10.02 (IH, s) APCI-MASS (m/z) : 189 (M+H + ) (8) 4- (2-Thienyl) benzaldehyde IR (KBr) : 1699, 1601, 1213, 1170 cm "1 NMR (CDCI3, δ) : 7.14 (IH, dd, J=5.1, 3.7Hz), 7.40 (IH, dd, J=5.1, 1.1Hz), 7.47 (IH, dd, J=3.7, l.IHz), 7.70-7.82 (2H, m) , 7.82-7.96 (2H, m) , 10.00 (IH, s) APCI-MASS : 189 (M+H + ) (9) 4- (Pyrazol-3-yl)benzaldehyde IR (Neat) : 2400-3700 (br) , 1697, 1606, 1211, 1171, 837 cm "1 NMR (DMSO-d 6 , δ) : 6.90 (IH, d, J=2.3Hz) , 7.83 (IH, br s), 7.85-8.12 (4H, m) , 10.00 (IH, s), 13.13 (IH, br) APCI-MASS (m/z) : 173 (M+HX (10) 4- ( l-Methylpyrazol-3-yl) benzaldehyde IR (KBr) : 1695, 1603, 1566, 1431, 1306 cm "1 NMR (CDC1 3 , δ) : 3.99 (3H, s), 6.64 (IH, d, J=2.3Hz), 7.43 (IH, d, J=2.3Hz) , 7.86-8.03 (4H, m) , 10.01 (IH, s) APCI-MASS (m/z) : 187 (M+H + ) (11) 4- (l-Methylpyrazol-5-yl) benzaldehyde IR (KBr) : 1695, 1608, 1568, 1390, 1215, 1184 cm "1 NMR (CDCI 3 , δ) : 3.95 (3H, s), 6.41 (IK, d, J=1.9Hz), 7.56 (IH, d, J=1.9Hz), 7.57-7.68 (2H, m) , 7.93-8.04 (2H, m) , 10.08 (IK, s) APCI-MASS (m/z) : 187 (M+K + ) (12) 3- (lH-Tetrazoi-5-yl)benzaldehyde IR (KBr) : 2400-3500 (br), 1674, 1612, 1560, 1373, 1207 cm "1 NMR (DMSO-d 6 , δ) : 7.86 (IH, dd, J=7.7, 7.7Hz) , 8.08-8.20 (IH, m) , 8.30-8.42 (IH, m) , 8.57 (IK, dd, J=1.5, 1.5Hz) , 10.13 (IH, s) APCI-MASS (m/z) : 175 (M+H + ) Preparation 47 To a suspension of 3- (pyrazol-3-yllbenzonitrile (37.70 g) in formic acid (300 ml) was added a suspension of Raney Nickel (Trademark : NDT-90) in water (130 ml) and the mixture was refluxed for 3.5 hours. The mixture was cooled to room temperature and Raney Nickel was removed by filtration and washed with formic acid (150 ml) . The filtrate was evaporated to dryness and dichloromethane and ice water were added to the residue. The mixture was adjusted to pH ca. 8.5 by addition of 5N sodium hydroxide aqueous solution. The insoluble materials were removed by celite pad and the filtrate was separated. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3- (pyrazol-3- yl)benzaldehyde (37.17 g) . IR (KBr) : 3190, 2975, 2840, 1690, 1605, 1585 cm "1 NMR (DMSO-d 6 , δ) : 6.84 (IH, d, J=2.2Hz), 7.65 (IH, dd, J=7.6, 7.6Hz), 7.75-7.85 (2H, m) , 7.84 (IH, d, J=7.6Hz), 8.35 (IH, s), 10.07 (IH, s) , 13.06 (IH, br s) Preparation 48 To a solution of 4-fluorobenzaldehyde (2.48 g) and 4- bromophenol (3.46 g) in N,N-dimethylacetamide (20 ml) was added powdered potassium carbonate (2.76 g) , and the mixture was refluxed for 17 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (4-bromophenoxy)benzaldehyde (1.51 a) . IR (KBr) : 3030, 2920, 2840, 2735, 1705, 1600, 1560 cm ~~ NMR (CDC1 3 , δ) : 6.95-7.1 (4H, ; , 7.45-7.55 (2H, m) , 7.8-7.9 (2H, ) , 9.94 (IH, s ) APCI-MASS (m/z) : 279, 277 (M+H + ) Preparation 49 To a solution of 4-bromobenzaldehyde (4.96 g) and - 58 - 4-fluorophenol (4.48 g) in N, -dimethylacetamide (25 ml) was added powdered potassium carbonate (5.53 g) , and the mixture was refluxed for 6 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (4- fluorophenoxy) benzaldehyde (1.92 g) as an orange oil. IR (Film) : 3360, 3075, 2835, 2740, 1695, 16C0, 1585, 1495 cm "1 NMR (CDC1 3 , δ) : 6.7-6.3 (IH, m) , 6.85-6.95 (IH, m) , 7.0-7.2 (4H, m) , 7.8-7.9 (2H, ) , 9.92 (IH, s) APCI-MASS (m/z) : 217 (M+H + ) Preparation 50 To a solution of 4-phenylthiobenzonitrile (12.23 g) in toluene (200 ml) was added dropwise diisobutylaluminu hydride (1.02M toluene solution) (114 ml) at -70°C over 50 minutes and the mixture was stirred at -70°C for 30 minutes. To the mixture were added sodium fluoride (19.45 g) and water (6.26 g) , and the mixture was warmed to room temperature. The insoluble materials were removed by filtration and washed with toluene. The filtrate was evaporated in vacuo and the residue was dissolved in tetrahydrofuran (50 ml) . To this solution was added 6N hydrochloric acid (19.3 ml) and the mixture was stirred at room temperature for 1 hour. The mixture was extracted with ethyl acetate, and the organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (phenylthio) benzaldehyde (9.83 g) as a yellow oil. IR (Film) : 3055, 2830, 2745, 1695, 1595, 1560, 1505 cm - 1 NMR (CDC1 3 , δ ) : 7 . 15- 7 . 3 ( 4H, m) , 7 . 35-7 . 6 ( 3H, m) , 7 . 65-7 . 75 ( 2H, ) , 9 . 91 ( IH, s ) APCI-MASS (m/ z ) : 215 (M÷H + ) Preparation 51 To a solution of 4- (pyrazol-l-yl)benzonitrile (5.0 g) in dichloromethane (150 ml) was added dropwise diisobutylaluminum hydride (1.02M toluene solution, 58 ml) keeping the temperature below -60°C. After stirring for one hour, sodium fluoride (9.95 g) and water (3.2 ml) were added thereto. The reaction mixture was warmed to room temperature over 30 minutes and stirred for 1.5 hours. Insoluble material was removed by filtration. The filtrate was concentrated by evaporation in vacuo. The residue was dissolved in tetrahydrofuran (25 ml) . To he solution was added IN-hydrochloric acid and stirred for one hour at room temperature. To the mixture was added 5N-sodium hydroxide solution (10 ml) . The objective compound was extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (100 g, n-hexane - ethyl acetate (1:1)) to give 4-(pyrazol- 1-yl)benzaldehyde (4.36 g) . IR (KBr) : 1695, 1605, 1390, 1200 cm "1 NMR (CDC1 3 , δ) : 6.54 (IH, dd, J=2.5, 1.8Hz), 7.79 (IH, d, J=1.5Hz), 7.85-8.10 (5H, m) , 10.02 (IH, s) APCI-MASS (m/z) : 173 (M+H + ) Preparation 52 The following compound was obtained according to a similar manner to that of Preparation 51. 4- (Imidazol-1-yl)benzaldehyde IR (KBr) : 1686, 1606, 1522, 1313 cm "1 NMR (CDC1 3 , δ) : 7.15-8.10 (7H, m) , 10.05 (IH, s) APCI-MASS (m/z) : 173 (M+H + ) Preparation 53 To a solution of methyl 5-phenyl-3- isoxazolecarboxylate (4.73 g) in dichloromethane (150 ml) was added dropwise diisobutylaluminum hydride (1.02M toluene solution 45.7 ml) at -7C°C - -60°C. After stirring for one hour at the same temperature, sodium fluoride (7.83 g) and water (2.52 ml) were added thereto. The mixture was warmed to room temperature over 30 minutes and stirred for one hour. Insoluble materials were removed by filtration. The filtrate was evaporated in vacuo. The residue was chromatographed on silica gel (85 g, n-hexane - ethyl acetate (3:1) ) to give 5-phenyl-3-isoxazolecarbaldehyde (1.94 g) . IR (KBr) : 3126, 1713, 1568, 1456, 1184 cm "1 NMR (CDC1 3 , δ) : 6.90 (IH, s), 7.35-7.68 (3H, m) , 7.75-7.92 (2H, m) , 10.20 (IH, s) Preparation 54 To the solution of 4-bromobenzaldehyde (462 mg) and 1- methyl-4-tri-n-butylstannylpyrazole (1.1 g) was added tetrakis (triphenylphosphine)palladium(0) (87 mg) . Then the mixture was heated for 3 hours at 140°C. After cooling, the reaction mixture was diluted with toluene (6 ml) . An aσueous solution (5 ml) of potassium fluoride (1X4 g) was added to the mixture and stirred for one hour. Insoluble material was removed by filtration. The filtrate was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed on silica gel (40 g, eluting with n-hexane - ethyl acetate (1:2)) to give 4- (l-methylpyrazol-4-yl) benzaldehyde (427.4 mg) . - 61 - IR (KBr) : 1693, 1605, 1169, 831 cm "1 NMR (CDC1 3 , δ) : 3.98 (3H, s) , 7.57-7.67 (2H, m) , 7.73 (IH, s), 7.85 (IH, s) , 7.80-7.92 (2H, m) , 9.98 (IH, s) APCI-MASS (m/z) : 187 (M+H " * " ) Preparation 55 To a solution of oxalyl chloride (1.5 ml) in dichloromethane (30 ml) was added a solution of dimethyl sulfoxide (1.83 ml) in dichloromethane (4 ml) keeping the temperature below -60°C. After 20 minutes, 4-(oxazol-5- yDbenzyl alcohol (2.5 g) in dichloromethane (25 ml) and dimethyl sulfoxide (2 ml) was added dropwise at the same temperature then stirred for one hour. To the mixture was added triethylamine (8 ml) and stirred for 30 minutes. The reaction mixture was warmed to room temperature over 30 minutes. After stirring for one hour, the mixture was diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (80 g, elutmg with n-hexane - ethyl acetate (1:1)) to give 4-(cxazol-5- yl)benzaldehyde (2.20 g) . IR (KBr) : 1693, 1610, 1211, 1111, 829 cm "1 NMR (CDC1 3 , δ) : 7.54 (IH, s), 7.75-8.05 (4H, m) , 8.00 (IH, s), 10.03 (IH, s) APCI-MASS (m/z) : 174 (M+H + ; Preparation 56 .To the solution of 3- (lH-tetrazol-5-yl)benzaldehyde (1.0 g) in pyridine (15 ml) was added triphenylchloromethane (1.76 g) at 0~5°C. The mixture was stirred for 4 hours at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with dil. hydrochloric acid, water, brine, dried over magnesium sulfate, evaporated in vacuo to give 3- (1-trityl-lK- tetrazol-5-yl)benzaldehyde (2.51 g) . IR (KBr) : 1699, 1516, 1491, 1446, 1201 cm "1 NMR (DMSO-d 6 , δ) : 7.05-7.20 and 7.38-7.53 (15H, m) , 7.80 (IH, dd, 3=1 . 1 , 7.7Hz), 8.05-8.14 (IH, m) , 8.30-8.40 (IH, m) , 8.50-8.55 (IH, m) , 10.12 (IH, s) Preparation 57 The mixture of 4-formylbiphenyl (3.64 g) and cycloheptylamine (2.49 g) was heated at 120°C for 6 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (30 ml) . To the solution was added carefully sodium borohydride (757 mg) , and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-(4- biphenylylmethyl) cycloheptylamine (5.24 g) as a yellow oil. IR (Film) : 3030, 2920, 2850 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.5-2.7 (IH, m) , 3.72 (2H, s), 7.3-7.7 (9H, m) APCI-MASS (m/z) : 280 (M+H + ) Preparation 58 The suspension of 4- [4- (dimethylamino) phenyl] - benzaldehyde (640 mg) and cycloheptylamine (643 mg) in toluene (3 ml) was stirred at 120°C for 5 hours under nitrogen. The mixture was evaporated to dryness and dissolved in ethanol (20 ml) . To this solution was added sodium borohydride (107 mg) and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated to dryness and the residue was extracted with dichloromethane. The organic layer was washed with br e, dried over magnesium sulfate and evaporated vacuo. The residue was purified by column chromatography on silica gel to give N- cycloheptyl 4- [4- (dimethylammo)phenyl]benzylamine (945 mg) . IR (KBr) : 3275, 3025, 2920, 2850, 2805, 1610, 1535, 1505 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 2.65-2.85 (IH, m) , 2.99 (6H, s), 5.79 (2H, s), 6.80 (2H, d, J=8.8Hz), 7.34 (2H, d, J=8.8Hz), 7.45-7.65 (4H, m) APCI-MASS (m/z) : 323 (M+H + ) Preparation 59 The mixture of 4-phenoxybenzaldehyde (1.98 g) and benzylamine (1.61 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved m ethanol (20 ml) . To this solution was added sodium borohydride (378 mg) and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated tc dryness and the residue was extracted witn dichloromethane. The organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel to give N- benzyl-4-phenoxybenzylamme (2.07 g) . IR (Film) : 3035, 2915, 2820, 1680, 1505 cm "1 NMR (CDCI3, δ) : 3.78 (2H, s) , 3.82 (2H, s), 6.9- 7.4 (14H, m) APCI-MASS (m/z) : 290 (M+H + ) Preparation 60 The mixture of 4-phenoxyben∑aldehyde (1.98 g) and furfurylamme (1.61 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (20 ml) . To this solution was added sodium borohydride (378 mg) and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated to dryness and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-furfuryl-4-phenoxybenzylamine (2.51 g) . IR (Film) : 3060, 3035, 2920, 2830, 1590, 1505 cm "1 NMR (CDC1 3 , δ) : 3.76 (2H, s) , 3.80 (2H, s), 6.15-6.2 (IH, m) , 6.3-6.35 (IH, m) , 6.9-7.4 (10H, m) APCI-MASS (m/z) : 280 (M+H + ) Preparation 61 The following compounds were obtained according to similar manners to those of Preparation 57, 58, 59 and 60. ( 1 ) N- (2-Biphenylylmethyl ) -cycloheptylamine IR (Film) : 3060, 3020, 2935, 2910, 2850, 1460 cm "1 NMR (CDCI3, δ) : 1.2-1.8 (12H, m) , 2.4-2.6 (IH, m) , 3.71 (2H, s) , 7.2-7.5 (9H, m) APCI-MASS (m/z) : 280 (M+H + ) (2 ) N-Cycloheptyl-4-phenoxybenzylamine IR (Film) : 3030, 2920, 2850, 1590, 1505 cm "1 NMR (CDCI3, δ) : 1.4-2.0 (12H, m) , 2.6-2.8 (IH, m) , 3.75 (2H, s) , 6.9-7.4 (9K, m) APCI-MASS (m/z) : 296 (M+H + ) (3) N-Cyclohexyl-3-phenoxybenzylamine IR (Film) : 3035, 2925, 2850, 1585 cm "1 NMR (CDCI3, δ) : 1.3-2.0 (12H, m) , 2.6-2.8 (IK, m) , 3.75 (2H, s) , 6.8-7.4 (9H, m) APCI-MASS (m/z) : 296 (M+H + ) (4) N-Cycloheptyl- [2- (4-chlorophenyl) thiazol-4- yl]methylamine IR (KBr) : 2930, 2850, 1595 cm "1 NMR (DMSO-d 6 , δ) : 1.3-2.2 (12H, m) , 2.6-2.8 (IH, m) , 3.84 (2H, s) , 7.49 (IH, s), 7.5-7.6 (2H, ) , 7.9-8.0 (2H, m) APCI-MASS (m/z) : 321 (M+H + ) (5) N-Cycloheptyl- (2-phenylimidazol-5-yl)methylamine IR (KBr) : 3080, 2925, 2855, 1575 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.6-2.75 (IH, ) , 3.62 (2H, br s), 6.82 and 7.06 (total IH, br s), 7.25-7.45 (3H, m) , 7.8-7.95 (2H, m) , 12.28 (IH, br) APCI-MASS (m/z) : 270 (M+H + ) (6) N-Cycloheptyl-4- (pyrrol-1-yl) benzylamine IR (Film) : 2925, 2850, 1610, 1525 cm "1 NMR (CDC1 3 , δ) : 1.3-2.0 (12H, m) , 2.6-2.8 (IH, m) , 3.79 (2H, s), 6.3-6.4 (2H, ) , 7.0-7.1 (2H, ) , 7.3-7.45 (4H, ) APCI-MASS (m/z) : 269 (M+H + ) (7) N-Cycloheptyl-3- (pyrrol-1-yl)benzylamine IR (Film) : 2925, 2850, 1610, 1595, 1545, 1500 cm "1 NMR (CDCI3, δ) : 1.4-1.95 (12H, m) , 2.6-2.8 (IH, m) , 6.30-6.35 (2H, m) , 7.10-7.15 (2H, ) , 7.15- 7.45 (4H, m) APCI-MASS (m/z) : 269 (M+H + ) (8) N-Cycloheptyl- [4- (pyrrol-1-yl) yridin-2-yl]methylamine IR (Film) : 3305, 3135, 3100, 2925, 2855, 1600, 1575 cm "1 NMR (DMS0-d 6 , δ) : 1.3-2.0 (12H, m) , 2.55-2.7 (IH, m) , 3.82 (2H, s), 6.35-6.4 (2H, m) , 6.5-6.55 (2H, - 66 - m) , 6.55-6.6 (IH, m) , 6.65-6.7 (IH, d, J=2.2Hz), 8.47 (IH, d, J=5.6Hz) APCI-MASS (m/z) : 282 (M+H + ) (9) N-Cycloheptyl (6-phenylpyridin-3-yl)methylamine IR (Film) : 3030, 2910, 2850, 1560 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12K, m) , 2.6-2.8 (IH, m) , 3.83 (2H, s), 7.3-7.5 (2H, m) , 7.65-7.8 (2H, m) , 7.95-8.05 (2H, m) , 8.61 (IH, s) APCI-MASS (m/z) : 281 (M+H + ) (10) N-Cycloheptyl-3- (pyrazol-3-yl)benzylamine IR (Film) : 3210, 2915, 2850, 1610, 1540 cm -1 NMR (DMS0-d 6 δ) : 1.3-1.9 (12H, m) , 2.5-2.7 (IH, m) , 3.72 (2H, s), 6.68 (IH, d, J=2.1Hz), 7.15-7.8 (5H, m) APCI-MASS (m/z) : 270 (M+H + ) (11 ) N-Cycloheptyl-4- (4-fluorophenyl)benzylamine IR (Film) : 2925, 2855, 1500 cm "1 NMR (CDCI3, δ) : 1.4-2.0 (12K, m) , 2.65-2.85 (IH, m) , 3.81 (2H, s), 7.05-7.2 (2K, m) , 7.35-7.6 (6H, m) APCI-MASS (m/z) : 298 (M+H + ) (12) N-Cycloheptyl-4- (4-chlorophenyl) benzylamine IR (KBr) : 3030, 2925, 2855, 1485 cm "1 NMR (CDCI3. δ) : 1.35-2.0 (12H, m) , 2.6-2.8 (IK, m) , 3.82 (2H, s) , 7.4-7.6 (8H, m) APCI-MASS (m/z) : 314 (M+H + ) (13) N-Cycloheptyl-4- (4-bromophenyl) benzylamine IR (KBr) : 3035, 2925, 2855, 1480 cm "1 NMR (CDCI3, δ) : 1.3-2.0 (12H, m) , 2.6-2.8 (IH, ) , 3.81 (2H, s), 7.35-7.65 (8H, m) APCI-MASS (m/z) : 360, 358 (M+H + ) (14) N-Cycloheptyl-4- (4-methylphenyl)benzylamine IR (Film) : 3025, 2910, 2855, 1500 cm "1 NMR (CDC1 3 , δ) : 1.3-2.0 (12H, m) , 2.39 (3H, s), 2.65-2.8 (IH, m) , 3.81 (2H, s), 7.24 (2H, d, J=7.6Hz), 7.37 (2H, d, J=8.3Hz), 7.4-7.6 (4H, m) APCI-MASS (m/z) : 294 (M+H + ) (15) N-Cycloheptyl-4- (4-bromophenoxy)benzylamine IR (Film) : 3030, 2925, 2850, 1585, 1505, 1480 cm "1 NMR (CDC1 3 , δ) : 1.3-2.0 (12H, m) , 2.6-2.8 (IH, m) , 3.75 (2H, s), 6.8-7.0 (4H, ) , 7.25-7.5 (4H, m) APCI-MASS (m/z) : 376, 374 (M+H + ) (16; N-Cycloheptyl-4- (4-phenylthιo)benzylamine IR (Film) : 2920, 2850, 1510 cm "1 NMR (CDCI3, δ) : 1.3-2.0 (12H, m) , 2.55-2.75 (IH, m) , 3.75 (2H, s), 7.2-7.5 (9H, m) APCI-MASS (m/z) : 312 (M+H τ ) (1 7 ) N-Cycloheptyl- (6-phenylthιopyrιdm-3-yl)methylamine IR (Film) : 3305, 2925, 2850, 1700, 1585, 1560 cm "1 NMR (CDCI3, δ) : 1.3-2.0 (12H, m; , 2.55-2.75 (IH, m) , 3.71 (2H, s), 6.87 (IK, d, J=8.2Hz , 7.4-7.7 (6H, m) , 8.35-8.4 (IH, iX APCI-MASS (m/z) : 313 (M+HX (13) N-Cycloheptyl-4- (4-benzoylammo) benzylamine IR (Film) : 3265, 3150, 3070, 2925, 2850, 1645, 1615, 1595, 1555 cm "1 NMR (DMS0-d 6 , δ) : 1.3-1.9 (12H, ) , 2.55-2.7 (IK, m) , 3.69 (2H, s), 7.07 (IH, d, J=7.7Hz), 7.2 ^ (IH, t, J=7.7Hz), 7.5-7.8 (5H, m) , 7.9-8.0 (2H, m) , 10.22 (IH, s) APCI-MASS (m/z) : 323 (M+H + ) (19) N-Cycloheptyl-4- (2-pyridylcarbamoyl) benzylamine IR (KBr) : 3305, 2925, 2855, 1680, 1610, 1580, 1535, 1505 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.5-2.7 (IH, m) , 3.76 (2H, s), 7.17 (IH, dd, J=6.3, 4.9Hz), 7.45 (2H, d, J=8.2Hz), 7.98 (2H, d, J=8.2Hz), 7.8-7.9 (IH, m) , 8.19 (IH, d, J=8.4Hz), 8.35-8.4 (IH, m) , 10.70 (IH, s) APCI-MASS (m/z) : 324 (M+H + ) (20) N-Cycloheptyl-4- (4-fluorophenoxy)benzylamine IR (Film) : 2925, 2855, 1505 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 2.65-2.8 (IH, m) , 3.75 (2H, s) , 6.85-7.1 (6H, m) , 7.2-7.35 (2H, m) APCI-MASS (m/z) : 314 (M+H + ) (21) N-Cycloheptyl-4- (phenylsulfamoyl) benzylamine NMR (DMS0-d 6 , δ) : 1.2-1.8 (12H, m) , 2.5-2.6 (IH, m) , 3.70 (2H, s), 7.0-7.15 (3H, m) , 7.15-7.25 (2H, m) , 7.47 (2H, d, J=8.3Hz), 7.68 (2H, d, J=8.3Hz), 10.23 (IH, s) APCI-MASS (m/z) : 359 (M+H + ) (22) N-Cycloheptyl-4- (3-thienyl) benzylamine IR (KBr) : 2924, 1458, 1201, 775 cm "1 NMR (CDCI3, δ) : 1.30-1.98 (12H, m) , 2.62-2.78 (IK, m) , 3.80 (2H, s) , 7.30-7.47 (5H, m) , 7.50-7.60 (2H, m) APCI-MASS (m/z) : 286 (M+H + ) (23) N-Cycloheptyl-4- (2-thιenyl)benzylamine IR (Neat) : 2924, 1502, 1458, 1101, 810 cm "1 NMR (CDCI3, δ) : 1.30-1.98 (12H, m) , 2.62-2.78 (IK, - 69 - m) , 3.79 (2H, s), 7.07 (IK, dd, J=5.1, 3.6Hz), 7.22-7.40 (4H, m) , 7.50-7.65 (2H, m) APCI-MASS (m/z) : 286 (M+H + ) (24) N-Cycloheptyl-4- (pyrazol-1-yl)benzylamine IR (Neat) : 2927, 1610, 1525, 1460, 1394 cm "1 NMR (CDC1 3 , δ) : 1.30-1.95 (12H, m) , 2.60-2.78 (IH, m) , 3.81 (2H, s), 6.46 (IH, t, J=2.1Hz), 7.36- 7.46 (2H, m) , 7.58-7.68 (2H, m) , 7.71 (IH, d, J=1.6Hz), 7.91 (IH, d, J=2.1Hz) APCI-MASS (m/z) : 270 (M+H + ) (25) N-Cycloheptyl-4- (imidazol-1-yl)benzylamine IR (Neat) : 2922, 1522, 1303, 1057 cm "1 NMR (CDC1 3 , δ) : 1.30-1.98 (12H, m) , 2.60-2.80 (IH, m) , 3.83 (2H, s) , 7.20 (IH, d, J=1.0Hz), 7.27 (IH, d, J=1.0Hz), 7.30-7.50 (4H, m) , 7.84 (IH, s) APCI-MASS (m/z) : 270 (M+H + ) (26) N-Cycloheptyl-4- (l-methylpyrazol-4-yl)benzylamine IR (KBr) : 3277, 2924, 1572, 1443, 1194, 802 cm "1 NMR (CDC1 3 , δ) : 1.30-2.20 (12H, m) , 2.62-2.80 (IH, m) , 3.78 (2H, s), 3.94 (3H, s), 7.27-7.47 (4H, m) , 7.58 (IH, s) , 7.74 (IH, s) APCI-MASS (m/z) : 284 (M+H + ) (27) N-Cycloheptyl-2- (2-phenylthiophen-5-yl)methylamine IR (Neat) : 2924, 1599, 1462, 754 cm "1 NMR (CDCI3, δ) : 1.30-1.98 (12H, m) , 2.66-2.85 (IH, m) , 3.98 (2H, s) , 6.87 (IH, d, J=3.6Hz), 7.15 (IH, d, J=3.6Hz), 7.18-7.45 (3H, m) , 7.52-7.64 (2H, m) APCI-MASS (m/z) : 286 (M+H + ) (28) N-Cycloheptyl-4- (oxazol-5-yl)benzylamine - 70 - IR (KBr) : 2924, 1510, 1485, 1103, 822 cm "1 NMR (CDC1 3 , δ) : 1.30-1.98 (12H, m) , 2.60-2.80 (IH, m) , 3.81 (2H, s), 7.33 (IH, s), 7.33-7.46 (2H, m) , 7.55-7.69 (2H, m) , 7.90 (IH, s) APCI-MASS (m/z) : 271 (M+H + ) (29) N-Cycloheptyl- (2-phenylfuran-5-yl)methylamine IR (Neat) : 2924, 1545, 1456, 1020, 760 cm "1 NMR (CDCI3, δ) : 1.30-1.95 (12H, m) , 2.64-2.80 (IH, m) , 3.84 (2H, s), 6.24 (IH, d, J=3.3Hz), 6.57 (IH, d, J=3.3Hz), 7.17-7.45 (3H, m) , 7.58-7.72 (2H, m) APCI-MASS (m/z) : 270 (M+H + ) (30) N-Cycloheptyl- (5-phenylisoxazol-3-yl)methylamine IR (Neat) : 2926, 2854, 1616, 1574, 1456, 1113, 766 cm "1 NMR (CDCI3, δ) : 1.30-1.98 (12H, m) , 2.65-2.82 (IH, m) , 3.90 (2H, s), 6.53 (IH, s), 7.34-7.53 (3H, m) , 7.70-7.86 (2H, m) APCI-MASS (m/z) : 271 (M+H + ) (31) N-Cycloheptyl- (3-phenylpyrazol-5-yl)methylamine IR (Neat) : 2300-3600 (br), 1570, 1460, 1358, 1026 cm "1 NMR (CDCI3, δ) : 1.30-1.98 (12H, m) , 2.65-2.82 (IH, m) , 3.92 (2H, s) , 6.46 (IH, s), 7.20-7.50 (3H, m) , 7.64-7.80 (2H, m) APCI-MASS (m/z) : 270 (M+H + ) (32) N-Cycloheptyl- ( -phenylthiophen-2-yl)methylamine IR (Neat) : 2924, 2852, 1502, 1458, 1367, 841, 735 cm "1 NMR (CDCI3, δ) : 1.32-1.98 (12H, m) , 2.70-2.88 (IH, m) , 4.01 (2H, s) , 7.19-7.62 (7K, m) 559 - 71 - APCI-MASS (m/z) : 286 (M+H + ) ' 33) N-Cycloheptyl-4- (pyrazol-3-yl)benzylamine IR (Neat) : 2300-3600 (br) , 1514, 1456, 1350, 1205 c "1 NMR (DMSO-d 6 , δ) : 1.20-1.93 (12H, m) , 2.50-2.72 (IH, ) , 3.73 (2H, s), 6.67 (IH, d, J=1.9Hz), 7.30-7.90 (5H, m) , 12.70-13.40 (IH, br) APCI-MASS (m/z) : 270 (M+H x ) (34) N-Cycloheptyl-4- (l-methylpyrazol-3-yl)benzylamine IR (KBr) : 2922, 2852, 1510, 1462, 1429, 1358, 1234 cm -1 NMR (CDC1 3 , δ) : 1.30-1.98 (12H, m) , 2.61-2.78 (IH, ) , 3.80 (2H, s), 3.95 (3H, s), 6.52 (IH, d, J=2.2Hz), 7.29-7.40 (3H, m) , 7.70-7.80 (2H, m) APCI-MASS (m/z) : 284 (M+H + ) (35) N-Cycloheptyl-4- (l-methylpyrazol-5-yl)benzylamine IR (Neat) : 2924, 2854, 1493, 1462, 1385, 1273 cm "1 NMR (CDCI3. δ) : 1.32-1.98 (12H, m) , 2.62-2.81 (IK, m) , 3.83 (2H, s) , 3.89 (3H, s), 6.29 (IH, d, J=1.9Hz), 7.33-7.46 (4H, m) , 7.51 (IH, d, J=1.9Hz) APCI-MASS (m/z) : 284 (M+H + ) (36) N-Cycloheptyl-3- (l-trityl-lH-tetrazol-5-yl)benzylamine IR (KBr) : 2922, 2852, 1697, 1515, 1452, 750, 698 cm "1 NMR (CDCI3, δ) : 1.30-1.95 (12H, m) , 2.62-2.78 (IH, m) , 3.83 (2H, s), 7.10-7.50 (17H, m) , 7.96-8.12 (2H, m) FAB-MASS (m/z) : 514 (M+H + ) (37) N-Cycloheptyl-4- (phenylcarbamoyl)benzylamine IR (KBr) : 3475, 3345, 3055, 2925, 2850, 1645, 1600, 1525, 1505 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.5-2.65 (IH, m) , 3.78 (2H, s), 7.09 (IH, t, J=7.3Hz), 7.35 (2H, s), 7.48 (2H, d, J=8.2Kz) , 7.78 (2K, d, J=7.5Hz), 7.90 (2H, d, J=8.2Hz), 10.20 (IH, s) APCI-MASS (m/z) : 323 (M+H + ) (38) N-Cycloheptyl-4- (phenylsulfonylamino) benzylamine IR (KBr) : 3130, 3015, 2930, 2855, 1610, 1570, 1505 cm "1 NMR (DMSO-d 6 , δ) : 1.2-1.8 (12H, m) , 2.5-2.6 (IH, m) , 3.58 (2H, s) , 6.99 (2H, d, J=8.5Hz), 7.16 (2H, d, J=8.5Hz), 7.45-7.6 (3H, ) , 7.65-7.75 (2H, m) APCI-MASS (m/z) : 359 (M+H + ) Preparation 62 The mixture of 4-formyl-2- (4-chlorophenyl) thiazole (2.24 g) and benzylamine (2.14 g) was stirred at 120°C under nitrogen for 5 hours. The mixture was cooled to roo temperature and dissolved in ethanol (30 ml) . To this solution was added sodium borohydride (378 mg) ana the mixture was stirred at room temperature for 1.1 nours. Th mixture was evaporated to dryness and the residue was extracted with dichloromethane. The organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography to give N-benzyl- [2- (4-chlorophenyl) thiazol- 4-yl]methylamine (3.22 g) . IR (Film) : 3060, 3030, 2915, 2835, 1495 cm "1 NMR (DMS0-d 6 , δ) : 2.64 (IH, br s), 3.67 (2H, s) , 3.78 (2H, s), 7.2-7.4 (5K, ml , 7.52 (IH, s), 7.5- 7.6 (2H, m) , 7.9-8.0 (2H, m) APCI-MASS (m/z) : 315 (M+H + ) Preparation 63 The mixture of 3-bromomethylbiphenyl (6.58 g) and cycloheptylamine (6.03 g) was stirred at 120°C for 3.5 hours under nitrogen. The mixture was cooled to room temperature, and the mixture of dichloromethane and water were added thereto. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N- (3-biphenylylmethyl) - cycloheptylamine (4.49 g) as an orange oil. IR (Film) : 3060, 3030, 2920, 2850, 1460 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 2.7-2.85 (IH, m) , 3.85 (2H, s), 7.3-7.7 (9H, m) APCI-MASS (m/z) : 280 (M+H + ) Preparation 64 The following compounds were obtained according to similar manners to those of Preparations 62 and 63. (1) N-Cycloheptyl-4- (pyridin-3-yl)benzylamine NMR (CDCI3, δ) : 1.3-1.9 (12H, m) , 2.9-3.05 (IH, m) , 7.3-7.6 (5H, m) , 7.8-7.9 (IH, m) , 8.5-8.6 (IH, m) , 8.8-8.85 (IH, m) APCI-MASS (m/z) : 281 (M+H + ) (2) N-Cycloheptyl-4- (pyridin-2-yl) benzylamine IR (Film) : 3050, 3005, 2920, 2850, 1585, 1565 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, ) , 2.6-2.7 (IH, m) , 3.74 (2H, s), 7.25-7.5 (3H, m) , 7.8-8.1 (4H, m) , 8.6-8.7 (IH, m) APCI-MASS (m/z) : 281 (M+H + ) (3) N-Cycloheptyl-4- (4-benzoyl)benzylamine IR (Film) : 3050, 2925, 2850, 1655, 1605 cm "1 NMR (CDCI3, δ) : 1.4-2.0 (12H, m) , 2.6-2.8 (IH, m) , - 74 - 3.87 (2H, s), 7.4-7.65 (5H, m) , 7.75-7.9 (4H, m) APCI-MASS (m/z) : 308 (M+H + ) Preparation 65 To a solution of 3- (2-methylthiazol-4-yl) - benzylamine-hydrochloride (2.41 g) in a mixture of dichloromethane (30 ml) and water (10 ml) was added 5N sodium hydroxide aqueous solution and adjusted to pH 9-10. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. To the residual oil was added cycloheptanone (1.68 g) and the mixture was stirred at 120°C under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (30 ml) . To this solution was added sodium borohydride (378 mg) and the mixture was stirred at room temperature for 2.5 hours. The mixture was evaporated to dryness and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatogaphy on silica gel to give N-cycloheptyl-3- (2-methylthiazol-4-yl)benzylamine (2.07 g) as a yellow oil. IR (Film) : 3380, 2915, 2855, 1455 cm "1 NMR (CDC1 3 , δ) : 1.30-2.0 (12H, m) , 2.7-2.85 (IH, m) , 2.76 (3H, s), 3.82 (2H, s), 7.32 (IH, s) , 7.25-7.4 (2H, m) , 7.75-7.9 (2H, m) APCI-MASS (m/z) : 301 (M+H + ) Preparation 66 To a suspension of N-cycloheptyl-4- (4- benzoyl) benzylamine (1.87 g) in ethylene glycol (10 ml) were added potassium hydroxide (511 mg) and hydrazine monohydrate (1.95 g) , and the mixture was stirred at 150°C for 5 hours and at 200°C for 4 hours. The mixture was poured into a mixture of dichloromethane and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cycloheptyl-4- (4-benzyl)benzylamine (1.29 g) as an orange oil. IR (Film) : 3025, 2905, 2850, 1510 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 2.6-2.8 (IH, m) , 3.74 (2H, s), 3.96 (2H, s), 7.1-7.4 (9H, m) APCI-MASS (m/z) : 294 (M+H + ) Preparation 67 To a solution of 3- (pyrazol-3-yl)benzaldehyde (4.33 g) in pyridine (20 ml) was added trityl chloride (7.71 g) under ice cooling. The mixture was stirred for 30 minutes, and then warmed to room temperature. After stirring for 3 hours at the same temperature, the reaction mixture was poured into ice aqueous hydrochloric acid, extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (eluting with n-hexane - ethyl acetate (2:1)) to give 3- (l-tritylpyrazol-3-yl)benzaldehyde (9.26 g) . IR (KBr) : 3477, 3060, 3030, 1697, 1601, 1491, 1444 cm "1 NMR (DMSO-d 6 , δ) : 6.93 (IH, d, J=2.5Hz), 7.1-7.5 (16H, m) , 7.63 (IH, dd, J=7.7, 7.7Hz), 7.85 (IH, d, J=7.7Hz), 8.08 (IH, d, J=7.7Hz), 8.25 (IH, s), 10.04 (IH, s) Preparation 68 The mixture of 3- (l-tritylpyrazol-3-yl)benzaldehyde (15.31 g) and benzylamine (7.91 g) was stirred at 120°C for 5 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (120 ml). To this solution was added carefully sodium borohydride (1.40 g) at room temperature and the mixture was stirred for 2 hours. - 76 - The mixture was concentrated in vacuo and to the residue were added dichloromethane and ice water. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-benzyl-3- (l-tritylpyrazol-3-yl)benzylamine (12.18 g) as an amorphous solid. IR (KBr) : 3059, 3028, 1599, 1493 cm "1 NMR (DMSO-d 6 , δ) : 3.65-3.75 (4H, m) , 6.77 (IH, d, J=2.5Hz), 7.05-7.45 (18H, m) , 7.55-7.75 (2H, m) Preparation 69 To a suspension of N-benzyl-3- (l-tritylpyrazol-3- yl) benzylamine (8.60 g) in anisole (17.2 ml) was added trifluoroacetic acid (34.4 ml) at room temperature and the mixture was stirred at 80°C for 3.5 hours. The mixture was concentrated in vacuo and the residue was pulverized with diisopropyl ether. The powder was collected by filtration, washed with diisopropyl ether and dried in vacuo to give N- benzyl-3- (pyrazol-3-yl)benzylamine bis ( rifluoroacetate) (7.35 g) . IR (KBr) : 3059, 3005, 1669, 1510, 1489 cm "1 NMR (DMSO-d 6 , δ) : 4.2-4.3 (4H, m) , 6.70-6.75 (IK, m) , 7.1-7.6 (7H, m) , 7X5-8.0 (3K, m) Preparation 70 To a solution of 2, 4-dichloro-6-methyl-3-nitropyridine (30.33 g) in acetonitrile (100 ml) was added dropwise sodium methoxide (28 ' * methanol solution) (85.1 ml) at 5°C, and the mixture was stirred at 80°C for 6 hours. The mixture was cooled and poured into a mixture of ethyl acetate and ice water. The separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 2, 4-dimethoxy- 6-methyl-3-nitropyridine (28.21 g) as a pale yellow crystal . IR (KBr) : 3093, 3035, 3005, 2960, 2868, 1601, 1581, 1531 cm "1 NMR (DMSO-d 6 , δ) : 2.44 (3H, s) , 3.92 and 3.94 (6H, s x 2) , 6.97 (IH, s) APCI-MASS (m/z) : 199 (M+H + ) Preparation 71 To a solution of 2, 4-dimethoxy-6-methyl-3- nitropyridine (28.1 g) in 1,4-dioxane (200 ml) and methanol (100 ml) was added 101 palladium on carbon (14 g) under nitrogen and the mixture was hydrogenated under atmospheric pressure for 4.5 hours. Palladium on carbon was filtered off and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-amino-2, 4-dimethoxy-6-methylpyridine (23.41 g) as an orange oil. IR (Film) : 3458, 3373, 2945, 2856, 1605 cm "1 NMR (DMSO-d 6 , δ) : 2.26 (3H, s) , 3.79 and 3.82 (6K, s x 2), 3.96 (2H, br s) , 6.52 (IH, s) APCI-MASS (m/z) : 169 (M+H + ) Preparation 72 To a solution of 3-amino-2, 4-bis (methylthio) -6- methylpyridine (7.90 g) in dichloromethane (160 ml) was added N,N-dimethylaniline (5.73 g) at 5°C, followed by dropwise addition of phenyl chloroformate (6.78 g) . The mixture was warmed to room temperature and stirred at 4 hours. To the mixture were added ice water (60 ml) and 6N hydrochloric acid (10 ml), and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized, and the crystal was collected by filtration, washed with diisopropyl ether and dried in vacuo to give 3- - 78 - phenoxycarbonylamino-2, 4-bis (methylthio) -6-methylpyridine (10.46 g) . IR (KBr) : 3410, 3228, 3196, 3145, 3003, 2926, 1732, 1591, 1556, 1537 cm "1 NMR (DMS0-d 6 , δ) : 2.45 (6H, s) , 2.46 (3H, s) , 6.94 (IH, s) , 7.0-7.5 (5H, m) , 9.48 (IH, br s) APCI-MASS (m/z) : 321 (M+H + ) Preparation 73 To a solution of 2, 4, 6-trifluoroaniline (883 mg) and N,N-dimethylaniline (0.91 ml) in methylene chloride (18 ml) was added phenyl chloroformate (0.83 ml) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was washed with IN-hydrochloric acid (three times), water, aqueous sodium bicarbonate, water, and brine. The organic layer was dried over magnesium sulfate and evaporated in vacuo. The resulting solid was collected an washed with n-hexane to give phenyl N- (2,4,6- trifluorophenyl) carbamate (1.46 g) . IR (KBr) : 3253, 1749, 1722, 1538, 1240, 1200 cm -1 NMR (CDC1 3 , δ) : 6.26 (IH, br s), 6.70-6.86 (2H, mj , 7.10-7.46 (5H, m) APCI-MASS (m/z) : 268 (M+H + ) Preparation 74 To a solution of 3-amino-2, 4-dimethoxy-6- methylpyridine (23.40 g) in dichloromethane (200 ml) was added N,N-dimethylaniline (20.23 g) , followed by dropwise addition of phenyl chloroformate (23.94 g) at 5°C. The mixture was warmed to room temperature and stirred for 3 hours. The resulting precipitates were collected by filtration, washed with dichloromethane and diisopropyl ether, and dried in vacuo to give 2, -dimethoxy-6-methyl-3- phenoxycarbonylaminopyridine (21.95 g) as a white crystal. IR (KBr) : 3408, 3251, 3147, 3064, 2983, 2947, 286C, 1713 , 1593 , 1497 cm " 1 NMR (DMSO-d 6 , δ ) : 2 . 38 ( 3H, s ) , 3 . 85 ( 6H, s ) , 6.72 (IH, s), 7.05-7.3 (3H, m) , 7.35-7.45 (2H, m) , 8.83 (IH, br) APCI-MASS (m/z) : 289 (M+H + ) Preparation 75 A mixture of 4- (4-bromophenoxy)benzaldehyde (10.0 g) and benzylamine (5.42 g) was stirred at 120°C for 4 hours. After cooling to room temperature, the resulting solid was suspended in ethanol (150 ml) . To the suspension was added carefully sodium borohydride (1.36 g) , and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with methylene chloride. The organic layer was washed with water, brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (250 g, eluting with methylene chloride - methanol (20: IX to give N-ben∑yl-4- (4- bromophenoxy)benzylamine (11.51 g) as a pale yellow oil. IR (Neat) : 3061, 3028, 2700-3000 (br) , 1608, 1583, 1504, 1481, 1240 cm "1 NMR (CDC1 3 , δ) : 3.79 (2H, s), 3.82 (2H, s), 6.80-7.00 (4H, m) , 7.20-7.5C (9H, ) APCI-MASS (m/z) : 368, 370 (M+H " ) Preparation 76 The mixture of 3- (l-trityIpyrazol-3-yl)benzaldehyde (9.18 g) and cycloheptylamine (3.75 g) was stirred at 12C°C for 4 hours. The mixture was cooled to room temperature and dissolved in ethanol (120 ml) . To this solution was added sodium borohydride (836 mg) and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and extracted with methylene chloride. The organic layer was washed with water and brme, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel (eluting with methylene chloride - methanol ,40:1 to 10:1) ) to give N-cycloheptyl-3- (l-trιtylpyrazol-3-yl)benzylamine (7.92 g) . NMR (DMSO-d 6 , δ) : 1.20-1.90 (12K, m) , 2.50-2.70 (IH, ) , 3.69 (2H, s), 6.77 (IH, d, J=2.5Hz), 7.05- 7.50 (12H, m) , 7.55-7.65 (IH, m) , 7.71 (IH, s) APCI-MASS (m/z) : 512 (M-^H + ) Preparation 77 To a suspension of 3-amιno-2, , 6- trimethylpyndine-hydrochloride (5.18 g) m 1,2- dichloroethane (120 ml; was added dnsopropylethylamine (19.39 g) at room temperature, followed by addition of phenyl chloroformate (7.05 g) . The mixture was refluxed for 10 hours under nitrogen. The mixture was cooled and poured into ice water. The separated organic layer was washed with brme, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3- phenoxycarbonylamιno-2, 4, 6-trιmethyl pyridme as a crude orange oil (3.17 g) . IR (KBr) : 3275, 2924, 1740, 1713, 1605, 1550 cm "1 NMR (DMSO-d 6 , δ) : 2.22 (3H, s), 2.39 (6H, s), 7.01 (IH, s), 7.2-7.6 (5H, m) , 9.42 (IH, brs) APCI-MASS (m/z) : 257 (M+H + ) Preparation 78 To a suspension of 4-chloro-6-methyl-2-methylthιo-3- mtropyridme (16.0 g) in a mixture of 1,4-dιoxane (200 ml and methanol (50 ml) was added Raney-N ckel (NDT-90; trademark: Kawaken fine chemicals) (ca. 30 g) under nitrogen, and the mixture was hydrogenated under atomospheric pressure for 3 hours. Raney-Nickel was filtered off and the filtrate was evaporated in vacuo. The residue was purified by column chromatography ' on silica gel to give 3-amino-2-chloro-6-methyl-4-methylthiopyridine (12.86 g) as an orange oil. IR (film) : 3424, 3322, 2922, 1707, 1606, 1570, 1529 cm "1 NMR (DMSO-d 6 , δ) : 2.29 (3H, s), 2.31 (3H, s), 4.93 (2H, brs), 6.98 (IH, s) APCI-MASS (m/z) : 191, 189 (M+H + ) Preparation 79 To a solution of 3-amino-4-ch_loro-6-methyl-2- methylthiopyridine (12.75 g) in dichloromethane (200 ml) was added N,N-dimethylaniline (6.00 g; at 5°C, followed by dropwise addition of phenylchloroformate (7.11 g) . The mixture was warmed to room temperature and stirred at the same temperature for 4 hours. The mixture was washed with dilute hydrochloric acid and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was triturated with diisopropyl ether and collected by filtration, washed with diisopropyl ether and dried n vacuo under phosphorus pentoxide to give 2-chloro-6-methyl- 4-methylthio-3-phenoxycarbonylaminopyridine (9.58 g) . IR (KBr) : 3194, 2924, 1751, 1579, 1514, 1489 cm "1 NMR (DMSO-d 6 , δ) : 2.29 (3H, s), 2.50 (3H, s), 6.7-6.85 (3H, ) , 6.98 (IH, s), 7.1-7.25 (2H, m) , 9.35 (IH, brs) Preparation 80 To a solution of 3, 5-di-tert-butyl-4-hydroxyphenol (9.65 g) and imidazole (3.55 g) in N,N-dimethylformamide (80 ml) was added tert-butyldimethylsilyl chloride (6.54 g' at 5°C, and the mixture was stirred at room temperature for 3 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-tert- butyldimethylsilyloxy-3, 5-di-tert-butyl-4-hydroxybenzene (13.91 g) as a white solid. IR (KBr) : 3651, 2958, 2929, 2858, 1601, 1470 cm "1 NMR (CDC1 3 , δ) : 0.18 (6H, s), 0.91 (9H, s) , 1.41 (18H, s), 6.73 (2H, s) APCI-MASS (m/z) : 336 (M + ) Preparation 81 To a suspension of sodium hydride (60% oil dispersion) (1.65 g) in N,N-dimethyl ormamide (100 ml) was added dropwise a solution of l-tert-butyldimethylsilyloxy-3, 5-di- tert-butyl-4-hydroxybenzene (13.89 g) in N,N- dimethylformamide (70 ml) at 5°C, and the mixture was stirred at the same temperature for 1 hour. To the resulting solution was added chloromethyl methyl ether (4.99 g) at 5°C and the mixture was stirred at room temperature for 5 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- tert-butyldimethylsilyloxy-3, 5-di-tert-butyl-4-methoxy methoxybenzene (13.49 g) as a yellow solid. IR (KBr) : 2962, 2929, 2897, 2860, 1597 cm "1 NMR (CDCI3, δ) : 0.19 (6H, s) , 0.9S (9K, s) , 1.41 (18H, s), 3.62 (3H, s), 4.86 (2H, s) , 6.72 (2H, s) AFCI-MASS (m/z) : 331 (M+H + ) Preparation 92 To a solution of l-tert-butyldimethylsilyloxy-3, 5-di- tert-butyl-4-methoxymethoxybenzene (13.42 g) in tetrahydrofuran (20 ml) was added 1.0M solution of tetrabutylammonium fluoride (38.8 ml) at room temperature and the mixture was stirred at the same temperature for 2 hours. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3,5-di-tert- butyl-4-methoxymethoxyphenol (9.43 g) as a yellow crystal. IR (KBr) : 3369, 3012, 2958, 2910, 2870, 2779, 1610, 1589 cm "1 NMR (CDC1 3 , δ) : 1.42 (18H, s) , 3.63 (3H, s) , 4.87 (2H, s), 6.74 (2H, s) Preparation 83 To a solution of 1- (4-fluorophenoxy) -4-nitrobenzene (22.9 g) in ethyl acetate (200 ml) was added 10% palladium- carbon (50% wet) (9.16 g) , and the mixture was hydrogenated under atmospheric pressure at room temperature for 3 hours. Palladium on carbon was filtered off and washed with tetrahydrofuran. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 4- (4-fluorophenoxy)aniline (18.27 g) as a red powder. IR (KBr) : 3450, 3395, 3325, 3230, 3070 3045, 3020, 1635, 1490 cm -1 NMR (CDCI3, δ) : 6.65-6.75 (2H, m) , 6.8-7.05 (6H, ) APCI-MASS (m/z) : 204 (M+H + ) Preparation 84 To a solution of 3- (4-fluorophenoxy)benzyl alcohol (3.97 g) in chloroform (50 ml) was added activated manganese dioxide (15.82 g) and the mixture was refluxed for 4.5 hours. Manganese dioxide was filtered off and the filtrate was evaporated in vacuo to give crude 3- (4- fluorophenoxy) benzaldehyde (3.81 g) as a yellow oil. IR (Film) : 3074, 2837, 2819, 2731, 1701, 1585, 1502, 1481, 1450 cm "1 NMR (DMSO-d 6 , δ) : 7.1-7.45 (6H, m) , 7.55-7.75 (2H, m) , 9.98 (IH, s) Preparation 85 To a suspension of lithium aluminum hydride (5.69 g) in tetrahydrofuran (300 ml) was added dropwise a solution of 4- (4-fluorophenoxy) benzonitrile (21.32 g) in tetrahydrofuran (200 ml) at 5°C, and the mixture was stirred at room temperature for 4 hours. To the mixture was added sodium fluoride (16.80 g) , followed by dropwise addition of cold water (5.41 g) and the mixture was stirred at room temperature for 45 minutes. The insoluble materials were filtered off and washed with tetrahydrofuran. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 4- (4-fluorophenoxy)benzylamine (21.39 g) as a yellow oil. IR (KBr) : 3352, 3269, 3043, 2864, 1645, 1606, 1495 cm "1 NMR (DMSO-d 6 , δ) : 3.69 (2H, s), 6.9-7.4 (8H, m) APCI-MASS (m/z) :201 (M+K + -NH 3 ! Preparation 86 To a solution of phenyl chloroformate (31.2 g) in 1,2- dichloroethane (250 ml) was added dropwise a solution of 3-amino-2, 4, 6-trimethylpyridine (22.62 g) in 1,2- dichloroethane (120 ml) at 100°C, and the mixture was refluxed for 1 hour under nitrogen. The mixture was cooled to room temperature and added dropwise a mixture of ethyl acetate (2 .) and tetrahydrofuran (1 C) . The precipitates were collected by filtration, washed with ethyl acetate and diisopropyl ether and dried in vacuo over phosphorus pentoxide to give 2, 4, 6-trimethyl-3- phenoxycarbonylaminopyridine-hydrochloride (48.84 g) . IR (KBr) : 3413, 1741, 1645, 1541, 1483 cm "1 NMR (DMS0-d 6 , δ) : 2.49 (3H, s), 2.69 (6H, s), 7.2-7.5 (5H, m) , 7.65-7.75 (IH, m) , 9.63 and 10.20 (total IH, br s) APCI-MASS (m/z) : 257 (M+H + -HC1) Preparation 87 To a solution of 5-amino-4, 6-bis (methylthio) -2- methylpyrimidine (4.10 g) in dichloromethane (80 ml) was added N,N-dimethylaniline (2.96 g) at 5°C, followed by dropwise addition of phenyl chloroformate (3.51 g) . The mixture was stirred at room temperature for 2 hours under nitrogen. The mixture was washed with dilute hydrochloric acid and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was triturated with diisopropyl ether collected by filtration, washed with diisopropyl ether and dried in vacuo to give 4, 6-bis (methylthio) -2- methyl-5-phenoxycarbonylaminopyrimidine . (5.74 g) . IR (KBr) : 3217, 3005, 2924, 1711, 1595, 1485 cm "1 NMR (DMSO-d 6 , δ) : 2.49 (6H, s), 2.59 (3H, s), 7.0-7.5 (5H, m) , 9.27 and 9.68 (total IH, s) APCI-MASS (m/z) : 322 (M+H + ) Preparation 88 To a solution of 2- (3-bromophenyl) -1, 3-dioxoiane (20.42 g) and triisopropoxyborane (25.14 g) in tetrahydrofuran (350 ml) was added dropwise n-butyllithium (1.70M hexane solution, 78.8 ml) at -72°C over 2-hours under nitrogen. The mixture was warmed to room temperature and stirred for 21 hours. The mixture was poured into a mixture of ethyl acetate and dilute hydrochloric acid and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in - 66 - vacuo. The residue was purified by column chromatography on silica gel to give crude dihydroxy- (3-formylphenyl) - borane (14.83 g) . IR (KBr) : 3354, 2840, 1678, 1603, 1581 cm "1 NMR (DMSO-d 6 , δ) : 7.55-7.7 (IH, ) , 7.8-8.15 (2H, ) , 8.33 (2H, s), 10.03 (IH, s) Preparation 89 To a suspension of 4-bromo-l-tritylpyrazole (18.96 g) and crude dihydroxy- (3-formyiphenyl)borane (14.6 g) in toluene (400 ml) were added powdered potassium carbonate (10.10 g) and tetrakis (triphenylphosphine)palladium(C) (2.81 g) , and the mixture was refluxed for 6 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with brine., dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3- (l-tritylpyrazol-4-yl)benzaldehyde (2.65 g) as a yellow solid. IR (KBr) : 3057, 3024, 2812, 2727, 1699, 1603, 1585 cm "1 NMR (DMSO-d 6 , δ) : 7.0-7.15 (5H, ) , 7.35-7.5 (ICK, m) , 7.7-7.85 (2H, m) , 7.97 (IK, d, J=7.7Hz), 8.13 (IH, d, J=7.7Hz), 8.31 (IH, s), 10.13 (IH, s) Preparation 90 To a solution of 3-bromobenzaldehyde (1.25 g) and l-methyl-4-tri-n-butylstanniopyrazole (3.0 g) was added tetrakis (triphenylphosphine)palladiu (0) (234 mg) . Then the mixture was heated for 4 hours at 140°C. After cooling, the reaction mixture was diluted with toluene (16 ml) . An aqueous solution (14 ml) of potassium fluoride (4.7 g) was added to the mixture and stirred for one hour. Insoluble material was filtered off. The filtrate was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed on silica gel (60 g, eluting with n-hexane - ethyl acetate (1:2)) to give 3- (l-methylpyrazol-4-yl)benzaldehyde (978.1 mg) . IR (Neat) : 2943, 2818, 1686, 1608, 1230, 1174 cm "1 NMR (CDC1 3 , δ) : 3.98 (3H, s) , 7.47-7.58 (IH, ) , 7.65-7.78 (3H, m) , 7.83 (IH, s), 7.93-7.98 (IH, m) , 10.04 (IH, s) APCI-MASS (m/z) : 187 (M+H + ) re p aration 9 To a solution of 3- [ (E) -3-dimethylaminopropenoyl] - benzonitrile (8 g) in acetic acid (80 ml) was added methylhydrazine (2.23 ml) . The mixture was stirred for 3.5 hours at room temperature. To the solution was added 5N- sodium hydroxide aqueous solution in order to basify under ice cooling and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate solution, water, brine, dried over magnesium sulfate, evaporated in vacuo. After chromatography on silica gel (eluting with dichloromethane-methanol) , 3-(l- methylpyrazol-3-yl)benzonitrile (4.45 g) and 3-(l- methylpyrazol-5-yl)benzonitrile (2.09 g) were obtained. 3- (l-Methylpyrazol-3-yl)benzonitrile; mp : 97-98°C IR (KBr) : 3115, 2935, 2220, 1602, 1471, 1352, 1246 cm "1 NMR (CDC1 3 , δ) : 3.97 (3H, s), 6.56 (IH, d, J=2.3Hz), 7.37-7.60 (3H, m) , 7.95-8.10 (2H, m) APCI-MASS (m/z) : 184 (M+H + ) 3- (l-Methylpyrazol-5-yl)benzonitrile, • p : 95-97°C IR (KBr) : 3066, 2951, 2231, 1475, 1416, 1335, 1236 cm 1 NMR (CDCI3, δ) : 3.92 (3H, s), 6.37 (IH, d, J=1.5Hz), 7.50-7.75 (5H, m) APCI-MASS (m/z) : 184 (M+H + ) Preparation 92 A mixture of 3- (bromoacetyl) benzonitrile (38.2 g) and formamide (190 ml) was heated for 30 minutes at 185°C and cooled to room temperature. The mixture was poured into saturated sodium bicarbonate solution (400 ml) and extracted with ethyl acetate (1.8 t) . The organic layer was washed with water and brine, dried over magnesium sulfate. After evaporation to 200 ml, the resulting precipitate was collected by filtration, washed with ethyl acetate - isopropyl ether (2:1) to give 3- (imidazol-4- yl) benzonitrile (13.3 g) . mp : 190-191°C IR (KBr) : 2250-3240 (br) , 2224, 1606, 1477, 1333, 1070, 970, 824, 789 cm "1 NMR (DMSO-d 6 , δ) : 7.50-7.68 (2H, m) , 7.70-7.87 (2H, m) , 8.05-8.20 (2H, m) , 12.32 (IH, br) APCI-MASS (m/z) : 170 (M+H + ) Preparation 93 To a solution of methyl 4-formylbenzoate (5.0 g) in ethanol (50 ml) was added sodium borohydride (576 mg) carefully at 0-5°C and stirred for 30 minutes. The mixture was poured into water and extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give methyl 4-hydroxymethylbenzoate (5.06 g) . IR (KBr) : 2750-3670 (br) , 1722, 1614, 1437, 1286, 1111, 1047, 1016, 756 cm "1 NMR (CDCI3, δ) : 1.89 (IH, t, J=5.9Hz), 3.92 (3H, s), 4.77 (2H, d, J=5.9Hz), 7.37-7.50 (2H, m) , 7.97- 8.10 (2H, ) APCI-MASS (m/z) : 167 (M+H + ) Preparation 94 To a solution of methyl 4-hydroxymethylbenzoate (5.0 g) and imidazole (4.1 g) in N,N-dimethylformamide (25 ml) was added tert-butyldi ethylsilyl chloride (4.77 g) carefully at 0-5°C and stirred for 2 hours at room temperature. The reaction mixture was poured into 0.1N hydrochloric acid (100 ml) and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give methyl 4- (tert-butyldimethylsilyloxymethyl)benzoate (8.43 g) . IR (Neat) : 2954, 2859, 1724, 1464, 1281, 1107, 841 cm "1 NMR (CDC1 3 , δ) : 0.11 (6H, S), 0.95 (9H, s) , 3.91 (3H, s), 4.79 (2K, s), 7.34-7.44 (2H, m) , 7.95- 8.05 (2H, m) APCI-MASS (m/z) : 281 (M+H + ) Preparation 95 A mixture of methyl 4- (tert-butyldimethylsilyloxy- methyl)benzoate (1.0 g) and hydrazine monohydrate (0.87 ml) in ethanol (0.8 ml) was refluxed for one hour. After cooling to room temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give [4-(tert- butyldimethylsilyloxymethyl)benzoyl]hydrazine (1.0 g) . mp : 83-85°C IR (KBr) : 3273 (br) , 2954, 2858, 1662, 1599, 1539, 1335, 1254, 1093, 841 cm "1 NMR (DMSO-d 6 , δ) : 0.08 (6H, s), 0.91 (9H, s), 4.47 (2H, s), 4.75 (2H, s), 7.30-7.40 (2K, m) , 7.75- - 90 - 7.85 (2H, m) , 9.72 (IH, s) APCI-MASS (m/z) : 281 (M+H + ) Preparation 96 To a mixture of [4- (tert-butyldimethylsilyloxymethyl) - benzoyl] hydrazine (8.0 g) and ethyl acetimidate-hydrochloride (4.24 g) in ethanol (160 ml) was added triethylamine (4.8 ml) at room temperature and stirred for 30 minutes. The reaction mixture was evaporated in vacuo. Then the residue was dissolved in ethyl acetate (120 ml), washed with water and brine. The organic layer was dried over magnesium sulfate, evaporated in vacuo. And the residue was heated for 10 minutes at 200°C, cooled to room temperature, chromatographed on silica gel (200 g, eluting with n-hexane - ethyl acetate (2:1) ) to give 2- [4- (tert-butyldimethylsilyloxymethyl) - phenyl] -5-methyl-l, 3, 4-oxadiazole (6.35 g) . mp : 62-65°C IR (KBr) : 2956, 2933, 2897, 2860, 1576, 1502, 1257, 1086, 843 cm "1 NMR (DMSO-d 6 , δ) : 0.10 (6H, s), 0.92 (9H, s) , 2.58 (3H, s), 4.80 (2H, s), 7.45-7.55 (2K, m; , 7.90- 8.00 (2H, m) APCI-MASS (m/z) : 305 (M-*-H + ) Preparation 97 To a solution of 2- [4- (tert-butyldimethylsilyloxy- methyl) phenyl] -5-methyl-l, 3, 4-oxadiazole (2.0 g) in methanol (20 ml) was added IN hydrochloric acid (13 ml) dropwise at 0-5°C and stirred for one hour. The reaction mixture was recooled to 0-5°C, and sodium bicarbonate (1.15 g) was added thereto carefully. The mixture was extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The resulting precipitate was collected by filtration ana washed with 559 - 91 - n-hexane to give 2- (4-hydroxymethylphenyI) -5-methyl- (1, 3, - oxadiazole (0.75 g) . IR (KBr) : 3323 (br) , 2877, 2819, 1614, 1576, 1416, 1257, 1053, 833, 729 cm "1 NMR (DMSO-d 6 , δ) : 2.58 (3H, s) , 4.59 (2H, d, J=5.4H∑), 5.39 (IH, t, J=5.4Kz), 7.47-7.57 (2H, ) , 7.87-7.97 (2H, m) APCI-MASS (m/z) : 191 (M+H + ) Preparation 98 A mixture of 2- [4- (tert-butyldi ethylsilyloxymethyl) - phenyl] -5-methyl-l, 3, 4-oxadiazole (5.05 g) and benzylamine (18 ml) was heated for 2 drops at 150°C. After cooling to room temperature, the mixture was chromatographed on silica gel (250 g, eluting with dichloromethane-methanol (20:1)) to give 4-benzyl-3- [4- (tert-butyldimethylsilyloxymethyl) - phenyl] -5-methyl-4H-l,2, 4-triazole (5.04 g) . mp : 90-91°C IR (KBr) : 2953, 2929, 2885, 2854, 1524, 1460, 1431, 1255, 1101, 1003, 835 cm "1 NMR (CDC1 3 , δ) : 0.08 (6H, s), 0.94 (9H, s), 2.37 (3H, s), 4.77 (2H, s), 5.16 (2H, s), 6.90-7.03 (2H, m) , 7.27-7.55 (7H, m) APCI-MASS (m/z) : 394 (M+K + ) Pre aration 99 To the solution of N-cycloheptyI-4- (4-benzyl-5-methyl- 4H-1, 2, 4-triazol-3-yl)benzylamine (500 mg) in methanol (25 ml) was added Palladium Black (500 mg) and formic acid (1.25 ml) . The mixture was stirred for 4.5 hours at the room temperature. Palladium Black was removed by filtration. The filtrate was basified with IN sodium hydroxide aqueous solution under ice cooling and evaporated in vacuo to dryness. The residue was diluted with dichloromethane-methanol (5:1), dried over magnesium - 92 - sulfate, evaporated in vacuo. After chromatography on silica gel (15 g, eluting with dichloromethane-methanol (4:1) ) N-cycloheptyl-4- (5-methyl-4H-I, 2, 4-triazol-3- yl) benzylamine (219.6 mg) was isolated. IR (KBr; : 2500-3700 (br) , 2926, 2854, 1564, 1458, 1099 cm "1 NMR (CDC1 3 , δ) : 1.30-2.00 (12H, m) , 2.48 (3H, s), 2.65-2.80 (IH, ) , 3.83 (2H, s), 4.60-5.15 (2H, br), 7.30-7.40 (2H, m) , 7.90-8.00 (2H, m) APCI-MASS (m/z) : 285 (M÷H T ) Preparation 100 To the solution of 3- (lH-tetrazol-5-yl) benzaldehyde (600 mg) in N, -dimethylformamide (6 ml ) was added sodium hydride (60 r 6 oil suspension, 138 mg) at 0-5°C. After stirring for 15 minutes, to the mixture was added methyl iodide (0.43 ml) . The solution was stirred for 3 hours at room temperature, then stirred for 30 minutes at 40°C. The reaction mixture was poured into water and extracted with ethyl acetate, washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. After chromatography on silica gel (25 g, eluting with n-hexane - ethyl acetate (1:1), 3- (2-methyl-2H-tetrazol-5- yl) benzaldehyde (510.7 mg) and 3- (l-methyl-lH-tetrazoI-5- yl) benzaldehyde (81.6 mg) was obtained. 3- (2-Methyl-2H-tetrazol-5-yl) benzaldehyde mp : 98-99°C IR (KBr) : 3072, 2839, 1691, 1587, 1520, 1443 cm "1 NMR (DMSO-d 6 , δ) : 4.47 (3H, s), 7.81 (IH, dd, J=7.7, 7.7Hz), 8.05-8.10 (IH, ) , 8.33-8.40 (IH, m) , 8.55-8.58 (IH, m) , 10.14 (IH, s) APCI-MASS (m/z) : 189 (M+H ÷) 3- (1-Methyl-lH-tetrazol-5-yl) enzaldehyde - 93 - IR (KBr) : 1699, 1608, 1535, 1450, 1394 cm "1 NMR (DMSO-d 6 , δ) : 4.22 (3H, s), 7.87 (IH, dd, J=7.7, 7.7Hz), 8.13-8.25 (2H, m) , 8.38-8.40 (IH, m) , 10.14 (IH, s) APCI-MASS (m/z) : 189 (M+H + ) Preparation 101 To the solution of 4-fluoroben∑aldehyde (3.0 g) and iH-1, 2, 4-trιazole (2.0 g) m N,N-dimethylformamide (30 ml) was added potassium carbonate (4.0 g) . Then the mixture was heated for one hour at 120°C. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water, brme, dried over magnesium sulfate and evaporated m vacuo. The resulting solid was collected and washed with diisopropyl ether to give 4- (1H-1, 2, 4-tπazol- 1-yl)benzaldehyde (1.95 g) . mp : 147-148°C IR (KBr) : 3130, 2856, 1709, 1603, 1518, 1441, 1275 cm - NMR (CDC1 3 , δ) : 7.88-8.01 (2H, m) , 6.01-8.14 (2H, m) , 8.16 (IH, s), 8.70 (IH, s), 10.07 (IH, si APCI-MASS (m/z) : 174 (M-"-H + ) Preparation 102 To a solution of 4-fluorobenzaldehyde (5.0 g) and 1K- 1, 2, 3-trιazole (3.33 g) in N, -dimethylformamide (50 il was added potassium carbonate (6.68 g) . Then the mixture was heated for one hour at 120°C. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml) , washed with water, brme, dried over magnesium sulfate ana evaporated to about 50 ml m vacuo. The resulting precipitate was collected by filtration, washed witn n- hexane to give 4- (1H-1,2, 3-trιazol-l-yl)oenzaldehyde (3.44 g) . The mother liquid was evaporated to about 10 mi n vacuo. The resulting precipitate was also collected the - 94 - similar procedure as mentioned above to give 4-(2H-l,2,3- trιazol-2-yl) benzaldehyde (297 mg) . 4- (1H-1, 2, 3-Tπazol-l-yl)benzaldehyde IR (KBr) : 3138, 3116, 2845, 1695, 1603, 1516, 1419, 1389 cm "1 NMR (CDC1 3 , δ) : 7.91 (IH, s) , 7.93-8.11 (4H, m) , 8.12 (IH, s), 10.09 (IH, s) APCI-MASS (m/z) : 174 (M+H + ) 4- (2H-1, 2, 3-Trιazol-2-yl)benzaldehyde IR (KBr) : 3114, 3084, 2715, 1699, 1603, 1508, 1408, 1383 cm "1 NMR (CDCI3, δ) : 7.89 (2H, s) , 7.95-8.06 (2H, m) , 8.23-8.33 (2H, m) , 10.06 (IH, s) APCI-MASS (m/z) : 174 (M+H + ) Preparation 103 To a solution of 4-fluorobenzaldehyde (6.21 g) in N, -dimethylformamide (100 ml) were added 11-methylpιperazme (6.01 g) and powdered potassium carbonate (8.29 g) , and the mixture was stirred at 150°C for 4.5 hours under nitrogen. The mixture was poureα into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brme, αried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to g ve 4- (4-methylpιperazm-l-yl)benzaldehyde (5.31 g) as a yellow solid. IR (KBr) : 2935, 2840, 2790, 2750, 1690, 1600, 156C, 1520 cm "1 NMR (DMSO-d 6 , δ) : 2.22 (3H, s), 2.4-2.5 (4H, m) , 3.35-3.45 (4H, m) , 7.04 (2H, d, J=8.8Hz) , X7C (2H, d, J=8.8Hz), 9.71 (IK, s) Preparation 104 To a solution of 4-bromoaniline (6.88 g) in pyridine (20 ml) was added dropwise methanesulfonyl chloride (4.58 g) at 5°C and the mixture was stirred at 5°C for 1.5 hours and at room temperature for 1.5 hours. The mixture was poured into a mixture of ethyl acetate and dilute hydrochloric acid and the insoluble materials were filtered off. The filtrate was separated and the organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized and the crystal was collected by filtration, washed with diisopropyl ether and dried to give 4-bromo-N- methylsulfonylaniline (8.30 g) . IR (KBr) : 3290, 1490 cm "1 NMR (DMSO-d 6 , δ) : 3.00 (3H, s) , 7.16 (2H, d, J=8.7Hz), 7.52 (2H, d, J=8.7Hz), 9.92 (IH, br) Preparation 105 To a suspension of N-methyl-N-methoxy-4- sulfamoylbenzamide (3.53 g) and benzole acid (1.95 g) in dichloromethane (100 ml) were added 4-dimethylaminopyridme (1.96 g) and 1- (3-dimethylaminopropyl) -3-ethyl carbodiimide-hydrochloride (3.07 g) at room temperature and the mixture was stirred at the same temperature for 18 hours. The mixture was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-methyl-N-methoxy 4- (N-benzoylsulfamoyl) benzamide (1.35 g) . IR (KBr) : 3072, 2970, 2937, 1649, 1597, 1560, 1544 cm "1 NMR (DMSO-d 6 , δ) : 3.27 (3H, s), 3.55 (3H, s), 7.35- 7.5 (3K, m) , 7.68 (2H, d, J=8.2Hz), 7.85-7.95 (2H, m) , 7.96 (2H, d, J=8.2Hz) APCI-MASS (m/z) : 349 (M+H + ) - 96 - Preparation 106 To a suspension of 4-cyanobenzaldehyde (26.23 g) was added carefully sodium borohydride (3.78 g) at room temperature, and the mixture was stirred at the same temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo to give crude 4-cyanobenzyl alcohol (24.97 g) as an oil. IR (Film) : 3419, 2916, 2875, 2229, 1610 cm "1 NMR (CDC1 3 , δ) : 2.07 (IH, br) , 4.79 (2H, br s) , 7.41 (2H, d, J=8.1Hz), 7.65 (2H, d, J=8.1Hz) APCI-MASS (m/z) : 134 (M+H + ) Preparation 107 To a solution of 4-cyanobenzyl alcohol (24.96 g) in N,N-dimethylformamide (100 ml) were added imidazole (16.0 g) and tert-butyldimethylsilyl chloride (31.0 g) at room temperature and the mixture was stirred for 2 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(tert- butyldimethylsilyloxymethyl)benzonitrile (40.78 g) as an oil. IR (Film) : 2954, 2429, 2885, 2858, 2229, 1610 cm "1 NMR (CDCI3, δ) : 0.11 (6H, s), 0.95 (9H, s), 4.79 (2H, s), 7.43 (2H, d, J=8.3Hz), 7.63 (2H, d, J=8.3Hz) APCI-MASS (m/z) : 248 (M+H " X Preparati n 108 To a solution of n-butyllithium (1.71M hexane solution, 58.5 ml) in diethyl ether (150 ml) was added dropwise 3-bromopyridine (15.8 g) at 5°C, and the mixture was stirred at 5°C for an hour. The mixture was cooled to -6C°C and a solution of 4- (tert-butyldimethylsiiyl- oxymethyl)benzonitrile (19.79 g) in diethyl ether (80 ml) was added dropwise over 1.2 hours under nitrogen. The mixture was gradually warmed to room temperature and stirred at the same temperature for additional 2 hours. The mixture was poured into a mixture of ethyl acetate and dilute hydrochloric acid, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-[(4-tert- butyldimethylsilyloxymethyl)benzoyl]pyridine (4.96 g) as a red oil. IR (Film) : 3034, 2954, 2930, 2835, 2856, 1660, 1608, 1585, 1537 c "1 NMR (CDC1 3 , δ) : 0.16 (όH, s), 0.99 (9H, s), 4.87 (2H, s), 7.50 (2H, d, J=7.6Hz), 7.83 (2H, d, J=7.6Kz), 7.4-7.5 (IH, m) , 8.1-8.2 (IH, ) , 8.6- 8.9 (IH, n) , 8.99 (IH, d, J=2.1Hz) APCI-MASS (m/z) :328 (M J -H + ) Preparation 109 To a suspension of 3- [ (4-tert-butyldimethylsilyloxy- methyl)benzoyl]pyridine (4.94 g) in ethylene glycol (40 ml) were added potassium hydroxide (1.27 g) and hydrazine hydrate (4.84 g) and the mixture was stirred at 150°C for 2 hours and at 200°C for 4 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (3-pyridylmethyl)benzyl alcohol (1.26 g) as an orange oil. IR (Film) : 3323, 3030, 2920, 2868, 1579, 1549, 1514 cm "1 NMR (CDC1 3 , δ) : 1.85 (IH, br) , 3.97 (2H, s), 4.67 (2H, ε), 7.15-7.5 (6H, ) , 8.45-8.55 (2H, ml APCI-MASS (m/z) : 200 (M+H~i ■ 5 Preparation 110 To a solution of 4- (3-pyridylmethyl)benzyl alcohol (1.26 g) in chloroform (30 mi) was activated manganese dioxide (5.50 g) and the mixture was refluxed for 2 hours. 10 Manganese dioxide was removed off and the filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 4- (3-pyridylmethyl) - benzaldehyde (1.09 g) as an orange oil. IR (Film) : 3029, 2989, 2910, 2831, 2738, 1697, 1599, 15 1510 cm "1 NMR (CDCI3, δ) : 4.07 (2H, s), 7.24 (IH, dd, J=7.8, 4.8Hz), 7.35 (2H, d, J=8.1Hz), 7.47 (IK, dd, J=7.8, 1.4Hz), 7.83 (2H, d, J=8.1Hz), 8.49 (IH, d, J=1.4Hz), 8.51 (IH, s), 9.99 (IH, s) 20 APCI-MASS (m/z) : 198 (M+K + ) Preparation 111 To a solution of l-ethoxycarbonyl-4-diethylphosphono- 1, -dihydropyridine (34.71 g) in tetrahydrofuran (200 ml) 25 was added dropwise n-butyllithium (1.71M hexane solution, 70.2 ml) at -60°C over 30 minutes under nitrogen, and the mixture was stirred at -60°C for 40 minutes. To this solution was added dropwise a solution of 4-cyanobenzyI bromide (27.40 g) in tetrahydrofuran (SO ml) at -60°C and 30 the mixture was gradually warmed to room temperature and stirred for 21 hours. The mixture was poured into a mixture of ethyl acetate and dilute hydrochloric acid, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in 35 vacuo. The residue was purified by column chromatography on silica gel to give l-ethoxycarbonyI-4- (4-cyanobenzyl) -4- diethylphosphono-1, 4-dihydropyridine (47.10 g) as a crude red oil. IR (Film) : 3053, 2891, 2933, 2903, 2227, 1728, 1689, 1626, 1606 cm "1 NMR (CDC1 3 , δ) : 1.2-1.4 (9H, m) , 3.06 (2H, d, J=7.6Hz), 4.1-4.3 (6H, m) , 4.7-4.9 (2H, m) , 7.65-7.9 (2H, ) , 7.22 (2H, d, J=8.2Hz), 7.55 (2H, d, J=8.2Hz) APCI-MASS (m/z) : 405 (M+H x ) Preparation 112 To a solution of l-ethoxycarbonyl-4- (4-cyanobenzyl) -4- diethylphosphono-1, -dihydropyridine (42.10 g) in dichloromethane (350 ml) was added dropwise diisobutylaluminum hydride (1.01M toluene solution, 515 ml) at -60°C over 55 minutes and the mixture was stirred at - 60°C for 1.5 hours. The mixture was gradually warmed to 5°C and stirred at 5°C for 1.5 hours. To the mixture were added sodium fluoride (87.34 g) and water (28.11 g) and tne mixture was stirred at room temperature for an hour. The insoluble materials were filtered off and washed with dichloromethane. The filtrate was evaporated in vacuo and the residue was dissolved in tetrahydrofuran (200 mi) . To this solution was added 6N hydrochloric acid (30 ml) and the mixture was stirred at room temperature for 3 hours. The mixture was adjusted to pH ca. 8 by addition of 5N sodium hydroxide and extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (4-pyridylmethyl)benzaldehyde (4.62 g) as a red oil. IR (Film) : 3381, 3053, 3030, 2924, 2831, 2738, 1697, 1606, 1576 cm "1 NMR (CDC1-5, δ) : 4.08 (2H, s), 7.1-7.2 (2K, ) , 7 . 3- 7 . 4 5 ( 2H, m) , 7 . 8-7 . 9 ( 2K, m) , 8 . 5- 8 . 6 ( 2H, m) , 10 . 00 ( IH, s ) Preparation 113 To a solution of pyrazole (1.67 g) in N,N-dimethylformamide (30 ml) was added sodium hydride (60% oil suspension, 950 mg) at 0-5°C. After stirring for 30 minutes, to the mixture was added a solution of 4-bromomethylbenzonitrile (4.0 g) in N,N-dimethylformamide (10 ml) dropwise under ice cooling, and the mixture was stirred for two hours at room temperature. The reaction mixture was diluted with ethyl acetate (240 ml), washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (100 g, eluting with n-hexane - ethyl acetate (1:1) ) to give 4- (pyrazol-1-ylmethyl)benzonitrile (3.49 g) . mp : 80-81°C IR (KBr) : 3055, 2958, 2229, 1610, 1510, 1446, 1392, 1275 cm "1 NMR (CDC1 3 , δ) : 5.39 (2H, s), 6.33 (IH, dd, J=2.1, 2.1Hz), 7.18-7.30 (2H, ) , 7.44 (IH, d, J=2.1Hz), 7.55-7.70 (3H, m) APCI-MASS (m/z) : 184 (M+H + ) Preparation 114 To a solution of imidazole (1.67 g) in N,N-dimethylformamide (30 ml) was added sodium hydride (60- oil suspension, 950 mg) at 0-5°C. After stirring for 30 minutes, to the mixture was added a solution of 4-bromomethylbenzonitrile (4.0 g) in N,N-dimethylformamide (10 ml) dropwise under ice cooling, and the mixture was stirred for two hours at room temperature. The reaction mixture was diluted with ethyl acetate (240 ml), washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (100 g, eluting with dichloromethane - methanol (15:1)) to give 4- (imidazol-1-ylmethyl)benzonitrile (3.26 g ) • IR (KBr) : 3095, 3057, 2229, 1608, 1510, 1425, 1236, 1074, 731 cm "1 NMR (CDC1 3 , δ) : 5.21 (2H, s), 6.90 (IH, s), 7.14 (IH, s), 7.15-7.27 (2H, m) , 7.57 (IH, s), 7.60- 7.72 (2H, m) APCI-MASS (m/z) : 184 (M+H τ ) Preparation 115 To a suspension of 3, 5-di-tert-butyl-4-hydroxybenzoic acid (10.0 g) in methanol (100 ml) were added sodium hydroxide (1.6 g) and water (6 ml) and the mixture was stirred at room temperature for 35 minutes. The mixture was evaporated in vacuo and dried thoroughly. The sodium salt was suspended in petroleum ether (60 ml), and thionyl Cxhloride (30.93 g) was added thereto and the mixture was stirred at room temperature for 16 hours. The mixture was evaporated in vacuo and the residue was redissolved in petroleum ether (200 ml) . The insoluble materials were filtered off and the filtrate was evaporated in vacuo to give 3, 5-di-tert-butyl-4-hydroxybenzoyl chloride (9.81 g) as a yellow solid. IR (KBr) : 3554, 2974, 2956, 1736, 1597, 1574 cm "1 Preparation 116 To a solution of sodium azide (4.61 g) in water (30 ml) was added dropwise a solution of 3, 5-di-tert-butyl-4- hydroxybenzoyl chloride (12.72 g) in tetrahydrofuran (60 ml) at 5°C over 30 minutes, and the mixture was stirred at 5°C for 1.5 hours. The mixture was extracted with ethyl acetate, and the organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. To the residue was added n-hexane (60 ml) and the insoluble materials were filtered off. The filtrate was evaporated m vacuo to give 3, 5-dι-tert-butyl-4-hydroxybenzoyl azide (1.49 g) as a yellow solid. IR (KBr) : 3593, 2966, 2912, 2873, 2141, 1668, 1599 cm "1 Preparation 117 A suspension of 3, 5-dι-tert-butyl-4-hydroxybenzoyl azide (1.49 g) in benzene (30 ml) was refluxed for an hour under nitrogen. To tne mixture was added tert-butanol (4.01 g) and the mixture was refluxed for 3 hours. The mixture was evaporated m vacuo and the residue was purified by column chromatography on silica gel to give N-tert-butoxycarbonyl-3, 5-dι-tert-butyl-4-hydroxyanιlme (1.17 g) as a white solid. IR (KBr) : 3647, 3331, 2958, 2913, 2873, 1693, 1606, 1547 cm "1 NMR (DMSO-d 6 , δ) : 1.34 (18H, s), 1.44 (9H, s) , 6.60 (IH, s), 7.22 (2H, s), 8.84 (IH, br s) Preparation 118 To a solution of N-tert-butoxycarbonyl-3, 5-dι-tert- butyl-4-hydroxyanιlme (3.97 g) in ethyl acetate (60 mil and ethanol (15 ml) was added 4N hydrochloric acid ethyl acetate (30.8 ml) and the mixture was stirred at room temperature for 24 hours. The mixture was evaporateα m vacuo and the residue was tπturateα with diisopropyl ether. The powder was collected by filtration, washed with diisopropyl ether and dried in vacuo to give 3,5-dι-tert- butyl-4-hydroxyanιlme-hydrochlorιde (2.85 g) . IR (KBr) : 2966, 2912, 2873, 2590, 1581, 1512 cm "1 NMR (DMSO-d 6 , δ) : 1.38 (18K, s), 7.12 (2H, s), 7.34 (IK, s) , 9.83 (2H, br si Preparation 119 To a suspension of 4-formylbenzoic acid (1.65 g) , 3,5- di-tert-butyl-4-hydroxyaniline-hydrochloride (2.83 g) and 1-hydroxybenzotriazole (1.49 g) in dichloromethane (60 ml) was added 3- (3-dimethylaminopropyl) -1-ethylcarbodiimide (1.71 g) at room temperature and the resulting solution was stirred at the same temperature for 20 hours. The mixture was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-[(3,5-di- tert-butyl-4-hydroxyphenyl) carbamoyl]benzaldehyde (2.53 g) . IR (KBr) : 3624, 3286, 2958, 2912, 2872, 1703, 1645, 1606, 1547 cm "1 NMR (DMSO-d 6 , δ) : 1.43 (18H, s), 6.83 (2H, d, J=5.1Hz), 7.09 (2H, d, J=5.1Hz), 7.12 (2H, s), 10.07 (IH, s), 10.19 (IH, s) APCI-MASS (m/z) : 354 (M+H + ) Preparation 120 To a suspension of 4-formylbenzoic acid (7.5 g) in dichloromethane (25 ml) were added thionyl chloride (11.9 g) and N,N-dimethylformamide (365 mg) at room temperature, and the mixture was refluxed for 4 hours under nitrogen. The mixture was evaporated in vacuo and dried in vacuo to give crude 4-formylbenzoyl chloride (8.53 g) as a white powder. IR (KBr) : 3066, 2856, 1745, 1691, 1576, 1504 cm "1 Preparation 121 To a solution of 4-fluoroaniline (5.0 g) and triethyla ine (6.07 g) in dichloromethane (60 ml) was added portionwise 4-formylbenzoyl chloride (8.53 g) at 5°C and the mixture was stirred at room temperature for 2 hours. The mixture was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized from hexane - ethyl acetate (3:1) and collected by filtration, washed with hexane - ethyl acetate (3:1) and dried in vacuo to give 4- [N- (4-fluorophenyl) - carbamoyl]benzaldehyde (4.58 g) . IR (KBr) : 3356, 2872, 1703, 1651, 1606, 1537, 1514 cm "1 NMR (DMSO-d 6 , δ) : 7.15-7.3 (2H, m) , 7.8-7.9 (2H, m) , 8.06 (2H, d, J=8.4Hz), 8.14 (2H, d, J=8.4Hz), 10.12 (IH, s) , 10.53 (IH, br s) APCI-MASS (m/z) : 244 (M+H + ) Preparation 122 To a suspension of sodium hydride (60% oil dispersion, 464 mg) in N,N-dimethylformamide (50 ml) was added dropwise a solution of 4- [N- (4-fluorophenyl) carbamoyl]benzaldehyde (2.63 g) in N,N-dimethylformamide (40 ml) at 5°C under nitrogen, and the mixture was stirred at room temperature for an hour. To the mixture was added methyl iodide (3.29 g) , and the mixture was stirred at room temperature for 3 hours. The mixture was poured into a mixture of ethyl acetate and ice water. The separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-[N-(4- fluorophenyl) -N-methylcarbamoyl]benzaldehyde (2.24 g) as an orange oil. IR (Film) : 3068, 2981, 2939, 2839, 2737, 1703, 1639, 1608, 1571, 1510 cm "1 NMR (DMSO-d 6 , δ) : 3.37 (3H, s), 7.05-7.2 (2H, m) , 7.25-7.35 (2H, m) , 7.46 (2H, d, J=8.1Hz), 7.77 (2H, d, J=8.1Hz), 9.93 (IH, s) APCI-MASS (m/z) : 258 (M+H + ) Preparation 123 To a solution of 1, 4-bis (hydroxymethyl) benzene (25.72 g) in N,N-dimethylformamide (300 ml) were added imidazole (15.21 g) and tert-butyldimethylsilyl chloride (28.06 g) at room temperature, and the mixture was stirred for 10 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(tert- butyldimethylsilyloxymethyl)benzyl alcohol (27.89 g) as an oil. IR (Film) : 3352, 2954, 2931, 2887, 2858, 1541, 1514, 1466 cm "1 NMR (DMSO-d 6 , δ) : 0.07 (6H, s) , 0.90 (9H, s) , 4.47 (2H, d, J=5.7Hz), 4.68 (2H, s), 5.10 (IH, t, J=5.7Hz), 7.2-7.3 (4H, m) Preparation 124 To a solution of 4- (tert-butyldimethylsilyloxymethyl) - benzyl alcohol (27.86 g) in chloroform (300 ml) was added activated manganese dioxide (47.98 g) and the mixture was refluxed for 3.5 hours. Manganese dioxide was filtered off and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (tert-butyldimethylsilyloxy ethyl)benzaldehyde (26.86 g) as a pale yellow oil. IR (Film) : 2955, 2931, 2889, 2858, 2731, 1703, 1608, 1578, 1541 cm "1 NMR (DMSO-d 6 , δ) : 0.10 (6H, s), 0.92 (9H, s), 4.82 (2H, s), 7.53 (2H, d, J=8.2Hz), 7.89 (2H, d, J=8.2Hz), 9.99 (IH, s) Preparation 125 To a solution of N-cycloheptyl-4- (tert- butyldi ethylsilyloxymethyl)benzylamine (53.74 g) in methanol (250 ml) was added dropwise cone, hydrochloric acid (38.6 ml) at 5°C, and the mixture was stirred at room temperature for 3 hours . The mixture was evaporated in vacuo and the residue was pulverized with tetrahydrofuran and ethyl acetate. The powder was collected by filtration, washed with ethyl acetate and tetrahydrofuran and ethyl acetate (1:1), and dried in vacuo under phosphorus pentoxide to give N-cycloheptyl-4- hydroxymethylbenzylamine-hydrochloride (37.92 g) . IR (KBr) : 3294, 2927, 2858, 2791, 1578, 1541, 1514, 1456 cm "1 NMR (DMSO-d 6 , δ) : 1.4-2.2 (12H, m) , 3.05-3.25 (IH, m) , 4.12 (2H, s), 4.52 (2H, d, J=5.7Hz), 5.27 (IH, t, J=5.7Hz), 7.36 (2H, d, J=8.0Hz), 7.48 (2H, d, J=8.0Hz), 8.7-8.9 (IH, br) APCI-MASS (m/z) : 234 (M+H + -HC1) Preparation 126 To a suspension of N-cycloheptyl-4- hydroxymethylbenzylamine-hydrochloride (37.9 g) in chloroform (400 ml) were added activated manganese dioxiαe (60.86 g) and triethylamine (14.21 g) , and the mixture was refluxed for 4 hours. Manganese dioxide was filtered off and the filtrate was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cycloheptyl-4-formylbenzylamme (18.27 g) as a yellow oil. IR (Film) : 3051, 2924, 2854, 2731, 1701, 1606, 1576, 1468 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.0-2.2 (IH, br) , 2.5-2.7 (IH, m) , 3.77 (2H, s), 7.56 (2H, d, J=8.1Hz), 7.85 (2H, d, J=8.1Hz) , 9.97 (IH, s) APCI-MASS (m/z) : 232 (M+H + ) Preparation 12.1 To a solution of N-cycloheptyl-4-formylbenzylamine (18.26 g) in ethanol (200 ml) were added thiazolidin 2,4- dione (9.25 g) and piperidine (6.72 g) , and the mixture was refluxed for 17 hours. The mixture was cooled to 5°C and the precipitates were collected by filtration, washed with ethanol and diisopropyl ether and dried in vacuo to give N-cycloheptyl-4-[ (2, -dioxothiazolidin-5-ylidene)methyl]- benzylamine (9.61 g) as a yellow crystal. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give the second crop (4.13 g ) • IR (KBr) : 3429, 3024, 2929, 2858, 1684, 1622, 1576, 1547, 1458 cm "1 NMR (DMSO-d 6 , δ) : 1.3-2.2 (12H, m) , 3.05-3.25 (IH, m) , 4.12 (2H, s), 7.35 (IH, s), 7.52 (2H, d, J=8.5Hz), 7.58 (2H, d, J=8.5Hz) APCI-MASS (m/z) : 331 (M+H + ) Preparation 1 8 To a suspension of N-cycloheptyl-4- [ (2, 4- dioxothiazolin-5-ylidene)methyl]benzylamine (13.61 g) in tetrahydrofuran (300 ml) and methanol (300 ml) was added 5 ' sodium-amalgam (56.8 g) , and the mixture was stirred at room temperature for 24 hours. The insoluble materials were removed by filtration on celite and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cycloheptyl-4- [ (2, 4- dioxothiazolidin-5-yl)methyl]benzylamine (5.84 g) as a yellow solid. IR (KBr) : 3028, 2933, 2862, 2764, 1674, 1630, 1581, 1460 cm -1 NMR (DMSO-d 6 , δ) : 1.3-2.2 (12H, m) , 2.9-3.1 (IH, m) , 2.95 (IH, dd, J=13.8, 9.3Hz), 3.36 (IH, dd, J=9.3, 4.0Hz), 4.54 (IH, dd, J=9.3, 4.0Hz), 7.25 (IH, d, J=8.1Hz), 7.38 (IH, d, J=8.1Hz) APCI-MASS (m/z) : 333 (M+H + ) Preparation 129 To a solution of 4-fluorobenzaldehyde (20.11 g) and 4- chlorophenol (25.0 g) in N,N-dimethylformamide (250 ml) was added powdered potassium carbonate (26.81 g) , and the mixture was stirred at 150°C under nitrogen for 7 hours. The mixture was cooled and poured into a mixture of ethyl acetate and water. The separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (4- chlorophenoxy)benzaldehyde (32.49 g) as a yellow oil. IR (Film) : 3070, 2985, 2830, 2740, 1735, 1695, 1605, 1580, 1485 cm "1 NMR (CDC1 3# δ) : 7.0-7.15 (4H, m) , 7.35-7.45 (2H, m) , 7.8-7.9 (2H, m) , 9.93 (IH, s) APCI-MASS (m/z) : 235, 233 (M+H + ) Preparation 130 To a solution of 4-fluorobenzaldehyde (5 g) and 3- fluorophenol (5.42 g) in N,N-dimethylformamide (50 mi) was added potassium carbonate (6.68 g) . Then the mixture was heated for 3.5 hours at 150°C. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel (200 g, eluting with n-hexane - ethyl acetate (10:1)) to give 4- (3-fluorophenoxy)benzaldehyde (8.67 g) . IR (Neat) : 3072, 2831, 2738, 1697, 1587, 1483 cm "1 NMR (CDCI3, δ) : 6.75-7.00 (3H, m) , 7.05-7.18 (2H, m) , 7.28-7.42 (IH, m) , 7.82-7.95 (2H, m) , 9.95 (IH, s) APCI-MASS (m/z) : 217 (M+H^) Preparation 131 To a solution of 4-fluorobenzaldehyde (3 g) and 4-trifluoromethylphenol (4.7 g) in N,N-dimethylformamide (30 ml) was added potassium carbonate (4.0 g) . Then the mixture was heated for 5 hours at 150°C. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel (200 g, eluting with n-hexane - ethyl acetate (15:1) ) to give 4- (4-trifluoromethylphenoxy)benzaldehyde (982.1 mg) . IR (Neat) : 3074, 2831, 2738, 1701, 1587, 1502 cm "1 NMR (CDC1 3 , δ) : 7.05-7.25 (4H, m) , 7.60-7.75 (2H, m) , 7.85-7.98 (2H, m) , 9.96 (IH, s) FAB-MASS (m/z) : 267 (M+H + ) Preparation 132 To a solution of 4-fluorobenzaldehyde (3 g) and 3,4- methylenedioxyphenol (4 g) in N,N-dimethylformamide (30 ml) was added potassium carbonate (4 g) . Then the mixture was heated for 2 hours at 150°C. After cooling, the reaction mixture was diluted with ethyl acetate (200 ml), washed with water, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed en silica gel (120 g, eluting with n-hexane - ethyl acetate (5:1)) to give 4- (3, 4-methylenedioxyphenoxy)benzaldehyde (2.67 g) . mp : 65-66°C IR (KBr) : 1691, 1600, 1481, 1227 cm "1 NMR (CDC1 3 , δ) : 6.02 (2H, s), 6.50-6.65 (2K, m) , 6.82 (IK, d, J=8.3Hz), 6.96-7.07 (2H, m) , 7.78- 7.89 (2H, m) , 9.91 (IH, s) APCI-MASS (m/z) : 243 (M-^H + ) Preparation 133 To a solution of 4-fluorobenzaldehyde (2.48 g) and 3, 5-di-tert-butyl-4-methoxymethoxyphenol (5.33 g) in N,N- dimethylformamide (40 ml) was added powdered potassium carbonate (2.76 g) , and the mixture was stirred at 150°C for 6 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (3, 5-di-tert-butyl-4-methoxymethoxyphenoxy)benzaldehyde (4.03 g) as an orange oil. IR (Film) : 2960, 2872, 2740, 2693, 1581, 1504 cm "1 NMR (CDC1 3 , δ) : 1.43 (18H, s) , 3.66 (3H, s), 4.94 (2H, s), 6.99 (2H, s), 7.02 (2H, d, J=8.8Hz), 7.83 (2H, d, J=8.8Hz), 9.92 (IH, s) APCI-MASS (m/z) : 371 (M+H + ) Preparation 13 To a solution of 4-fluoronitrobenzene (14.11 g) and 4- fluorophenol (12.33 g) in N,N-dimethylformamide (150 ml) was added powdered potassium carbonate (15.20 g) , and the mixture was stirred at 100°C for 4.5 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized and the crystal was collected by filtration and washed with hexane and dried to give 4- (4-fluorophenoxy) nitrobenzene (22.96 g) as a yellow crystal. IR (KBr) : 3110, 3075, 2925, 2835, 1585, 1510 cm -1 NMR (CDCI3, δ) : 6.95-7.2 (6H, m) , 8.15-8.3 (2H, m) APCI-MASS (m/z) : 234 (M+H + ) - I l l - Preparation 135 To a suspension of 3-hydroxybenzyl alcohol (12.41 g) and l-chloro-4-fluorobenzene (19.58 g) in 1, 3-dimethyl-2- imidazolidinone (40 ml) were added powdered potassium carbonate (8.29 g) , cuprous chloride (198 mg) and 8-hydroxyquinoline (290 mg) at room temperature, and the mixture was stirred at 150°C for 8 hours. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3- (4-fluorophenoxy)benzyl alcohol (3.98 g) as a yellow oil. IR (Film) : 3352, 3074, 2931, 2875, 1610, 1585, 1502, 1448 cm -1 NMR (DMSO-d 6 , δ) : 4.47 (2H, d, J=5.6Hz), 5.22 (IH, t, J=5.6Hz), 6.8-7.4 (8H, m) Preparation 1 6 To a solution of 4-fluorobenzonitrile (50.0 g) and 4- fluorophenol (50.93 g) in N,N-dimethylformamide (400 ml) was added powdered potassium carbonate (62.75 g) , and the mixture was stirred at 150°C for 6 hours. The mixture was cooled to 5°C and poured into ice water (2.5 I) . The precipitates were collected by filtration, washed with water and dried in vacuo to give 4- (4-fluorophenoxy) - benzonitrile (87.56 g) . IR (KBr) : 3188, 3076, 2220, 1649, 1608, 1483 cm "1 NMR (DMSO-d 6 , δ) : 7.05-7.15 (2H, m) , 7.2-7.45 (4H, m) , 7.8-7.9 (2H, m) APCI-MASS (m/z) : 214 (M+H "1" ) Preparation 137 To a stirred suspension of 3-acetylbenzonitrile (25.4 g) m ethyl ether - 1,4-dioxane (10:1, 275 ml) was added bromine (9 ml) dropwise at room temperature. After 40 minutes, to the mixture was added sodium bicarbonate (15 g) in water (200 ml) at 0-5°C, and extracted with ethyl acetate. The organic layer was separated and washed with saturated sodium bicarbonate solution, water and brine, dried over magnesium sulfate, evaporated in vacuo to give 3- (bromoacetyl)benzonitrile (39.2 g) . IR (KBr) : 3103, 3068, 2941, 2229, 1707, 1599, 1429, 1279, 1223, 1149 cm "1 NMR (CDC1 3 , δ) : 4.42 (2H, s), 7.66 (IH, dd, J=8.1, 8.1Hz), 7.85-7.95 (IH, m) , 8.18-8.32 (2H, m) Preparation 138 A mixture of 3- (pyrazol-3-yl) benzaldehyde (56.0 g) and benzylamine (42.6 ml) in toluene (560 ml) was refluxed for 5 hours. The reaction mixture was cooled to room temperature, and evaporated in vacuo. The residue was suspended in ethanol (840 ml) and sodium borohydride (12.3 g) was added carefully under ice cooling. Then the mixture was stirred for one hour at 50°C. After additional stirring for 2 hours at room temperature, the reaction mixture was evaporated in vacuo. To the residue was added water (300 ml), and extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (1.5 kg, eluting with dichloromethane - methanol (10:1) ) to give N-benzyl-3- (pyrazol-3-yl)benzylamine (71.8 g) . mp : 82-83°C IR (KBr) : 2290-3310 (br) , 1606, 1543, 1441, 1354 cm "1 NMR (DMSO-d 6 , δ) : 3.71 (2H, s), 3.72 (2H, s), 6.68 (IH, d, J=2.1Hz), 7.15-7.42 (7H, m) , 7.50-7.90 (3H, m) , 12.85, 13.22 (total IH, each br) APCI-MASS (m/z) : 264 (M+H +) Preparation 139 To a solution of 4- (4-fluorophenoxy) aniline (2.03 g) ana cycloheptanone (1.35 g) in ethanol (40 ml) were aαded simultaneously a solution of sodium cyanoborohydride (314 mg) m ethanol (30 ml; and a solution of acetic acid (601 mg) in ethanol [ 10 ml) over 1 hour at room temperature. The mixture was stirreα at room temperature for additional 1.2 hours. The mixture was evaporated in vacuo and the residue was poured into a mixture of ethyl acetate and water and adjusteα to pH 8 by addition of 5N sodium hydroxide aqueous solution. The separated organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel to give N-cycIoneptyl-4- (4- fluorophenoxy) aniline (2.11 g) as a red oil. IR (Film) : 3405, 2925, 2855, 1735, 161C, 1495 cm "1 NMR (CDC1 3 , δ) : 1.4-2.15 (12H, m) , 3.3-3.5 (IH, m) , 6.4-6.6 (2K, m) , 6.75-7.05 (6H, m) APCI-MASS (m/z) : 300 'M+HX Prepar tio 140 The mixture of 4- (4-fluorophenoxy) Penzaiαenyαe (1.73 g) and benzylamine (1.29 g) was stirreα at 120°C for 4 nours under nitrogen. The mixture was cooled to room temperature and dissolved m ethanol ( 40 ml) . To this solution was added carefully sodium oorohydride (303 mgi and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted witn dichloromethane. Tne organic layer was washed with brme, dried over magnesium sulfate and evaporated in vacuo. The residue was pur fieα py column chromatography on silica gel to give N-benzyl- 14- (4- fluorophenoxy) ]benzylamine (1.78 g) as a yellow oil. IR (Film) : 3062, 3028, 2916, 2821, 1605, 1497 c " i NMR (CDCI3, δ! 3.78 (2H, s), 3.82 (2H, 6.9- - 114 - (6H, m) , 7.2-7.4 (7H, m) APCI-MASS (m/z) : 308 (M+H + ) Preparation 141 The mixture of 4- (4-fluorophenoxy) benzaldehyde (1.73 g) and pentylamine (1.40 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml) . To this solution was added carefully sodium borohydride (303 mg) , and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-pentyl-4- (4- fluorophenoxy)benzylamine (1.72 g) as a yellow oil. IR (Film) : 3051, 2956, 2929, 2858, 2818, 1610, 1498 cm "1 NMR (CDC1 3 , δ) : 0.89 (3H, t, J=6.4Hz), 1.2-1.4 (4H, m) , 1.5-1.7 (2H, m) , 2.63 (2H, t, J=7.1Hz), 3.76 (2H, s), 6.9-7.1 (6H, m) , 7.28 (2H, d, J=9.1Hz) APCI-MASS (m/z) : 288 (M+H + ) Preparation 142 The mixture of 4- (4-fluorophenoxy) benzaldehyde (2.16 g) and cyclohexylamine (1.49 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml) . To this solution was added carefully sodium borohydride (378 mg) , and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cyclohexyl-4- (4- fluorophenoxy)benzylamine (3.06 g) as a yellow oil. IR (Film) : 3034, 2929, 2852, 1608, 1497 cm "1 NMR (CDC1 3 , δ) : 1.0-1.4 and 1.5-2.0 (10H, m) , 2.4-2.6 (IH, m), 3.78 (2H, s), 6.9-7.1 (6H, ) , 7.28 (2H, d, J=8.4Hz) APCI-MASS (m/z) : 300 (M+H + ) Preparation 143 The mixture of 4- (4-fluorophenoxy)benzaldehyde (2.16 g) and cyclopentylamine (1.28 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml) . To this solution was added carefully sodium borohydride (378 mg) and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cyclopentyl 4- (4- fluorophenoxy)benzylamine (2.67 g) as a yellow oil. IR (Film) : 3032, 2953, 2868, 2819, 1608, 1500 cm "1 NMR (CDC1 3 , δ) : 1.3-2.0 (8H, m) , 3.05-3.25 (IK, m) , 3.74 (2H, s), 6.9-7.1 (6H, m) , 7.27 (2H, d, J=8.4Hz) APCI-MASS (m/z) : 286 (M+H + ) Preparation 144 The mixture of 4- (4-fluorophenoxy)benzylamine (4.35 g) and 2, 3,5, 6-tetrahydro-4H-pyran-4-one (2.40 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (80 ml) . To this solution was added carefully sodium borohydride (757 mg) and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brme, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N- 2,3,5, 6-tetrahydro-4H-pyran-4-yl) -4- (4- fluorophenoxy) benzylamine (5.15 g) as an orange oil. IR (Film) : 2927, 2845, 1498, 1464 cm "1 NMR (CDC1 3 , δ) : 1.4-1.7 (4H, m) , 3.3-4.0 (4H, m) , 3.80 (2H, s), 6.8-7.1 (6H, m) , 7.2-7.4 (2H, m) APCI-MASS (m/z) : 302 (M+H + ) Preparation 145 The mixture of 4- (4-fluorophenoxy) benzaldehyde (3.24 g) and phenethylamme (2.73 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in etnanol (60 ml) . To this solution was added carefully sodium borohydride (567 mg) , and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. The resiαue was purified oy column chromatography on silica gel to give N- (2-phenethyl) -4- (4- fluorophenoxy) benzylamine (4.73 g) as a yellow oil. IR (Film) : 3061, 3028, 2927, 2821, 1608, 1497, 1454 cm "1 NMR (CDCI3, δ) : 1.47 (IH, br s), 2.75-3.0 (4H, m) , 3.77 (2H, s), 6.85-7.1 (6H, m) , 7.15-7.35 (7K, m) APCI-MASS (m/z) : 322 (M+H + ) Preparation 146 The mixture of 4- (4-fluorophenoxy) benzalαehyde (4.32 g) and 2-ethoxyethylamιne (3.57 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (80 ml) . To this solution was added carefully sodium borohydride (757 mg) , and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N- (2-ethoxyethyl) -4- (4-fluorophenoxy)benzylamine (5.50 g) as a yellow oil. IR (Film) : 3053, 2976, 2929, 2866, 1608, 1498, 1456 cm "1 NMR (CDC1 3 , δ) : 1.20 (3H, t, J=7.0Hz), 2.8-2.9 (2H, m) , 3.45-3.6 (4H, ) , 3.78 (2H, s), 6.9-7.1 (6H, m) , 7.25-7.35 (2H, m) APCI-MASS (m/z) : 290 (M+H + ) Preparation 47 The mixture of 3- (pyrazol-3-yl)benzaldehyde (1.27 g) and benzylamine (1.19 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml) . To this solution was added carefully sodium borohydride (280 mg) , and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-benzyl-3- (pyrazol-3- yl)benzylamine (1.22 g) as an oil. IR (Film) : 3169, 3062, 3026, 2916, 2839, 1606, 1589, 1537, 1495 cm "1 NMR (DMSO-d 6 , δ) : 3.70 (2H, s), 3.7 (2K, s), 6.69 (IH, d, J=2.1Hz), 7.2-7.5 (7H, m) , 7.7-7.9 (3H, s) APCI-MASS (m/z) : 264 (M+H + ) Preparation 148 The mixture of 3- (pyrazol-3-yl) benzaldehyde (1.72 g) and cyclohexylamine (1.49 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (30 ml) . To this solution was added carefully sodium borohydride (378 mg) and the mixture was stirred at room temperature for 3 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cyclohexyl-3- (pyrazol-3-yl)benzylamine (1.15 g) . IR (KBr) : 3246, 3118, 3041, 2924, 2854, 1608, 1558 cm "1 NMR (DMSO-d 6 , δ) : 1.0-2.0 (10H, m) , 2.4-2.6 (IH, m) , 3.88 (2H, s), 6.70 (IH, br s), 7.25-7.45 (2H, m) , 7.6-7.9 (3H, m) , 12.90 (IH, br s) APCI-MASS (m/z) : 256 (M+H + ) Preparation 149 The mixture of 3- (pyrazol-3-yl)benzaldehyde (1.72 g) and cyclopentylamine (1.70 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml) . To this solution was added carefully sodium borohydride (378 mg) , and the mixture was stirred at room temperature for 3 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cyclopentyl-3- (pyrazol-3-yl)benzylamine (1.26 g) . IR (Film) : 3265, 1610, 1589 cm "1 NMR (DMSO-d β , δ) : 1.3-1.9 (8H, m) , 3.05-3.25 (IH, m) , 3.78 (2H, s) , 6.68 (IH, s) , 7.2-7.4 (2H, ) , 7.6-7.9 (3H, m) , 12.88 (IH, br) APCI-MASS (m/z) : 242 (M+H + ) Preparation 150 A mixture of 3- (l-tritylpyrazol-3-yl)benzaldehyde (1.72 g) and 4-fluorobenzylamine (0.57 ml) was stirred at 120°C for 4 hours. The mixture was cooled to room temperature and dissolved in ethanol (26 ml) . To the mixture was added sodium borohydride (158 mg) and the reaction mixture was stirred at 50°C for 2 hours. The mixture was poured into water, extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (50:1)) to give N- (4-fluorobenzyl) -3- (l-tritylpyrazol-3-yl)benzylamine (1.40 g) . IR (Neat) : 3059, 2827, 1603, 1506, 1446, 1219 cm "1 NMR (CDC1 3 , δ) : 3.79 (2H, s), 3.82 (2H, s), 6.58 (IH, d, J=2.5Hz), 6.90-7.05 (2H, m) , 7.10-7.45 (20H, m) , 7.65-7.83 (2H, m) FAB-MASS (m/z) : 524 (M+H + ) Preparation 151 A mixture of 3- (pyrazol-3-yl)benzaldehyde (1.0 g) and 4-methoxybenzylamine (0.91 ml) was heated for 3 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml) . To the solution was added sodium borohydride (220 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (10:1)) to give N- (4-methoxybenzyl) -3- (pyrazol-3- yl) benzylamine (1.17 g) . IR (Film) : 2370-3680 (br) , 1610, 1512, 1248, 1036 cm "1 NMR (CDC1 3 , δ) : 3.77 (2H, s), 3.79 (3H, s), 3.84 (2H, s), 6.60 (IH, d, J=2.2Hz), 6.80-6.92 (2H, m) , 7.17-7.41 (4H, m) , 7.54-7.66 (2H, m) , 7.85 (IH, s) APCI-MASS (m/z) : 294 (M+H ÷ ) Preparation 152 A mixture of 3- (pyrazol-3-yl)benzaldehyde (1.0 g) and 4-fluorobenzylamine (0.8 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml) . To the solution was added sodium borohydride (220 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (10:1) ) to give N- (4-fluorobenzyl) -3- (pyrazol-3- yl) benzylamine (1.28 g) . IR (Film) : 2370-3680 (br) , 1605, 1508, 1220, 1095 cm "1 NMR (CDCI3, δ) : 3.79 (2H, s), 3.84 (2H, s), 6.61 (IH, d, J=2.3Hz), 6.90-7.10 (2H, m) , 7.18-7.45 (4H, m) , 7.52-7.70 (2H, m) , 7.75 (IH, s) APCI-MASS (m/z) : 282 (M+H + ) Preparation 153 A mixture of 3- (pyrazol-3-yl) benzaldehyde (1.2 g) , 4- (dimethylamino) benzylamine-dihydrochloride (1.87 g) and triethylamine (11.7 ml) in toluene (30 ml) was refluxed for 5 hours. An insoluble material was removed by filtration and evaporated in vacuo. The residue was dissolved in ethanol (18 ml) . To the solution was added sodium borohydride (264 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (8:1)) to give N- [ 4- (dimethylamino)benzylJ -3- (pyrazol-3- yl)benzylamine (1.68 g) . IR (Film) : 2330-3700 (br) , 1614, 1524, 1446, 1350, 804, 766 cm "1 NMR (CDC1 3 , δ) : 2.93 (6H, s), 3.75 (2H, s), 3.84 (2H, s), 6.59 (IH, d, J=2.2Hz), 6.65-6.75 (2H, m) , 7.15-7.40 (4H, m) , 7.55-7.66 (2H, m) , 7.76 (IH, s) Preparation 154 The following compounds were obtained according to a similar manner to that of Preparation 57, 58, 59, 60, 62, 75, 76, 138, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152 or 153. (1) N-Cycloheptyl-4- (4-chlorophenoxy)benzylamine IR (Film) : 3035, 2925, 2855, 1610, 1590, 1505, 1485 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 2.6-2.8 (IH, m) , 3.76 (2H, s) , 6.9-7.05 (4H, m) , 7.25-7.4 (4H, m) APCI-MASS (m/z) : 332, 330 (M+H + ) (2) N-Cycloheptyl-4- (3-fluorophenoxy) benzylamine IR (Neat) : 2926, 2854, 1599, 1483, 1269, 1213 cm "1 NMR (CDC1 3 , δ) : 1.30-2.10 (12H, m) , 2.62-2.80 (IH, m) , 3.77 (2H, s), 6.62-6.85 (3H, m) , 6.93-7.05 (2H, m) , 7.18-7.40 (3H, m) APCI-MASS (m/z) : 314 (M+H + ) (3) N-Cycloheptyl-4- (4-trifluoromethylphenoxy) benzylamine IR (Neat) : 2926, 2854, 1601, 1504, 1462, 1327 cm "1 NMR (CDCI3, δ) : 1.30-2.00 (12H, m) , 2.65-2.80 (IH, ) , 3.78 (2H, s) , 6.95-7.10 (4H, m) , 7.30-7.40 (2H, m) , 7.50-7.62 (2H, m) APCI-MASS (m/z) : 364 (M+H + ) (4 ) N-Cycloheptyl-4- (3, 4-methylenedioxyphenoxy) benzylamine IR (Neat) : 2924, 2854, 1606, 1502, 1481, 1354 cm "1 NMR (CDCI3, δ) : 1.30-1.95 (12H, m) , 2.60-2.75 (IH, m) , 3.74 (2H, s) , 5.97 (2H, s) , 6.47 (IH, dd, J=8.4, 2.4Hz) , 6.56 (IH, d, J=2.4Hz) , 6.75 (IH, d, J=8.4Hz), 6.85-6.96 (2H, m; , 7.20-7.31 (2H, m) APCI-MASS (m/z) : 340 (M+H + ) (5) N-Cycloheptyl-4- (3, 5-di-tert-butyl-4- methoxymethoxyphenoxy) benzylamine IR (Film) : 2920, 2860, 1587 cm "1 NMR (CDCI3, δ) : 1.40 and 1.42 (total I8H, s) , 1.4-2.2 (14H, m) , 2.8-2.95 (IH, m) , 3.62 and 3.64 (total 3H, s), 4.87 and 4.92 (total 2H, s) , 6.92 (2H, s) , 6.85-6.95 (2H, ) , 7.4-7.5 (2H, ; APCI -MASS (m/ z ; 4 68 (M+H (6) N-Cycloheptyl-3- (4-fluorophenoxy) benzylamine IR (Film) : 3062, 2926, 2854, 1608, 1583, 1502, 1446 cm "1 NMR (CDCi 3 , δ) : 1.4-2.0 (12H, m) , 2.6-2.8 (IH, 3.75 (2H, s) , 6.8-7.3 (8K, m) - 123 - APCI-MASS (m/z) : 314 (M+H + ) (7) N-Cycloheptyl-2- (l-tritylpyrazol-4-yi ) benzylamine NMR (DMSO-d β , δ) : 1.2-1.9 (12H, m) , 2.6-2.7 (IH, m) , 3.70 (2H, s), 7.1-7.6 (19H, m) , 7.76 (IH, s), 8.06 (IH, s) APCI-MASS (m/z) : 512 (M+H + ) (8) N-Cycloheptyl-3- (l-methylpyrazol-4-yl)benzylamine IR (Neat) : 2926, 2852, 1610, 1460, 1410, 1230 cm "1 NMR (CDC1 3 , δ) : 1.30-1.98 (12H, m) , 2.63-2.80 (IH, m) , 3.79 (2H, s), 3.94 (3H, s), 7.13-7.48 (4H, m) , 7.63 (IH, s) , 7.76 (IK, s) APCI-MASS (m/z) : 284 (M+H + ) (9) N-Cycloheptyl-3- (l-methylpyrazol-3-yl)benzylamine IR (Neat) : 3400 (br) , 2924, 2854, 1610, 1462, 1354, 1242 cm "1 NMR (CDC1 3 , δ) : 1.30-2.00 (12H, ) , 2.64-2.80 (IH, m) , 3.83 (2H, s), 3.95 (3H, s) , 6.56 (IH, d, J=2.2Hz), 7.25-7.40 (3H, m; , 7.60-7.78 (2H, m) APCI-MASS (m/z) : 284 (M+H + ) (10) N-Cycloheptyi-3- (l-methylpyrazol-5-yl)benzylamine IR (Neat) : 2924, 2854, 1608, 1462, 1385, 12~5 cm "1 NMR (CDC1 3 , δ) : 1.30-1.98 (12H, m) , 2.62-2.80 (IH, m) , 3.83 (2H, s), 3.90 (3H, s), 6.31 (IH, d, J=1.8Hz), 7.25-7.48 (4H, m) , 7.51 (IH, d, J=1.8Hz) APCI-MASS (m/z) : 284 (M+H + ) (11) N-Cycloheptyl-3- (imidazol- -yl)benzylamine IR (Film) : 2300-3600 (br) , 2924, 2854, 1610, 1460 cm "1 NMR (DMS0-d 6 , δ) : 1.20-1.95 (12H, m) , 2.55-2.75 (IH, m) , 3.73 (2H, s), 7.05-7.80 (6H, m) , 12.00-12.25 (IH, br) APCI-MASS (m/z) : 270 (M+H + ) (12) N-Cycloheptyl-4- (5-methyl-l, 3, 4-oxadiazol-3- yl) benzylamine IR (KBr) : 3442, 3292, 3211, 2920, 2852, 1689, 1576, 1502, 1450 cm "1 NMR (CDC1 3 , δ) : 1.30-2.40 (12H, m) , 2.61 (3H, s), 2.63-2.80 (IH, m) , 3.87 (2H, s), 7.45-7.54 (2H, m) , 7.93-8.05 (2H, ) APCI-MASS (m/z) : 286 (M+H + ) (13) N-Cycloheptyl-4- (4-benzyl-5-methyl-4H-l, 2, 4-triazol-3- yl) benzylamine IR (Neat) : 3298, 2924, 2852, 1612, 1527, 1458, 1358 cm "1 NMR (CDCI3, δ) : 1.30-1.93 (12H, m) , 2.38 (3H, s), 2.60-2.77 (IH, m) , 3.81 (2H, s) , 5.16 (2H, s), 6.90-7.05 (2H, m) , 7.27-7.55 (7H, m) APCI-MASS (m/z) : 375 (M+H + ) (14) N-Cycloheρtyl-3- (2-methyl-2H-tetrazol-5-yl) benzylamine IR (Neat) : 2924, 2854, 1520, 1462, 1365 cm "1 NMR (CDCI3, δ) : 1.30-1.98 (12H, m) , 2.65-2.80 (IH, m) , 3.86 (2H, s), 4.40 (3H, si, 7.40-7.48 (2H, m) , 7.95-8.05 (IH, m) , 8.09 (IH, s) APCI-MASS (m/z) : 286 (M+H + ) (15) N-Cycloheptyl-3- (l-methyl-lH-tetrazol-5-yl) benzylamine IR (Neat) : 2924, 2854, 1533, 1452, 1292 cm "1 NMR (CDCI3, δ) : 1.30-1.98 (12H, m) , 2.65-2.80 (IK, m) , 3.88 (2H, s), 4.18 (3H, s), 7.46-7.65 (3K, m) , 7.75 (IH, s) APCI-MASS (m/z) : 286 (M+H + ) (16) N-Cycloheptyl-4- (1H-1, 2, 4-triazoI-l-yl)benzylamine mp : 53-54°C IR (KBr) : 3101, 2922, 2852, 1518, 1460, 1277, 1147, 984 cm "1 NMR (CDC1 3 , δ) : 1.30-2.00 (12H, m) , 2.60-2.80 (IH, m) , 3.84 (2H, s), 7.40-7.55 (2H, m) , 7.55-7.70 (2H, ) , 8.10 (IH, s), 8.54 (IH, s) APCI-MASS (m/z) : 271 (M÷H + ) (17) N-Cycloheptyl-4- (1K-1,2, 3-triazol-l-yl)benzylamine mp : 78-79°C IR (KBr) : 3319, 3124, 2920, 2852, 1520, 1230, 1101, 1041 cm "1 NMR (CDCI3, δ) : 1.30-2.00 (12H, m) , 2.63-2.80 (IH, m) , 3.87 (2H, s), 7.45-7.57 (2H, m) , 7.64-7.76 (2H, ) , 7.85 (IH, s), 7.98 (IH, s) APCI-MASS (m/z) : 271 (M+H + ) (18) N-Cycloheptyl-4- (2H-1, 2, 3-triazoI-2-yI) benzylamine IP. (Neat) : 2926, 2854, 1608, 1514, 1460, 1412, 1381, 1259, 951, 824 cm "1 NMR (DMSO-d 6 , δ) : 1.20-1.90 (12H, m) , 2.50-2.70 (IH, m) , 3.74 (2H, s), 7.45-7.55 (2H, m) , 7.90-8. CO (2H, m) , 8.10 (2H, s) APCI-MASS (m/z) : 271 (M+H + ) (19) N-Cycloheptyl- (4-methylpiperazin-i-yl)benzylamine IR (Film) : 2925, 2850, 2795, 1615, 1515 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.21 (3H, s), 2.4-2.5 (4H, m) , 3.1-3.2 (4H, m) , 3.2-3.45 (IH, m) , 6.85 (2H, d, J=8.5Hz), 7.15 (2H, d, J=3.5K__^ APCI-MASS (m/z) : 302 (M+H + ) (20) N-Cycloheptyl-4- (4-methylsulfonylaminophenyl) - benzylamine - 126 - IR (KBr) : 3020, 2930, 2855, 1605, 1495 cm "1 NMR (DMSO-d 6 , δ) : 1.3-2.0 (12H, m) , 2.5-2.7 (IH, m) , 3.01 (3H, s), 3.72 (2H, s) , 7.27 (2H, d, J=8.5Hz), 7.39 (2H, d, J=8.5Hz), 7.57 (2H, d, J=8.2Hz), 7.63 (2H, d, J=8.2Hz) APCI-MASS (m/z) : 373(M+H + ) (21) N-Cycloheptyl-4- (N-benzoyisulfamoyl) benzylamine IR (KBr) : 3477, 3057, 2927, 2858, 1599, 1545 cm "1 NMR (DMSO-d 6 , δ) : 1.3-2.2 (12H, m) , 3.1-3.3 (IH, m) , 4.17 (2H, s), 7.2-7.45 (5H, m) , 7.4-7.5 (2H, m) , 7.75-7.9 (2H, m) , 8.4-8.7 (IH, br) APCI-MASS (m/z) : 387 (M+H + ) (22) N-Cycloheptyl-4- (N-phenylsulfonylcarbamoyl)benzylamine IR (KBr) : 3091, 2929, 2858, 1647, 1601, 1537 cm "1 NMR (DMSO-d 6 , δ) : 1.35-2.2 (12H, m) , 3.1-3.3 (IK, m) , 4.11 (2H, s), 7.35-7.5 (5H, m) , 7.8-7.9 (2H, m) , 7.93 (2H, d, J=8.1Hz) APCI-MASS (m/z) : 387 (M+H + ) (23) N-Cycloheptyl-4- (3-pyridylmethyl) benzylamine IR (Film) : 3304, 3026, 2924, 2852, 1574, 1512 cm "1 NMR (CDC1 3 , δ) : 1.4-2.2 (12H, m) , 2.6-2.8 (IK, m) , 3.75 (2H, s), 3.95 (2H, s) , 7.1-7.5 (6H, m; , 6.45 (IH, dd, J=4.8, 1.8Hz), 8.49 (IH, d, J=1.8Hz) APCI-MASS (m/z) : 295 (M+H + ) (24) N-Cycloheptyl-4- (4-pyridylmethyl) benzylamine IR (Film) : 3323, 3022, 2924, 2852, 1599 cm "1 NMR (CDCI3, δ) : 1.3-2.1 (12H, m) , 2.6-2.8 (IK, m) , 3.77 (2H, s), 3.94 (2H, s), 7.09 (IH, dd, 3=4 . 5 , 1.6Hz), 7.12 (2H, d, J=9.4Hz), 7.29 (IK, d, J=9.4Hz) , 8.48 (2H, dd, J=4.5, 1.6Hz) APCI-MASS (m/z) : 295 (M+H + ) (25) N-Cycloheptyl-4- (pyrazol-1-ylmethyl)benzylamine IR (Neat) : 2924, 2854, 1514, 1458, 1090, 750 cm "1 NMR (CDC1 3 , δ) : 1.30-1.98 (12H, m) , 2.56-2.77 (IH, m) , 3.76 (2H, s), 5.30 (2H, s) , 6.27 (IH, dd, J=2.0Hz), 7.10-7.40 (5H, m) , 7.54 (IH, d, J=2.0Hz) APCI-MASS (m/z) : 284 (M+H + ) (26) N-Cycloheptyl-4- (imidazol-1-ylmethyl)benzylamine IR (Neat) : 3280 (br) , 2924, 2854, 1506, 1458, 1230, 1107, 1076 cm -1 NMR (CDCI3, δ) : 1.20-1.95 (12H, m) , 2.60-2.78 (IH, m) , 3.76 (2H, s), 5.10 (2H, s), 6.90 (IH, s) , 7.00-7.40 (5H, m) , 7.54 (IH, s) APCI-MASS (m/z) : 284 (M+H + ) (27) N-Cycloheptyl- (6-hydroxy-2, 5, 7, 8-tetramethylchroman-2- yl)methylamine NMR (DMSO-d 6 , δ) : 1.17 (3H, s) , 1.3-1.9 (4H, m) , 1.97 (3H, s), 2.01 (3H, s) , 2.04 (3H, s), 2.5-2.7 (3H, m) , 7.39 (IH, s) APCI-MASS (m/z) : 332 (M+H + ) (28) N-Cycloheptyl-4- [N- (3, 5-di-tert-butyl-4- hydroxyphenyl) carbamoyl]benzylamine • IR (KBr) : 3639, 3304, 2926, 2858, 1643, 1606, 1547 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 1.39 (18H, s), 2.5-2.7 (IH, m) , 3.77 (2H, s), 6.78 (IH, s), 7.45 (2H, d, J=8.2Hz), 7.88 (2H, d, J=8.2Hz), 7.58 (2H, s), 9.87 (IH, s) APCI-MASS (m/z) : 451 (MτH + ) (29) N-Cycloheptyl-4- [N- (4-fluorophenyl) carbamoyl] - benzylamine IR (KBr) : 3354, 2927, 2854, 1651, 1612, 1529, - 128 - 1512 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.5-2.65 (IH, m) , 3.77 (2H, s), 7.1-7.3 (2H, m) , 7.75-7.85 (2H, m) , 7.47 (2H, d, J=8.2Hz), 7.89 (2H, d, J=8.2Hz), 10.22 (IH, s) APCI-MASS (m/z) : 341 (M+H + ) (30) N-Cycloheptyl-4- [N- (4-fluorophenyl) -N- methylcarbamoyl]benzylamine IR (KBr) : 3475, 3187, 3120, 3024, 292 , 2853, 1643, 1597, 1541, 1500 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.4-2.6 (IH, m) , 3.33 (3H, s), 3.60 (2H, s), 7.05-7.3 (8H, m) APCI-MASS (m/z) : 355 (M^H + ) (31) N-Cycloheptyl-4- (tert-butyldimethylsilyloxymethyl) - benzylamine IR (Film) : 2927, 2850, 1514, 1464 cm "1 NMR (DMSO-d β , δ) : 0.08 (6H, s) , 0.89 (9H, s), 1.3- 1.9 (12H, m) , 2.5-2.65 (IH, m) , 3.67 (2H, s) , 4.67 (2H, s), 7.22 (2H, d, J=8.3Kz), 7.28 (2K, d, J=8.3Hz) APCI-MASS (m/z) : 348 (M+H + ) (32) N-Benzyl-3-phenoxybenzylamine IR (Film) : 3062, 3030, 2829, 1583, 1487, 1452 cm "1 NMR {DMSO-d 6 , δ) : 2.63 (IH, br s), 3.64 (2H, s), 3.66 (2H, s), 6.8-7.45 (14H, m) APCI-MASS (m/z) : 290 (M+H + ) (33) N-Benzyl-3- (4-fluorophenoxy)benzylamine IR (Film) : 3062, 3030, 2916, 2829, 1606, 1584, 1500, 1450 c "1 NMR (CDC1 3 , δ) : 3.78 (2H, s) , 3.79 (2H, s), 6.8-7.4 (13H, m) APCI-MASS (m/z) : 308 (M+H + ) ,'34) N-Benzyl-3- (l-Methylpyrazol-3-yl)benzylamine IR (Neat) : 3313, 3028, 2935, 1608, 1498, 1452, 1356, 1242 cm "1 NMR (CDC1 3 , δ) : 3.83 (2H, s) , 3.85 (2H, s), 3.9 (3H, s), 6.55 (IH, d, J=2.3Hz), 7.18-7.42 (8H, m) , 7.64-7.73 (IH, m) , 7.77(1H, s) APCI-MASS (m/z) : 278 (M+H + ) (35) N-Benzyl-3- (l-methylpyrazol-5-yl)benzylamine IR (Neat) : 3310, 3026, 2830, 1606, 1454, 1387, 1275 cm "1 NMR (CDCI3, δ) : 3.84 (2H, s), 3.87 (2H, s), 3.89 (3H, s), 6.31 (IH, d, J=1.9Hz), 7.20-7.45 (9H, m) , 7.51 (IH, d, J=1.9Hz) APCI-MASS (m/z) : 278 (M+H + ) (36) N-Benzyl-4- (l-methylpyrazol-3-yi)benzylamine IR (Neat) : 3310, 3028, 2937, 2820, 1504, 1454, 1430 cm "1 NMR (CDCI3, δ) : 3.81 (2H, s) , 3.83 (2H, s), 3.95 (3H, s), 6.53 (IH, d, J=2.3Hz), 7.18-7.43 (8H, m) , 7.70-7.80 (2H, m) APCI-MASS (m/z) : 278 (M+H ÷ ) (37) N-Benzyl-4- (l-methylpyrazol-5-yl)benzylamine IR (Neat) : 3305, 3026, 2820, 1493, 1454, 1385, 1275 cm "1 NMR (CDCI3, δ) : 3.85 (2H, s), 3.87 (2H, s), 3.89 (3H, s), 6.30 (IH, d, J=i.9Hz), 7.20-7.50 (9H, m) , 7.51 (IH, d, J=1.9Hz) APCI-MASS (m/z) : 278 (M+H + ) (33) N-Benzyl-4- (pyrazol-3-yl)benzylamine IR (Neat) : 2250-3680 (br) , 1514, 1495, 1454, 1350 cm " NMR (DMSO-d 6 , δ) : 3.69 (4H, s), 6.67 (IH, d, J=2.1Hz), 7.15-7.50 (7H, m) , 7.60-7.90 (3H, m) , 12.81, 13.20 (total IH, each br) APCI-MASS (m/z) : 264 (M+H + ) (39) N-Benzyl-4- (l-methylpyrazol-4-yl) benzylamine mp : 90-91°C IR (KBr) : 3300, 3020, 2914, 2854, 1570, 1473, 1452, 1194, 1097 cm "1 NMR (CDC1 3 , δ) : 3.81 (2H, s) , .3.82 (2H, s) , 3.94 (3H, s), 7.20-7.50 (9H, m) , 7.60 (IH, s), 7.75 (IH, s) APCI-MASS (m/z) : 278 (M+H + ) (40) N-Benzyl-3- (imidazol-4-yl)benzylamine IR (Neat) : 2200-3560 (br) , 1608, 1491, 1454 cm "1 NMR (DMSO-d 6 , δ) : 3.72 (4H, s), 7.10-7.40 (7H, m) , 7.41-7.80 (4H, m) APCI-MASS (m/z) : 264 (M+H + ) (41) N-Benzyl-3- (2-methyl-2H-tetrazol-5-yl) benzylamine IR (Neat) : 3028, 2825, 1520, 1452, 1363, 804 cm "1 NMR {CDCI3, δ) : 3.84 (2H, s) , 3.89 (2H, s), 4.40 (3H, s) , 7.20-7.52 (7H, m) , 7.96-8.07 (IH, m) , 8.12 (IH, s) APCI-MASS (m/z) : 280 (M+H + ) (42) N-Benzyl-3- (l-methylpyrazol-4-yl) benzylamine IR (Neat) : 3305, 3028, 2935, 2827, 1610, 1450, 1363, 1230 cm "1 NMR (CDCI3, δ) : 3.84 (4H, s), 3.94 (3H, s), 7.13- 7.40 (8H, m) , 7.45 (IH, s), 7.62 (IH, s), 7.77 (IH, s) APCI-MASS (m/z) : 278 (M+H + ) ( 43 ) N- (4-Methoxybenzyl) -4- (4-fluorophenoxy)benzylamine IR (Neat) : 3001, 2903, 2833, 1610, 1500, ' 1460, 1248, 1213 cm "1 NMR (CDC1 3 , δ) : 3.75 (2H, s), 3.76 (2H, s), 3.80 (3H, s), 6.82-7.10 (8H, m) , 7.20-7.35 (4K, m! APCI-MASS (m/z) : 338 (M+H + ) Preparation 155 The following compound was obtained according to a similar manner to that of Preparation 31, 38, 39 or 89. 4- (l-Tritylpyrazol-4-yl) toluene NMR (DMSO-d β , δ) : 2.27 (3H, s), 7.1-7.5 (19H, m) , 7.73 (IH, s), 8.04 (IH, s) Preparation 156 The following compounds were obtained according to a similar manner to that of Preparation 28. (1) 4- (l-Tritylpyrazol-4-yl)benzyI bromide NMR (DMSO-d 6 , δ) : 4.70 and 4.77 (total 2H, s), 7.0-7.8 (21H, m) (2) 3-3enzoylbenzyi bromide IR (Film) : 3059, 3028, 1686, 1599 cm "1 NMR (CDCI3, δ) : 4.53 (2H, s), 7.35-7.9 (9H, rr.) APCI-MASS (m/z) : 277, 275 (M+H + ) Preparation 157 The following compounds were obtained according to a similar manner to that of Preparation 63. (1) N-Cycloheptyl-4- (l-tritylpyrazol-4-yl)benzylamine IR (Film) : 3057, 3028, 2918, 2852, 1641, 1605, 1566 cm " - - 132 - NMR (DMSO-d 6 , δ) : 1.3-2.0 (12H, m) , 2.55-2.75 (IH, m) , 3.68 and 3.75 (total 2H, s) , 7.05-7.25 (5H, m) , 7.3-8.1 (16H, m) APCI-MASS (m/z) : 512 (M+H" " ) (2) N-Cycloheptyl-4- (2-cyanophenyl) benzylamine IR (Film) : 3060, 3030, 2910, 2855, 2225, 1597, 1480 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 2.65-2.85 (IH, m) , 3.85 (2H, s), 7.4-7.8 (8H, m) APCI-MASS (m/z) : 305 (M+H + ) (3) N-Cycloheptyl-4- [2- (l-trityl-lH-tetrazol-5- yl ) phenyl]benzylamine IR (KBr) : 3058, 3026, 2924, 2854, 1603, 1493, 1446 cm "1 NMR (DMS0-d 6 , δ) : 1.3-1.9 (12H, m) , 2.6-2.75 (IH, m) , 3.68 (2H, s), 6.8-6.95 (5H, m) , 7.01 (2H, d, J=7.9Hz) , 7.20 (2H, d, J=7.9Hz) , 7.3-7.8 (14H, mi FAB-MASS (m/z) : 590 (M+K + ) (4 ) N-Cycloheptyl-3-benzoylbenzylamine IR (Film) : 3059, 2927, 2855, 1653, 1599, 1580 cm "1 NMR (CDCI3, δ) : 1.3-2.0 (12H, m) , 2.6-2.8 (IK, m) , 3.85 (2H, s) , 7.3-7.8 (9H, m) APCI-MASS (m/z) : 308 (M+H + ) Preparation 158 The following compounds were obtained according to a similar manner to that of Preparation 50 or 51. ( 1 ) 3- (l-Methylpyrazol-3-yl) benzaldehyde IR (Neat) : 2941, 2829, 2730, 1695, 1606, 1585, 1439, 1242 cm "1 NMR (CDCI3, δ) : 3.98 (3H, s) , 6.62 (IK, d, J=2.2Hz) , 7.42 (IH, d, J=2.2Hz), 7.51-7.62 (IH, m) , 7.77- 7.86 (IH, m) , 8.05-8.13 (IH, m) , 8.25-8.32 (IH, m) , 10.07 (IH, s) APCI-MASS (m/z) : 187 (M+K + ) (2) 3- (l-Methylpyrazol-5-yl)benzaldehyde p : 72-7 °C IR (KBr) : 3041, 2831, 2733, 1697, 1579, 1462, 1377 cm "1 NMR (CDC1 3 , δ) : 3.94 (3H, s), 6 . 39 (IH, d, J=1.4Hz), 7.56 (IH, d, J=1.4Hz), 7.58-7.74 (2H, ) , 7.89- 7.97 (2H, m) , 10.09 (IH, s) APCI-MASS (m/z) : 187 (M+H + ) (3) 4- (Pyrazol-1-yl)benzaldehyde mp : 53-55°C IR (KBr) : 3109, 2833, 2744, 1693, 1608, 1394, 1213, 760 cm "1 NMR (CDCI3, δ) : 5.43 (2H, s), 6.34 (IH, dd, J=2.1, 2.1Hz), 7.25-7.35 (2H, m) , 7.45 (IH, d, J=2.1Hz) , 7.59 (IH, d, J=2.1Hz), 7.80-7.90 (2H, m) , 9.99 (IH, s) APCI-MASS (m/z) : 187 (M+H + ) (4) 4- (Imidazol-1-ylmethyl) benzaldehyde IR (Neat) : 2600-3600 (br) , 1695, 1506, 1232, 1076, 818, 737 cm "1 NMR (CDCI3, δ) : 5.22 (2H, s), 6.85-7.95 (7H, m) , 10.01 (IH, s) APCI-MASS (m/z) : 187 (M+H + ) Preparation 1-59 The following compound was obtained according to a similar manner to that of Preparation 47. 3- (Imidazol-4-yl) benzaldehyde - 134 - mp : 135-138°C IR (KBr) : 2080-3390 (br) , 1691, 1606, 1479, 1327, 1186, 1066, 978, 781 cm "1 NMR (DMSO-d 6 , δ) : 7.59 (IH, dd, J=7.6, 7.6Hz), 7.67- 7.80 (3H, m) , 8.05-8.15 (IH, m) , 8.31 (IH, s), 10.04 (IH, s), 12.30 (IH, br) APCI-MASS (m/z) : 173 (M+H + ) Preparation 16 Q The following compounds were obtained according to a similar manner to that of Preparation 44, 45, 84, 110, 124 or 126. (1) 4- (5-Methyl-l, 3, 4-oxadiazol-2-yl) benzaldehyde IR (KBr) : 2829, 1701, 1610, 1590, 1550, 1421 cm "1 NMR (CDC1 3 , δ) : 2.66 (3H, s), 7.96-8.07 (2H, m) , 8.15-8.26 (2H, m) , 10.10 (IH, s) APCI-MASS (m/z) : 189 (M+H + ) (2) 4- (4-Benzyl-5-methyl-4H-l,2, 4-triazol-3- yl) benzaldehyde IR (KBr) : 3450 (br) , 1689, 1608, 1572, 1531, 1207 cm "1 NMR (CDCI3, δ) : 2.44 (3H, s), 5.22 (2H, s) , 6.93- 7.07 (2H, m) , 7.30-7.47 (3H, m) , 7.70-7.80 (2H, m) , 7.90-8.00 (2H, m) , 10.05 (IH, s) APCI-MASS (m/z) : 278 (M+H + ) Preparation 161 The following compound was obtained according to a similar manner to that of Preparation 97. 4-Benzyl-2- (4-hydroxymethyl)phenyl-5-methyl-4H-l, 2, 4- triazole mp : 118-121°C IR (KBr) : 2600-3650 (br) , 1535, 1487, 1425, 1363, 1039, 854, 739 cm "1 NMR (CDC1 3 , δ) : 2.36 (3H, s), 3.10-3.25 (IH, m) , 4.65-4.77 (2H, m) , 5.14 (2H, s), 6.90-7.03 (2H, m) , 7.25-7.50 (7H, m) APCI-MASS (m/z) : 280 (M+H + ) Preparation 162 The following compound was obtained according to a similar manner to that of Preparation 31. N-Methyl-N-methoxy-4- [4- (methylsulfonylamino)phenyl] - benzamide IR (KBr) : 3210, 2935, 1630, 1608, 1525 cm "1 NMR (DMSO-d 6 , δ) : 3.04 (3H, s), 3.28 (3H, s), 3.58 (3H, s), 7.32 (2H, d, J=8.6Hz) , 7.6-7.8 (6H, m) , 9.91 (IH, s) Preparation 163 The following compounds were obtained according to a similar manner to that of Preparation 36. (1 ) 4- (4-Methylsulfonylaminophenyl)benzaldehyde IR (KBr) : 3290, 2995, 2840, 2745, 1695, 1600, 1525, 1500 cm "1 NMR (DMSO-d β , δ) : 3.06 (3H, s), 7.33 (2H, d, J=8.5Hz), 7.78 (2H, d, J=8.5Hz) , 7.89 (2K, d, J=8.2Hz), 7.98 (2H, d, J=8.2Hz) , 9.98 (IK, br s) , 10.04 (IH, s) APCI-MASS (m/z) : 276 (M+H + ) (2) 4- (N-Benzoylsulfamoyl)benzaldehyde IR (KBr) : 3381, 3057, 2883, 1697, 1599, 1560 cm "1 NMR (DMSO-d 6 , δ) : 7.3-7.5 (3H, m) , 7.9-8.0 (2H, m) , 7.44 (2H, d, J=8.3Hz), 8.00 (2H, d, J=8.3Hz) , 10.03 (IH, s) APCI-MASS (m/z) : 290 (M+H + ) Preparation 164 The following compounds were obtained according to a similar manner to that of Preparation 33 or 34. (1 ) 4- (N-Methyl-N-methoxysulfamoyl) benzamide IR (KBr) : 3292, 3201, 3111, 2979, 2943, 1605, 1562, 1504 cm "1 NMR (DMSO-d 6 , δ) : 3.28 (3H, s) , 3.54 (3H, s), 7.49 (2H, br s) , 7.74 (2H, d, J=8.4Hz) , 7.88 (2H, d, J=8.4Hz) APCI-MASS (m/z) : 245 (M+H + ) (2) N-Methyl-N-methoxy-6-hydroxy-2, 5, 7, 8- tetramethylchroman-2-carboxamide IR (KBr) : 3479, 2983, 2935, 2870, 1655 cm "1 NMR (DMSO-d 6 , δ) : 1.49 (3H, s) , 1.97 (3H, s) , 2.05 (6H, s) , 1.6-1.75 (IH, m) , 2.4-2.6 (3H, m) , 3.34 (3H, s) , 3.57 (3H, s) , 7.48 (IH, s) APCI-MASS (m/z) : 294 (M+H + ) Preparation 165 The following compound was obtained according to a similar manner to that of Preparation 105. 4- (N-Phenylsulfonylcarbamoyl) benzaldehyde IR (KBr) : 3185, 3155, 3105, 2935, 2850, 1740, 1695, 1645, 1605, 1565, 1550 cm "1 NMR (DMSO-d 6 , δ) : 6.95 (2H, d, J=7.5Hz) , 7.35-7.45 (2H, m) , 7.75-7.9 (3H, m) , 8.20 (2H, d, J=7.5Hz) , 10.02 (IH, s) APCI-MASS (m/z) : 290 (M+H + ) Preparation 166 The following compound was obtained according to a similar manner to that of Preparation 66. N-Cycloheptyl-3-benzylbenzylamine IR (Film) : 3059, 3026, 2926, 2852, 1601, 1495 cm "1 NMR (CDC1 3 , δ) : 1.3-2.0 (12H, m) , 2.6-2.8 (IH, m) , 3.74 (2H, s), 3.97 (2H, s) , 7.0-7.5 (9H, m) APCI-MASS (m/z) : 294 (M+H + ) Preparation 167 The following compound was obtained according to a similar manner to that of Preparation 36. 2-Formyl-6-hydroxy-2, 5, 7, 8-tetramethylchromane IR (KBr) : 3541, 2981, 2933, 2872, 2833, 2727, 1732 cm "1 NMR (DMSO-d 6 , δ) : 1.66 (3H, s), 1.7-1.9 (IH, m) , 2.2-2.65 (3H, m) , 1.97 (3H, s), 2.07 (3H, s), 2.08 (3H, s), 7.55 (IH, s), 9.53 (IH, s) APCI-MASS (m/z) : 244 (M+H + ) Preparation 168 To a solution of 2-chloro-6-methyl-4-methylthio-3- nitropvridine (13.25 g) in methanol (150 ml) was added 28; sodium methoxide in methanol (23.4 ml), and the mixture was refluxed for 7 hours under nitrogen. The mixture was cooled and the precipitates were collected by filtration, washed with methanol and diisopropyl ether and dried under phosphorus pentoxide to give 2-methoxy-6-methyl-4- methylthio-3-nitropyridine (10.29 g) as a yellow powder. IR (KBr) : 3024, 2997, 2951, 2924, 2856, 1587, 1541, 1495, 1452 cm "1 NMR (DMSO-d 6 , δ) : 2.46 (3H, s), 2.57 (3H, s) , 3.94 (3H, S) , 7.07 (IH, s) - 138 - APCI-MASS (m/z) : 215 (M+H + ) Preparation 169 To a solution of 2, 4-dιchloro-6-methyl-3-nιtropyrιdme (41.40 g) in methanol (400 ml) was added dropwise a 28 solution of sodium methoxide in methanol (38.6 ml), and the mixture was stirred at 60°C for an hour under nitrogen. The mixture was evaporated in vacuo and the residue was extracted with ethyl acetate. The organic layer was washed with brme, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 2-chloro-4-methoxy-6-methyl-3- nitropyrid e (30.43 g) as a pale yellow crystal. IR (KBr) : 3088, 2987, 2953, 2883, 1601, 1552, 1524, 1471 cm "1 NMR (DMSO-d 6 , δ) : 2.51 (3H, s) , 4.01 (3H, s), 7.42 (IH, s) Preparation 170 To a solution of 2-chloro-4-methoxy-6-methyl-3- nitropyridme (30.42 g) in methanol (300 ml) was added dropwise a solution of sodium methanethiolate (12.63 g) m methanol (200 ml) at room temperature and the mixture was stirred at 50°C for 4 hours under nitrogen. The mixture was evaporated in vacuo and the residue was extracted with ethyl acetate. The organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel to give 4-methoxy-2-methylthιo-6-methyl-3-nιtropyrιdme (30.23 g) as a yellow powder. IR (KBr) : 3066, 2997, 2956, 2933, 2858, 1585, 1549, 1514, 1466 cm "1 NMR (DMSO-d 6 , δ) : 2.51 (3H, s), 2.53 (3H, s), 3.95 (3H, s), 7.11 (IH, s) APCI-MASS (m/z) : 215 (M+H + ) Preparation 1 1 To a suspension of 4-methoxy-2-methylthio-6-methvl-3- nitropyridine (30.15 g) in ethanol (300 ml) was added cone, hydrochloric acid (58.6 ml), and the mixture was refluxed for 10 hours. The mixture was cooled to 5°C and the precipitates were collected by filtration, washed with ethanol and diisopropyl ether, and dried in vacuo under phosphorus pentoxide to give 4-hydroxy-2-methylthio-6- methyl-3-nitropyridine (19.79 g) as a yellow powder. IR (KBr) : 2989, 2920, 2783, 1551, 1518 cm "1 NMR (DMSO-d 6 , δ) : 2.39 (3H, s), 2.50 (3H, s) , 6.62 (IH, s) Preparation 172 To a suspension of 4-hydroxy-2-methylthio-6-methyl-3- nitropyridine (30.65 g) in phosphorus oxychloride (140.8 g) was stirred at 100°C for 10 hours. The mixture was poured into a mixture of ethyl acetate and water, and neutralized by addition of 5N sodium hydroxide aqueous solution. The insoluble materials were filtered off, and the filtrate was separated. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-chloro-2-methylthio-6-methyl-3-nitropyridine (11.87 g) as a yellow powder. IR (KBr) : 3103, 3053, 2933, 1560, 1518 cm "1 NMR (DMSO-d 6 , δ) : 2.55 (3H, s), 2.59 (3H, s), 7.55 (IK, s) APCI-MASS (m/z) : 221, 219 (M+H + ) Preparation 173 To a solution of 2, -dichloro-6-methyl-3-nitropyridine (4.14 g) in 1,4-dioxane (50 ml) and methanol (50 ml) was added Raney Nickel (NDT-90, purchased from Kawaken Fine Chemicals) (ca. 2 g) , and the mixture was hydrogenated for 4 hours under atmospheric pressure. Raney Nickel was filtered off and washed with methanol, and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-ammo-2, 4-dιchloro- 5 6-methylpyrιdιne (3.53 g) as a yellow oil. IR (Film) : 3479, 3385, 3221, 3188, 2924, 1616, 1576, 1543, 1471 cm "1 NMR (DMSO-d 6 , δ) : 2.28 (3H, s), 5.52 (2H, or s), 7.23 (IH, si 0 APCI-MASS (m/z) : 181, 179, 177 (M^HX Preparation 174 To a solution of 3-amιno-2, 4-dιchloro-6-methylpyπdme (3.51 g) m dichloromethane (50 mil was added N,N- 5 dimethylanilme (2.88 g) at 5°C, followed by dropwise addition of phenyl chloroformate (3.41 g) , and the mixture was stirred at room temperature for 3.5 hours. The mixture was washed with dilute hydrochloric acid and brme, dried over magnesium sulfate and evaporated m vacuo. The C residue was crystallized from diisopropyl ether and the crystal was collected oy filtration, washed with diisopropyl ether and dried m vacuo to give 2, -dιchioro- 6-methyl-3-phenoxycarbonylammopyrιdιne (1.96 g) . IR (KBr) : 3282, 3244, 3184, 3013, 1718, 1637, 1608, 5 1524, 1491 cm "1 NMR (DMSO-d 6 , δ) : 2.27 (3H, s) , 7.1-7.5 (5H, m) , 7.65 (IH, s; , 10.10 (IH, br s) APCI-MASS (m/z) : 301, 299, 297 (M-rH + ) 0 Preparation 175 A mixture of 3- (pyrazol-3-yl) benzaldehyde (1.0 g) ana 2-methoxybenzylamme (0.91 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml) . To the solution was addeα 5 sodium borohydride (220 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (10:1)) to give N- (2-methoxybenzyl) -3- (pyrazol-3- yi) benzylamine (1.06 g) . IR (Film) : 2400-3600 (br) , 1603, 1493, 1462, 1244 cm "1 NMR (CDC1 3 , δ) : 3.81 (3H, s), 3.84 (2K, s) , 3.85 (2H, s), 6.59 (IH, d, J=2.2Hz), 6.80-6.98 (2H, m) , 7.17-7.50 (4H, m) , 7.53-7.67 (2H, m) , 7.79 (IH, s) APCI-MASS (m/z) : 294 (M+H + ) Preparation 176 A mixture of 3- (pyrazol-3-yl)benzaldehyde (1.0 g) and 3-methoxybenzylamine (0.91 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml) . To the solution was added sodium borohydride (220 mg) , and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed en silica gel (50 g, eluting with dichloromethane - methanol (15:1) ; to give N- (3-methoxybenzyl) -3- (pyrazol-3- yl) benzylamine (1.24 g) . IR (Neat) : 2370-3680 (br) , 1603, 1487, 1439, 1263, 1157, 1045 cm "1 NMR (CDCI3, δ) : 3.80 (3H, s), 3.81 (2K, s), 3.85 (2H, s), 6.61 (IH, d, J=2.2Hz) , 6.75-6.85 (IH, m), 6.86-6.97 (2H, m) , 7.19-7.43 (3H, m) , 7.55- 7.68 (2H, m) , 7.76 (IK, s) APCI-MASS (m/z) : 294 (M+H + ) Preparation 177 A mixture of 4- (4-fluorophenoxy)benzaldehyde (1.5 g) and 3-phenyipropylamine (1.19 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (30 ml) . To the solution was added sodium borohydride (262 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (15:1) ) to give N- (3-phenyipropyl) -4- (4-fluorophenoxy) - benzylamine (1.92 g) . IR (Neat) : 3028, 2929, 2856, 2818, 1606, 1497, 1454, 1250, 1211 cm "1 NMR (CDC1 3 , δ) : 1.85 (2H, qn, J=7.4Hz), 2.55-2.75 (4H, m) , 3.75 (2H, s), 6.83-7.10 (6H, ) , 7.10- 7.36 (7H, ) APCI-MASS (m/z) : 336 (M+H "r ) Preparation 178 A mixture of 3- (pyrazol-3-yl)benzaldehyde (1.0 c, and phenethylamine (0.875 ml) was heated for 4 hours at I20°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml) . To the solution was added sodium borohydride (220 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (15:1 to 10:1)) to give N- (2-phenylethyl) -3- (pyrazoi-3- yl)benzylamine (1.27 g) . IR (Neat) : 2300-3700 (br) , 1606, 1495, 1452, 1354, 1097 cm "1 NMR (CDCI3, δ) : 2.76-3.00 (4H, m) , 3.86 (2H, s,' / 6.59 (IH, d, J=2.2Hz), 7.10-7.43 (7H, m) , 7.53- 7.68 (2H, m) , 7.86 (IH, s) APCI-MASS (m/z) : 278 (M+H + ) Preparation 179 A mixture of 4- (4-fluorophenoxy)benzaldehyde (1.5 g) and (S) -1-phenylethylamine (1.08 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (30 ml) . To the solution was added sodium borohydride (262 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with n-hexane - ethyl acetate (4:1 to 2:1) to give N- [ (S) -1-phenylethyl] -4- (4- fluorophenoxy)benzylamine (2.23 g) . IR (Neat) : 3028, 2966, 2831, 1606, 1498, 1452, 1250, 1213 cm "1 NMR (CDCI3, δ) : 1.38 (3H, d, J=6.6Hz), 3.56 (IH, d, J=13.1Hz), 3.63 (IH, d, J=13.1Hz), 3.82 (IH, q, J=6.6Hz), 6.83-7.12 (6H, m) , 7.15-7.43 (7H, m) APCI-MASS (m/z) : 322 (M+H + ) [α] β 9 : -31.2° (C=1.05, CHCI3) Preparation 180 A mixture of 4- (4-fluorophenoxy)benzaldehyde (1.5 g) and (R) -1-phenylethylamine (1.08 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (30 mi) . To the solution was added sodium borohydride (262 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent _ 2 4 _ was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with n-hexane - ethyl acetate (4:1 to 2:1) to give N- [ (R) -1-phenylethyl] -4- (4- fluorophenoxy) benzylamine (2.12 g) . IR (Neat) : 3028, 2966, 2831, 1606, 1498, 1452, 1250, 1213 cm "1 NMR (CDC1 3 , δ) : 1.37 (3H, d, J=6.6Hz) , 3.56 (lH,d, J=13.1Hz), 3.63 (IH, d, J=13.1Hz) , 3.81 (IH, σ, J=6.6Hz), 6.83-7.12 (6H, m) , 7.15-7.42 (7H, m) APCI-MASS (m/z) : 322 (M+H + ) [α]§° : +31.7° (C=1.02, CHCI3) Preparation 181 The following compounds were obtained according to a similar manner to that of Preparation 71, 78 or 173. ( 1 ) 3-7Λmino-2-methoxy-6-methyl-6-methylthiopyridine IR (Film) : 3444, 3352, 2984, 2947, 2922, 2860, 1585, 1559, 1462 cm "1 NMR (DMSO-d 6 , δ) : 2.26 (3H, s) , 2.43 (3H, s) , 3.84 (3K, s) , 4.39 (2H, br s) , 6.64 (IK, s) APCI-MASS (m/z) : 185 (M+H + ) (2 ) 3-Amino-4-chloro-2-methylthio-6-methylpyridine IR (KBr) : 3417, 3300, 3207, 2922, 1618, 1558 cm "1 NMR (DMSO-d 6 , δ) : 2.31 (3H, s) , 2.51 (3K, s) , 4.96 (2H, br s) , 6.96 (IK, s) APCI-MASS (m/z) : 191, 189 (M+H + ) Preparation 182 The following compounds were obtained according to a similar manner to that of Preparation 74 or 79. (1 ) 2-Methoxy-6-methyl-4-methylthio-3- phenoxycarbonylaminopyridine IR (KBr) : 3217, 1740, 1700, 1649, 1541, 1518 cm "1 NMR (DMSO-d 6 , δ) : 2.39 (3K, s), 2.45 (3H, ≤), 3.86 (3H, s), 6.81 (IH, s), 7.0-7.5 (5H, ) , 8.76 and 9.17 (total IH, br s) APCI-MASS (m/z) : 305 (M+H + ) (2) 4-Chloro-2-methylthio-6-methyl-3- phenoxycarbonyliminopyridine IR (KBr) : 3207, 3026, 3001, 2926, 1724, 1597, 1554, 1524, 1489 cm "1 NMR (DMS0-d 6 , δ) : 2.48 (3H, s), 2.51 (3H, s) , 7.0- 7.5 (6H, m) , 9.37 and 9.77 (total IH, br s) APCI-MASS (m/z) : 311, 309 (M+H + ) Preparation 183 The following compound was obtained according to a similar manner to that of Example 7, 8, 9, 10, 13, 14, 15, 16 or 17. 1- [4- (4-FIuorophenoxy)benzyl] -3- [2, 4-bis (methylthio) - 6-methylpyridin-3-yl]urea IR (KBr) : 3305, 3107, 2924, 1633, 1574, 1498 cm "1 NMR (DMSO-d 6 , δ) : 2.39 (6H, s), 2.44 (3H, s), 4.22 (2H, d, J=5.8Hz), 6.53-6.7 (IH, br) , 6.86 (IH, s), 6.9-7.4 (8H, m) , 7.54 (IH, br s) APCI-MASS (m/z) : 444 (M+H ÷ ) Example 1 To a solution of N- (4-biphenylylmethyl) - cycloheptylamine (559 mg) in dichloromethane (10 ml) was added 2, 4, 6-trimethylphenylisocyanate (322 mg) , and the mixture was stirred at room temperature for 1.3 hours under nitrogen. The mixture was evaporated in vacuo and the crystalline compound was collected by filtration using hexane: ethyl acetate (5:1) to give 1- (4-biphenylylmethyl) - l-cycloheptyl-3- (2, , 6-trιmethylphenyl) urea (710 mg) . IR (KBr) : 3320, 2920, 2855, 1625, 1505 cm "1 NMR (DMSO-d 6 , δ) : 1.5-1.8 (12H, m) , 2.00 (6H, s) , 2.20 (3H, s), 4.4-4.55 (IH, m) , 4.55 (2H, s), 5.48 (IH, s), 6.79 (2H, s), 7.3-7.65 (9H, m) APCI-MASS (m/z) : 441 (M-^H + ) Example 2 To a solution of N- (4-biphenylylmethyl) - cycloheptylamine (559 mg) in dichloromethane (10 ml) was added 2, 6-dιisopropylphenylιsocyanate (406 mg) , and the mixture was stirred at room temperature for 1.1 hours. The mixture was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 1- (4-bιphenylylmethyl) -l-cycloheptyl-3- (2, 6- dnsopropylphenyl) urea (885 mg) as a crystal. IR (KBr) : 3415, 3340, 3060, 3030, 2960, 2930, 2865, 1625, 1500 cm "1 NMR (CDC1 3 , δ) : 0.9-1.3 (10H, m) , 1.5-1.8 (12H, m) , 1.95-2.1 (2H, m) , 2.8-3.0 (2H, m) , 4.4-4.6 (IH, m) , 4.56 (2H, s), 5.47 (1H/ s) / 7.0-7.65 (12H, m) APCI -MASS (m/ z ) : 483 ( .-~K + 1 Example 3 To a solution of 2-ammo-4 , 6-dιmethoxypynmιdme ( 465 mg ) and tnphosgene ( 297 mg ) in 1 , 2-d chloroethane ( 20 ml ) 0559 - 147 - was added triethylamine (304 mg) and the mixture was refluxed for 1.8 hours. The mixture was cooled to room temperature and a solution of N- (4-biphenylylmethyl) - cycloheptylamine (559 mg) in 1,2-dichloroethane (10 ml) was added thereto. After being stirred at room temperature for 3.1 hours, the mixture was poured into water and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- (4-biphenylylmethyl) -l-cycloheptyl-3- (4,6- dimethoxypyrimidin-2-yl) urea (205 mg) . IR (KBr) : 3390, 3225, 2925, 2855, 1685, 1600, 1525 cm "1 NMR (CDC1 3 , δ) : 1.4-2.1 (12H, m) , 3.86 (6H, s), 4.25-4.45 (IH, m) , 4.58 (2H, s), 6.88 (IH, s), 7.3-7.6 (9H, m) APCI-MASS (m/z) : 461 (M+H + ) Example 4 To a solution of 2, 4, 6-trifluoroaniline (441 mg) and triphosgene (297 mg) in dichloromethane (10 ml) was added triethylamine (304 mg) at 5°C and the mixture was refluxed for 2 hours under nitrogen. The mixture was cooled to room temperature and a solution of N- (4-biphenylylmethyli - cycloheptylamine (559 mg) in dichloromethane (3 ml) was added. The mixture was stirred at room temperature for 1.2 hours and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give i-(4- biphenylylmethyl) -l-cycloheptyl-3- (2,4,6- trimethylphenyl) urea (752 mg) . IR (KBr) : 3285, 2930, 2860, 1635, 1520 cm "1 NMR (CDC1 3 , δ) : 1.45-2.15 (12H, ) , 4.3-4.45 (IH, m) , 4.59 (2H, s), 5.56 (IH, s), 6.55-6.7 (2H, m. , 7.3-7.65 (9H, m) APCI-MASS (m/z) : 453 (M+H + ) Example 5 The following compounds were obtained according to similar manners to those of Examples 1, 2, 3 and 4. (1) 1-Cycloheptyl-l- (4-phenoxyphenylmethyl) -3- (2, 6- diisopropylphenyl) urea IR (KBr) : 3415, 3360, 2960, 2925, 2865, 1645, 1590 cm "1 NMR (CDC1 3 , δ) : 0.9-1.35 (12H, m) , 1.4-2.1 (12H, m) , 2.8-3.0 (2H, m) , 4.35-4.5 (IH, m) , 4.50 (2H, s), 5.46 (IH, s), 6.95-7.45 (12H, m) APCI-MASS (m/z) : 499 (M+H + ) (2) 1- (3-Biphenylylmethyl) -l-cycloheptyl-3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3325, 2925, 2855, 1625, 1505 cm "1 NMR (CDC1 3 , δ) : 1.4-2.1 (12H, m) , 1.97 (6H, s) , 2.20 (3H, s) , 4.2-4.4 (IH, m) , 4.57 (2H, s), 5.49 (IH, s), 6.78 (2H, s), 7.3-7.7 (9H, m) APCI-MASS (m/z) : 441 (M^H + ) (3) 1- (2-Bιphenylylmethyl) -l-cycloheptyl-3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3285, 2970, 2930, 2860, 1635, 1520 cm "1 NMR (CDCI3, δ) : 1.4-2.0 (12H, m) , 1.96 (6H, s) , 2.21 (3H, s), 4.25-4.4 (IH, m) , 4.37 (2H, s) , 5.30 (IH, s) , 6.80 (2H, s), 7.2-7.7 (9H, m) APCI-MASS (m/z) : 441 (M+H + ) (4) 1-Cycloheptyl-l- (4-phenoxyphenylmethyl) -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3295, 2920, 2855, 1620, 1590, 1510, 1490 cm "1 NMR (CDCI3, δ) : 1.4-1.8 (12K, m) , 2.00 (6H, s), 2.22 (3H, s), 4.35-4.5 (IH, m) , 4.48 (2H, s) , 5.47 (IH, s), 6.81 2H, s), 7.0-7.4 (9H, ) APCI-MASS (m/z) : 457 (M+H (5) 1-Cycloheptyl-l- (3-phenoxyphenylmethyI) - 3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3310, 2925, 2855, 1625, 1605, 1585, 1510 cm "1 NMR (CDC1 3 , δ) : 1.4-1.8 (12H, ' m), 2.00 (6H, s) , 2.21 (3H, s), 4.25-4.45 (IH, ) , 4.47 (2H, s), 5.44 (IH, s), 6.80 (2H, s), 6.85-7.4 (9H, m) APCI-MASS (m/z) : 457 (M+H + ) (6) 1-Cycloheptyl-l- [4- (pyridin-2-yl)benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3410, 3320, 2920, 2855, 1625, 1585, 1560, 1505 cm "1 NMR (CDCI3, δ) : 1.4-1.8 (12H, m) , 2.03 (6H, s), 2.20 (3H, s), 4.3-4.5 (IH, m) , 4.58 (2H, s), 5.49 (IH, s), 6.80 (2H, s), 7.2-7.3 (IH, m) , 7.51 (2H, d, J=8.3Hz), 7.7-7.85 (2H, m) , 8.02 (2H, d, J=8.3Hz), 8.7-8.75 (IH, m) APCI-MASS (m/z) : 442 (M+H + ) (7) 1-Cycloheptyl-l- [4- (pyridin-3-yl)benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3315, 2920, 2855, 1645, 1510 cm "1 NMR (CDCI3, δ) : 1.4-1.9 (12H, m) , 2.02 (6H, si , 2.21 (3H, s), 4.35-4.5 (lH,m), 4.58 (2H, s) , 5.48 (IH, s) , 6.80 (2H, s), 7.39 (IH, dd, J=7.9, 4.9Hz), 7.3-7.7 (4H, m) , 7.86 (IH, dt, J=8.2, 1.8Hz), 8.60 (IH, d, J=3.6Hz), 8.83 (IH, s) APCI-MASS (m/z) : 442 (MXK + ) (8) 1-Cycloheptyl-l- [ [2- (4-chlorophenyl) thiazol-4- - 150 - yl]methyl] -3- (2, , 6-trimethylphenyl) urea IR (KBr) : 3300, 2920, 2855, 1645, 1610, ' 1495 cm -1 NMR (CDC1 3 , δ) : 1.5-2.0 (12H, m) , 2.13 (6H, s), 2.24 (3H, s), 4.2-4.4 (IH, m) , 4.61 (2H, s), 6.85 (2H, s), 7.18 (IH, s), 7.24 (IH, s), 7.35-7.45 (2H, m) , 7.8-7.9 (2H, m) APCI-MASS (m/z) : 483 (M+H + ) (9) 1-Cycloheptyl-l- [ (2-phenylimidazol-5-yl)methyl] -3- (2, , 6-trimethylphenyl) urea IR (KBr) : 3100, 2925, 2855, 1620, 1570 cm "1 NMR (DMSO-d 6 , δ) : 1.35-1.8 (12H, m) , 2.06 (6H, s), 2.21 (3H, s), 4.05-4.2 (IH, m) , 4.36 (2H, s), 6.83 (2H, s), 7.23 (IH, s), 7.3-7.5 (3H, m) , 7.8- 7.9 (2H, m) , 8.68 (IH, s) , 12.55 (IH, s) APCI-MASS (m/z) : 431 (M+H + ) (10) 1-Cycloheptyl-l- [4- (pyrrol-1-yl) benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3310, 2920, 2855, 1625, 1525, 1510 cm "1 NMR (CDCI3, δ) : 1.4-2.05 (12H, ) , 2.01 (6H, ε) , 2.21 (3H, s), 4.3-4.5 (IH, m) , 4.53 (2H, ε) , 5.46 (IH, s), 6.3-6.4 (2H, m) , 6.80 (2H, s), 7.05-7.15 (2H, m) , 7.35-7.5 (4H, m) APCI-MASS (m/z) : 430 (M+H + ) (11) l-Cycloheptyl-l-[3- (pyrrol-1-yl) benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3320, 2920, 2855, 1625, 1610, 1505 cm "1 NMR (CDCI3, δ) : 1.45-2.05 (12H, m) , 2.01 (6H, s) , 2.21 (3H, s), 4.3-4.5 (IK, m) , 4.56 (2K, s;, 5.47 (IH, s), 6.35-6.4 (2H, m) , 6.80 (2H, s), 7.05- 7.10 (2H, m) , 7.25-7.5 (4H, m) APCI-MASS (m/z) : 430 (M+H + ) ,12) l-Cycloheptyl-l- [ [ 4- (pyrrcl-1-yl)pyridin-2-yl]methyl] - 3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3220, 2920, 1645, 1605, 1575, 1500 cm "1 NMR (DMSO-d 6 , δ) : 1.4-1.8 (12H, m) , 2.13 (6H, s), 2.21 (3H, s), 4.1-4.3 (IH, m) , 4.56 (2H, s) , 6.35-6.4 (2K, m), 6.84 (2H, s), 6.5-6.55 (2K, ) , 6.55-6.65 (2H, m) , 8.50 (IH, br s), 8.51 (IH, d, J=5.6Hz) APCI-MASS (m/z) : 431 (M+H + ) (13) l-Cycloheptyl-l- [ (6-phenylpyridin-3-yl)methyl] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3315, 2920, 2855, 1630, 1560, 1515 cm "1 NMR (CDC1 3 , δ) : 1.4-2.05 (12H, m) , 2.09 (6H, s), 2.23 (3H, s), 4.1-4.3 (IH, m) , 4.60 (2H, s), 5.53 (IH, s), 6.83 (2H, s), 7.35-7.55 (3H, m) , 7.7-7.9 (2H, m) , 7.95-8.05 (2H, m) , 8.70 (IK, s) APCI-MASS (m/z) : 442 (M÷H + ) (14) l-Cycloheptyl-l- [3- (2-me hylthiazol-4-yl) benzylj -3- (2,4, 6-trimethylphenyl) urea IR (KEr) : 3360, 2925, 2855, 1620, 1505 cm "1 NMR (CDC1 3 , δ) : 1.4-2.05 (12H, m) , 1.98 (6K, s), 2.20 (3H, s), 2.78 (3H, s), 4.4-4.55 (IH, m) , 4.57 (2H, s) , 5.49 (IH, s), 6.78 (2H, s), 7.33 (IH, s), 7.35-7.5 (2H, m) , 7.79 (IH, d, J=7.1Hz), 7.93 (IH, s) APCI-MASS (m/z) : 462 (M+H ÷ ) (15) l-Cycloheptyl-l- [3- (pyrazol-3-yl) benzyl] -3- (2, , 6- trimethylphenyl) urea IR (KBr) : 3405, 3210, 2925, 2855, 1640, 1610, 1500 cm "1 NMR (CDC1 3 , δ) : 1.4-1.9 (12H, m) , 2.08 (6H, s), 2.20 (3H, s), 4.1-4.25 (IH, m) , 4.54 (2H, s), 6.63 (IH, s), 6.82 (2H, s), 7.2-7.6 (6H, m) , 12.86 (IH, s) APCI-MASS (m/z) : 431 (M+H ÷ ) (16) 1-Benzyl-l- (4-phenoxybenzyl) -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3310, 3030, 2915, 1630, 1590, 1505 cm "1 NMR (CDC1 3 , δ) : 2.01 (6K, s), 2.22 (3H, s), 4.63 (2H, s), 5.64 (IH, s), 6.82 (2H, s), 7.0-7.4 (14H, m) APCI-MASS (m/z) : 451 (M+H + ) (17) 1-Furfuryl-l- (4-phenoxybenzyl) -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3280, 3030, 2975, 2915, 1625, 1595, 1530, 1505 cm "1 NMR (CDC1 3 , δ) : 2.10 (6H, s), 2.25 (3K, s), 4.55 (2H, s), 4.61 (2H, s), 6.03 (IH, s) , 6.25-6.3 (IH, m) , 6.35-6.4 (IH, m) , 6.86 (2H, s) , 6.95- 7.45 (10H, m) APCI-MASS (m/z) : 441 (M+H + ) (18) l-Cycloheptyl-l- [4- ( -chloropnenyl)benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3400, 3300, 2925, 2855, 1655, 1625, 1505 cm "1 NMR (CDCI3, δ) : 1.5-2.05 (12H, m) , 2.01 (6H, s), 2.21 (3H, s), 4.3-4.5 (IH, m) , 4.55 (2H, s), 5.46 (IH, s), 6.80 (2H, s), 7.4-7.65 (8H, m) APCI-MASS (m/z) : 476 (M+H + ) (19) l-Cycloheptyl-l- [4- (4-fluorophenyl) benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3400, 3300, 2925, 2855, 1655, 1625, 1490 cm "1 NMR (CDCl δ) : 1.5-2.15 (12H, ) , 2.01 (6H, s), 2.21 (3H, s), 4.4-4.6 (IH, m) , 4.55 (2H, s), 5.47 (IH, s), 6.80 (2H, s,X 7.05-7.2 (2H, m) , 7.45-7.6 (6H, m) APCI-MASS (m/z) : 459 (M+HX (20) l-Cycloheptyl-l- [4- (4-bromophenyl)benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3400, 3300, 2920, 2855, 1655, 1625, 1505 cm "1 NMR (CDCI3, δ) : 1.5-2.05 (12H, m) , 2.01 (6H, s) , 2.21 (3H, s), 4.35-4.55 (2K, s), 5.46 (IH, s) , 6.80 (2H, s), 7.45-7.6 (8H, m) APCI-MASS (m/z) 521 (M+H + : (21) l-Cycloheptyl-l- [4- (4-methylphenyl)benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3400, 3310, 3020, 2920, 2855, 1660, 1625, 1500 cm "1 NMR (CDCI3, δ) : 1.4-2.1 (12H, m) , 1.99 (6H, s), 2.20 (3H, s), 2.40 (3H, s), 4.35-4.55 (IK, ) , 4.54 (2H, s), 5.48 (IH, s), 6.79 (2H, s), 7.25 (2H, d, J=7.9Hz), 7.4-7.5 (4H, m) , 7.59 (2H, d, J=8.3Hz) APCI-MASS (m/z) : 455 (M+H + ) (22) l-Cycloheptyl-l- [4- (4-dimethylaminophenyl)benzyl] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3405, 3325, 2920, 2855, 2805, 1650, 1610, 1535, 1500 cm "1 NMR (CDCI3, δ) : 1.5-2.2 (12H, m. , 1.98 (6H, s;, 2.20 (3H, s), 3.00 (6H, s), 4.4-4.6 (IK, m) , 4.52 (2H, s), 5.50 (IH, s), 7.4-7.65 (8H, m) APCI-MASS (m/z) 484 (M+H + ) (23) l-Cycloheptyl-l- [4- (4-bromophenoxy) benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3410, 3325, 2920, 2855, 1635, 1585, 1505 cm "1 NMR (CDC1 3 , δ) : 1.5-2.1 (12H, m) , 2.01 (6H, s), 2.22 (3H, s), 4.35-4.55 (IH, m) , 4.49 (2H, s) , 5.46 (IH, s), 6.81 (2H, s), 6.85-7.05 (4H, m) , 7.3-7.5 (4H, m) APCI-MASS (m/z) : 537 (M+H + ) (24) l-Cycloheptyl-l- (4-benzoylbenzyl) -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3325, 2920, 2855, 1655, 1605, 1505 cm "1 NMR (CDCI3, δ) : 1.4-2.05 (12H, m) , 2.06 (6H, s), 2.22 (3H, s) , 4.2-4.4 (IK, m) , 4.61 (2H, s), 5.45 (IH, s), 6.82 (2H, s), 7.5-7.7 (5H, m) , 7.75-7.9 (4H, m) APCI-MASS (m/z) : 469 (M+H + ) (25) l-Cycloheptyl-l- (4-benzylbenzyl) -3- (2,4, 6- trimethylphenyl) urea IR (KBr) : 3305, 3025, 2920, 2855, 1625, 1505 cm "1 NMR (CDCI3, δ) : 1.5-2.05 (12H, m) , 1.93 (6H, s) , 2.21 (3H, s), 3.97 (2H, s), 4.35-4.55 (IH, m) , 4.46 (2H, s), 5.42 (IH, s), 6.78 (2H, s) , 7.1-7.4 (9H, m) APCI-MASS (m/z) : 455 (M+H + ) (26) l-Cycloheptyl-l- (4-phenylthiobenzyl) -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3315, 2920, 1630, 1610, 1505 cm "1 NMR (CDCI3, δ) : 1.4-2.05 (12H, m) , 2. CO (6K, s) , 2.22 (3H, s) , 4.3-4.5 (IH, m) , 4.48 (2H, si , 5.42 (IH, s), 6.81 (2H, s), 7.07 (IK, t, J=8.6Hz) , 7.25-7.45 (8H, m) APCI-MASS (m/z) : 473 (M+H + : (27) l-Cycloheptyl-l- [ (6-phenylthiopyridin-3-yl)methyl] -3- (2, , 6-trimethylphenyl) urea IR (KBr) : 3310, 2925, 2855, 1630, 1585, 1510 cm "1 NMR (CDC1 3 , δ) : 1.5-2.05 (12H, m) , 2.05 (6H, s) , 2.23 (3H, s), 4.05-4.2 (IH, m) , 4.47 (2H, s), 5.49 (IH, s), 6.84 (2H, s), 6.90 (IH, d, J=8.3Hz), 7.4-7.65 (6H, my, 8.43 (IK, d, J=1.8Hz) APCI-MASS (m/z) : 474 (M-K-T) (28) l-Cycloheptyl-l- (4-benzoylaminobenzyl) -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3350, 3055, 2920, 2855, 1655, 1610, 1550 cm -1 NMR (DMS0-d 6 , δ) : 1.4-1.9 (12H, m) , 2.06 (6H, s), 2.19 (3H, 5), 4.1-4.3 (IH, m) , 4.51 (2H, s), 6.81 (2H, s), 7.05 (IH, d, J=7.7Hz), 7.29 (IH, d, J=7.7Hz), 7.40 (IH, s), 7.5-7.7 (4H, m) , 7.77 (IH, s), 7.9-8.0 (2K, m) , 10.26 (IH, ε) APCI-MASS (m/z) : 484 (M+H + ) (29) l-Cycloheptyl-l- [4- (phenylcarbamoyl)benzyl) -3- (2, 4, 6- trimethylphenyl)urea IR (KBr) : 3425, 3300, 2920, 2860, 1670, 1635, 1600, 1540 cm "1 NMR (DMSO-d 6 , δ) : 1.4-1.9 (12H, m) , 2.11 (6H, s), 2.21 (3H, s), 4.1-4.3 (IH, m) , 4.58 (2H, s), 6.85 (2H, s), 7.13 (IH, t, J=7.3Hz), 7.3-7.5 (4H, m) , 7.65 (IH, s), 7.77 (2H, d, J=7.6Hz), 7.93 (2H, d, J=8.2Hz), 10.17 (IH, s) APCI-MASS (m/z) : 484 (M+H + ) (30) l-Cycloheptyl-l- [4- (2-pyridylcarbamoyl)benzyl] -3- (2, 4, 6-trιmethylphenyl) urea - 156 - IR (KBr) : 3335, 2920, 2855, 1675, 1635, 1610, 1580, 1525, 1505 cm "1 NMR (DMSO-d 6 , δ) : 1.4-1.9 (12H, m) , 2.10 (6H, s), 2.21 (3H, s), 4.1-4.3 (IH, m) , 4.57 (2H, s), 6.84 (2H, s), 7.16 (IH, dd, J=6.8, 5.8Hz), 7.42 (2H, d, J=8.2Hz), 7.63 (IH, br s), ■ 7.8-7.9 (IH, m) , 8.00 (2H, d, J=8.2Hz), 8.19 (IH, d, J=8.4Hz), 8.35-8.45 (IH, m) , 10.71 (IH, s) APCI-MASS (m/z) : 485 (M+H + ) (31) l-Cycloheptyl-l- [4- (4-fluorophenoxy) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3305, 2920, 2855, 1630, 1500 cm "1 NMR (CDC1 3 , δ) : 1.5-2.1 (12H, m) , 2.00 (6H, s), 2.22 (3H, s), 4.3-4.5 (IH, m) , 4.76 (2H, s), 5.47 (IH, s), 6.82 (2H, s), 6.9-7.1 (6H, m) , 7.36 (2H, d, J=8.5Hz) APCI-MASS (m/z) : 475 (M+H + ) (32) l-Cycloheptyl-l- [4- (phenylsulfamoyl) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3395, 3130, 2925, 2860, 1635, 1600, 1500 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.8 (12K, m) , 2.01 (6H, s), 2.20 (3H, s), 4.05-4.25 (IH, m) , 4.5C (2H, s), 6.81 (2H, s), 7.0-7.15 (3K, m) , 7.15-7.3 (2H, m) , 7.42 (2H, d, J=8.3Hz) , 7.57 (IH, br si, 7.70 (2K, d, J=8.3Hz), 10.23 (IH, s) APCI-MASS (m/z) : 520 (M+H 'r ) (33) l-Cycloheptyl-l- [4- (phenylsulfonylamino) oenzy1] -3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3410, 3110, 2925, 2860, 1630, 1510 cm "1 NMR (DMS0-d 6 , δ) : 1.3-1.8 (12H, m) , 1.99 (6H, s) , 2.20 (3H, s), 4.0-4.2 (IH, m) , 4.37 (2H, si , 6.81 (2H, s), 7.01 (2H, d, J=8.3Hz), 7.15 (2H, d, J=8.3Hz), 7.37 (IH, br s) , 7.5-7.65 (3H, m) , 7.7- 7.8 (2H, m) , 10.22 (IH, br s) APCI-MASS (m/z) : 520 (M+H + ) (34) l-Cycloheptyl-l- [4- (3-thienyl)benzyl]-3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3320, 2920, 1624, 1504, 1252, 775 cm "1 NMR (CDC1 3 , δ) : 1.40-2.10 (12H, m) , 2.00 (6H, s), 2.20 (3K, s), 4.35-4.55 (IH, m) , 4.53 (2H, s), 5.47 (IH, s), 6.79 (2H, s), 7.34-7.50 (5H, m) , 7.55-7.66 (2H, m) APCI-MASS (m/z) : 447 (M+H + ) (35) l-Cycloheptyl-l- [4- (2-thienyl)benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3319, 2922, 1624, 1504, 1253, 849 cm "1 NMR (CDCI3, δ) : 1.40-2.10 (12H, m) , 2.01 (6H, s), 2.20 (3H, s), 4.35-4.55 (IK, m) , 4.52 (2H, s), 5.46 (IH, s), 6.79 (2H, s), 7.09 (IK, dd, J=5.1, 3.6Hz), 7.25-7.35 (2H, m) , 7.36-7.46 (2H, m) , 7.58-7.68 (2H, m) APCI-MASS (m/z) : 447 (M+H + ) (36) l-Cycloheptyl-l- [4- (pyrazol-1-yl)benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3325, 2922, 1628, 1504, 1394 cm "1 NMR (CDCI3, δ) : 1.40-2.08 (12H, m) , 2.04 (6H, s), 2.21 (3H, s), 4.28-4.48 (IH, m) , 4.55 (2H, s), 5.48 (IK, s), 6.48 (IH, t, J=2.3Hz), 6.81 (2H, s), 7.42-7.54 (2H, m) , 7.65-7.78 (3H, m) , 7.92 (IH, d, J=2.3Hz) APCI-MASS (m/z) : 431 (M+H + ) (37) l-Cycloheptyl-l- [4- (imidazol-1-yl) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3310, 2922, 1637, 1520, 1305 cm "1 NMR (CDC1 3 , δ) : 1.38-2.10 (12H, m) , 2.05 (6K, s) , 2.22 (3H, s) , 4.20-4.40 (IH, m) , 4.57 (2H, s) , 5.47 (IH, s), 6.83 (2H, s), 7.21 (IH, s), 7.28 (IH, s), 7.33-7.44 (2H, m) , 7.45-7.57 (2H, m) , 7.85 (IH, s) APCI-MASS (m/z) : 431 (M+H + ) (38) l-Cycloheptyl-l- [4- (l-methylpyra∑ol-4-yl)benzyl] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3321, 2922, 1628, 1504, 1209, 955 cm "1 NMR (CDCI3, δ) : 1.38-2.08 (12H, m) , 1.99 (6H, s) , 2.20 (3H, s), 3.95 (3H, s), 4.35-4.55 (IH, m) , 4.50 (2H, s), 5.47 (IH, s), 6.79 (2H, s), 7.32- 7.53 (4H, m) , 7.61 (IH, s), 7.75 (IH, s) APCI-MASS (m/z) : 445 (M+H + ) (39) l-Cycloheptyl-l- [ (2-phenylthiophen-5-yl) ethyl] -3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3329, 2922, 1624, 1510, 758 cm "1 NMR (CDCI3, δ) : 1.42-2.15 (12H, m) , 2.04 (6H, s) , 2.22 (3H, s), 4.25-4.43 (IH, m) , 4.63 (2K, s) , 5.82 (IH, s), 6.81 (2H, s), 7.02 (IK, d, J=3.6Hz), 7.16 (IH, d, J=3.6Hz) , 7.22-7.43 (3H, m) , 7.50-7.61 (2H, ) APCI-MASS (m/z) : 447 (M+H + ) (40) l-Cycloheptyl-l- [4- (oxazol-5-yl) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3302, 2922, 1624, 1506, 1105, 941 cm "1 NMR (CDCI3, δ) : 1.38-2.08 (12H, m) , 2.03 (6H, s) , 2.21 (3H, s), 4.30-4.50 (IH, ) , 4.55 (2K, s) , 5.45 (IH, s), 6.81 (2H, s), 7.36 (IH, s) , 7.42- 7.53 (2H, m) , 7.63-7.74 (2H, m) , 7.92 (IK, s) APCI-MASS (m/z) : 432 (M+H + ) (41) l-Cycloheptyl-l- [ (2-phenylfuran-5-yl)methyl]-3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3340, 2920, 1628, 1508, 762 cm "1 NMR (CDC1 3 , δ) : 1.40-2.15 (12H, m) , 2.09 (6H, s), 2.23 (3H, s), 4.22-4.41 (IH, m) , 4.53 (2H, s), 5.93 (IH, s), 6.41 (IH, d, J=3.3Hz), 6.62 (IH, d, J=3.3Hz), 6.83 (2H, s), 7.20-7.43 (3H, m) , 7.57- 7.67 (2K, m) APCI-MASS (m/z) : 431 (M+H + ) (42) l-Cycloheptyl-l- [ (5-phenylisoxazol-3-yl)methyl]-3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3326, 2924, 1630, 1512, 766 cm "1 NMR (CDCI3, δ) : 1.40-2.10 (12H, m) , 2.14 (6H, s), 2.24 (3H, s), 4.05-4.25 (IH, m) , 4.56 (2H, s), 6.14 (IK, s), 6.63 (IH, s), 6.86 (2H, s), 7.40- 7.53 (3H, m) , 7.70-7.82 (2H, m) APCI-MASS (m/z) : 432 (M+H + ) (43) l-Cycloheptyl-l- [ (3-phenyipyrazol-5-yl)methyl ] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 2700-3600 (br) , 2924, 1633, 1508, 1250, 1201 cm "1 NMR (CDCI3, δ) : 1.35-2.10 (12H, m) , 2.12 (6K, s) , 2.23 (3H, s), 3.92-4.12 (IH, m) , 4.47 (2H, s), 6.24 (IH, br s), 6.50 (IH, s), 6.84 (2H, s), 7.25-7.46 (3H, m) , 7.62-7.75 (2H, m) APCI-MASS (m/z) : 431 (M+H + ) (44) l-Cycloheptyl-l- [ (4-phenylthiophen-2-yl)methyl] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3315, 2922, 2854, 1628, 1508, 1377, 1308 cm "1 - 160 - NMR (CDCI3, δ) : 1.40-2.13 (12H, m) , 2.03 (6H, s), 2.21 (3H, s), 4.26-4.45 (IH, m) , 4.66 (2H, s) , 5.82 (IH, s), 6.81 (2H, s), 7.21-7.45 (5H, m) , 7.50-7.60 (2H, m) APCI-MASS (m/z) : 447 (M+H + ) (45) l-Cycloheptyl-l- [4- (pyrazoi-3-yl) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 2800-3500 (br) , 2924, 2856, 1645, 1504, 1240 cm "1 NMR (CDCI3, δ) : 1.38-2.10 (12H, m) , 2.00 (6K, s), 2.19 (3H, s) , 4.35-4.55 (IH, m) , 4.54 (2H, s), 5.51 (IH, s), 6.60 (IH, d, J=2.3Hz), 6.78 (2H, s), 7.42-7.53 (2H, m) , 7.55 (IH, d, J=2.3Hz), 7.73-7.83 (2H, m) APCI-MASS (m/z) : 431 (M+H + ) (46) l-Cycloheptyl-l- [4- (l-methylpyrazoI-3-yI) benzyl] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3406, 3331, 2924, 2856, 1647, 1502, 1236, 849, 758 cm "1 NMR (CDCI3, δ) : 1.38-2.08 (12H, m) , 2.00 (6H, s) , 2.20 (3H, s), 3.96 (3H, s), 4.35-4.55 (IH, m) , 4.52 (2H, s), 5.50 (IH, s), 6.54 (IH, d, J=2.3Hz) , 6.78 (2H, s), 7.35-7.47 (3H, m) , 7.77-7.87 (2H, m) APCI-MASS (m/z) : 445 (M+KX (47) l-Cycloheptyl-l- [4- (l-methylpyrazoI-5-yl) benzyl] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3296, 2922, 2854, 1628, 1506, 1385 cm "1 NMR (CDCI3, δ) : 1.38-2.10 (12H, ml , 2.02 (6H, s) , 2.21 (3K, s), 3.89 (3H, s), 4.32-4.50 (IH, ) , 4.57 (2H, s), 5.45 (IH, s), 6.30 (IK, d, J=1.9Hz), 6.81 (2H, s), 7.39- 7 .56 (5K, m) , APCI-MASS (m/z) : 445 (M+H " X (48) l-Cycloheptyl-l- [3- (l-trityl-lH-tetrazol-5-yl)benzylJ - 3- (2, , 6-trimethylphenyl) urea IR (KBr) : 3340, 2924, 2856, 1649, 1495, 1448, 1240 cm "1 NMR (CDC1 3 , δ) : 1.38-2.10 (12H, m) , 1.96 (6H, s), 2.20 (3H, s), 4.30-4.50 (IH, m) , 4.57 (2H, s), 5.42 (IH, s), 6.77 (2H, s), 7.08-7.57 (17H, ) , 8.05-8.18 (2H, m) (49) l-Cycloheptyl-l- [4-phenoxybenzyl-3- (4, 6- dimethoxypyrimidin-2-yl) ]urea IR (KBr) : 3390, 2925, 2860, 1685, 1595 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 3.87 (6H, s) , 4.2-4.4 (IH, m) , 4.51 (2H, s), 5.66 (IH, s), 6.87 (IH, s), 6.95-7.4 (9H, ) APCI-MASS (m/z) : 477 (M+H + ) (50) l-Cycloheptyl-l- (4-phenyIbenzyl ) -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3360, 2925, 2855, 1660, 1565 cm "1 NMR (CDCI 3 , δ) : 1.45-2.1 (12H, m) , 2.36 (3H, si, 2.45 (3H, s) , 2.46 (3H, s;, 4.3-4.5 (IH, ) , 4.62 (2H, s), 5.52 (IH, s), 6.59 (IH, s) , 7.3-7.7 (9H, m) APCI-MASS (m/z) : 506 (M+H + ) (51) 1- (3-Phenylbenzyl) -l-cycloheptyl-3- (2, 4, 6- trifluorophenyl) urea IR (KBr) : 3285, 2925, 2860, 1635, 1610, 1520 cm "1 .NMR (CDCI3, δ) : 1.4-2.05 (12H, m) , 4.3-4.5 (IH, m) , 4.62 (2H, s), 5.60 (IH, ε), 6.55-6.7 (2H, m) , 7.3-7.65 (9H, m) APCI-MASS (m/z) : 453 (M+H + ) (52) 1- (2-Phenylbenzyl) -l-cycloheptyl-3- (2, 4, 6- trifluorophenyl) urea IR (KBr) : 3415, 3320, 3060, 3020, 2920, 2855, 1625, 1575 cm "1 NMR (CDCI 3 , δ) : 1.4-2.0 (12H, m) , 4.2-4.35 (IH, m) , 4.40 (2H, s) , 5.50 (IH, s), 6.55-6.75 (2H, m) , 7.25-7.6 (9H, m) APCI-MASS (m/z) : 453 (M+H + ) (53) l-Cycloheptyl-l- (4-phenoxybenzyl) -3- (2, 4, 6- trifluorophenyl) urea IR (KBr) : 3285, 2925, 2860, 1635,. 1590, 1520 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 4.2-4.4 (IH, m) , 4.51 (2H, s), 5.58 (IH, s) , 6.6-6.75 (2H, m) , 7.0-7.4 (9H, m) APCI-MASS (m/z) : 469 (M+H + ) (54) l-Cycloheptyl-l- (3-phenoxybenzyl) -3- (2, 4, 6- trifluorophenyl) urea IR (KBr) : 3280, 2930, 2860, 1635, 1615, 1585, 1520 cm "1 NMR (CDC1 3 , δ) : 1.4-2.0 (12H, m) , 4.2-4.4 (IK, m) , 4.50 (2H, s), 5.55 (IH, s), 6.6-6.75 (2H, m) , 6.9-7.4 (9H, ) APCI-MASS (m/z) : 469 (M+H + ) (55) l-Cycloheptyl-l- [4- (pyridin-2-yl) enzyl] -3- (2,4,6- trifluorophenyl) urea IR (KBr) : 3285, 2925, 2860, 1635, 1610, 1520 cm "1 NMR (CDCI3, δ) : 1.4-2.1 (12H, m) , 4.25-4.4 (IH, m) , 4.61 (2H, s), 5.59 (IH, s) , 6.6-6.75 (2H, m) , 7.2-7.3 (IH, m) , 7.47 (2H, d, J=8.4Hz) , 7.7-7.8 (2H, m) , 8.02 (2H, d, J=8.4Hz) , 8.65-8.75 (IH, m) APCI-MASS (m/z) : 454 (M+H + ) (56) 1-Benzyl-l- [ [2- (4-chlorophenyl) thiazol-4-yl]methyl] -3- - 163 - (2, 4, 6-trifluorophenyl) urea IR (KBr) : 3270, 3090, 1665, 1640, 1615, ' 1520 cm "1 NMR (CDC1 3 , δ) : 4.54 (2H, s), 4.64 (2H, s), 6.65-6.8 (2H, m) , 7.3-7.4 (5H, m) , 7.34 (IH, s), 7.4-7.5 (2H, m) , 7.85-7.95 (2H, m) APCI-MASS (m/z) : 488 (M+H + ) (57) 1- (Cycloheptyl-l-[4- (pyrrol-1-yl)benzyl] -3- (2,4,6- trifluorophenyl) urea IR (KBr) : 3285, 2925, 2860, 1635, 1610, 1520 cm "1 NMR (CDCI3, δ) : 1.4-2.05 (12H, m). , 4.2-4.4 (IH, m) , 4.56 (2H, s), 5.57 (IH, s) , 6.3-6.4 (2H, ) , 6.55-6.7 (2H, m) , 7.05-7.15 (2H, m) , 7.41 (4H, s) APCI-MASS (m/z) : 442 (M+H + ) (58) l-Cycloheptyl-l- [4- (3-thienyl)benzyl] -3- (2, 4, 6- trifluorophenyl)urea IR (KBr) : 3300, 2927, 1637, 1518, 1120, 777 cm "1 NMR (CDCI3, δ) : 1.40-2.08 (12H, m) , 4.27-4.47 (IK, m) , 4.56 (2H, s), 5.58 (IH, s), 6.58-6.73 (2H, m) , 7.30-7.50 (5H, m) , 7.57-7.70 (2H, m) APCI-MASS (m/z) : 459 (M+H + ) (59) l-Cycloheptyl-l-.4- (2-thienyl)benzyl] -3- (2,4,6- trifluorophenyl) urea IR (KBr) : 3300, 2930, 1635, 1520, 1120 cm "1 NMR (CDCI3, δ) : 1.38-2.08 (12H, m) , 4.25-4.45 (IH, m) , 4.55 (2H, s), 5.57 (IH, s), 6.55-6.72 (2H, m) , 7.09 (IH, dd, J=5.1, 3.6Hz), 7.22-7.42 (4H, m) , 7.57-7.70 (2H, m) APCI-MASS (m/z) : 459 (M+H + ) Example To a stirred suspension of 1-cycloheptyl-l- [3- (1- trityl-lH-tetrazol-5-yl)benzyI]-3-(2,4, 6- trimethylphenyl) urea (1.46 g) in methanol (14 ml) was added cone, hydrochloric acid (0.722 ml) . The mixture was stirred for one hour at room temperature. Insoluble white solid was collected by filtration, washed with methanol (x2), water (x3) to give 1-cycloheptyl-l- [3- (lH-tetrazol-5- yDbenzyl] -3- (2, 4, 6-trimethylphenyl) urea (0.79 g) . IR (KBr) : 3359, 2400-3300 (br) , 1595, 1512, 1456, 1257 cm "1 NMR (DMSO-d 6 , δ) : 1.35-1.90 (12H, m) , 2.06 (6H, s), 2.20 (3H, s), 4.14-4.34 (IH, m) , 4.59 (2H, s), 6.82 (2K, s), 7.46-7.66 (2H, m) , 7.80-7.90 (IH, m) , 8.00-8.08 (IH, m) APCI-MASS (m/z) : 433 (M+H + ) Example 7 To a solution of N-cycloheptyl-4- (4- fluorophenoxy) benzylamine (2.51 g) in toluene (100 ml) were added 3-phenoxycarbonylamino-2, -bis (methylthio) -6- methylpyridine (2.56 g) and triethylamine (2.43 g) and the mixture was refluxed for 4 hours under nitrogen. The mixture was cooled and poured into a mixture of ethyl acetate and water. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-l- [ - (4- fluorophenoxy)benzyl] -3- [2, 4-bis (methylthio) -6- methylpyridin-3-yl] urea (3.89 g) . IR (KBr) : 3379, 3080, 3055, 2924, 2856, 1651, 1568, 1529, 1497 cm "1 NMR (DMSO-d 6 , δ) : 1.4-2.0 (12H, m) , 2.39 (6H, s) , 2.44 (3H, s), 4.0-4.2 (IH, m) , 4.45 (2H, s) , 6.86 (IH, s), 6.93 (2H, d, J=8.5Hz), 7.0-7.1 (2H, m) , 7.15-7.3 (2H, m) , 7.36 (2H, d, J=8.5Hz), 7.83 (IH, br s) APCI-MASS (m/z) : 540 (M+H ÷ ) Example 8 To a solution of N-cycloheptyl-4- (4- fluorophenoxy)benzylamine (1.57 g) in toluene (150 ml) were added 2, -dimethoxy-6-methyl-3-phenoxycarbonylaminopyridine (1.44 g) and triethylamine (1.52 g) , and the mixture was refluxed for 3 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-l-[4- (4-fluorophenoxy)benzyl]-3- (2, 4- dimethoxy-6-methylpyridin-3-yl)urea (1.83 g) . IR (KBr) : 3388, 3062, 2927, 2856, 1668, 1599, 1498 cm "1 NMR (DMS0-d 6 , δ) : 1.3-1.9 (12H, m) , 2.35 (3H, s), 3.67 and 3.77 (6H, s x 2), 4.0-4.2 .(IH, ) , 4.43 (2H, s), 6.63 (IH, s) , 6.95-7.4 (8H, m) APCI-MASS (m/z) : 496 (M+H ÷ ) Example 9 To a suspension of N-benzyl-3- (pyrazol-3- yl) enzylamine bis (trifluoroacetate) (2.46 g) in toluene (80 ml) were added 2, 4-bis (methylthio)-6-methyl-3- phenoxycarbonylaminopyridine (1.60 g) and triethylamine (2.53 g) , and the mixture was refluxed for 4.5 hours under nitrogen. The mixture was cooled and poured into a mixture of ethyl acetate and ice water. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-benzyl-l- [3- (pyrazol-3-yl)benzyl]-3-[2, 4-bis (methylthio) -6- methylpyridin-3-yl]urea (831 mg) . IR (KBr) : 3238, 3061, 3028, 2959, 2924, 2870, 1641, 1564, 1495 cm "1 NMR (DMS0-d 6 , δ) : 2.42 (6H, s), 2.46 (3H, s), 4.49 (4H, br s), 6.6-6.7 (IH, m) , 6.90 (IH, s) , 7.2- 7.8 (10H, m) , 8.29 (IH, br s), 12.88 (IH, br s) APCI-MASS (m/z) : 490 (M+H + ) Example 10 The mixture of N-cycloheptyl-3- (l-tritylpyrazol-3-yl) - benzylamine (14.63 g) and phenyl N- (2,4,6- trifluorophenyl) carbamate (7.64 g) and triethylamine (20 ml) in toluene (360 ml) was stirred at 100°C for one hour. After cooling to room temperature, the reaction mixture was washed with water, aqueous sodium bicarbonate, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (700 g, eluting with n-hexane - ethyl acetate (4:1 to 3:1)) to give 1-cycloheptyl-l- [3- (1-tritylpyrazol- 3-yl)benzyl] -3- (2, 4, 6-trifluorophenyl) urea (19.6 g) . IR (KBr) : 2900-3600 (br) , 2927, 2858, 1635, 1607, 1520, 1446 cm "1 NMR (CDC1 3 , δ) : 1.35-2.10 (12H, m) , 4.26-4.48 (IH, m) , 4.55 (2H, s), 5.57 (IH, s), 6.52-6.70 (3H, m) , 6.75-6.97 (2K, ml, 7.10-7.45 (16H, m) , 7.68-7.80 (2H, m) Example 11 The following compounds were obtained according to similar manners to those of Examples 7, 8, 9 and 10. (1) 1-Cyclohexyl-l- [4- (4-fluorophenoxy) benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3377, 3084, 3057, 2927, 2856, 1653, 1566, 1533, 1497 cm "1 NMR (DMS0-d 6 , δ) : 1.3-1.8 (10H, m) , 2.39 (6H, ε) , 2.45 (3H, s), 3.85-4.05 (IH, m) , 4.47 (2H, s), 6.86 (IH, s), 6.93 (2H, d, J=8.5Hz) , 6.95-7.05 (2H, m) , 7.35 (2H, d, J=8.5Hz) , 7.88 (IH, s) - 167 - APCI-MASS (m/z) : 526 (M+H + ) (2) 1-Benzyl-l- [4- (4-fluorophenoxy)benzyl] -3- [2,4- bis (methylthio) -6-methylpyridin-3-yl) urea IR (KBr) : 3307, 3062, 3029, 2999, 2922, 1735, 1660, 1564, 1497 cm "1 NMR (DMSO-d 6/ δ) : 2.42 (6K, s), 2.46 (3H, s), 4.43 (2H, s), 4.46 (2H, s) , 6.89 (IH, s), 6.9-7.4 (13H, m) , 8.26 (IH, s) APCI-MASS (m/z) : 526 (M+H + ) (3) l-Cycloheptyl-l- (4-phenoxybenzyl) -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3371, 2922, 2856, 1653, 1485, 1219 cm "1 NMR (CDC1 3 , δ) : 1.35-2.10 (12H, m) , 2.36 (3H, s) , 2.45 (3H, s), 2.46 (3H, s), 4.22-4.42 (IH, m) , 4.55 (2H, s), 5.49 (IH, s) , 6.59 (IH, s), 6.95- 7.15 (5H, m) , 7.24-7.46 (4H, m) APCI-MASS (m/z) : 522 (M+H + ) (4) l-Cycloheptyl-l- [4- (4-bromophenoxy) benzyl] -3- [2, - bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3377, 2924, 2852, 1668, 1481, 1238 cm "1 NMR (CDCI3, δ) : 1.40-2.10 (12H, m) , 2.37 (3H, s) , 2.46 (3H, s), 2.47 (3H, s), 4.25-4.40 (IH, m) , 4.55 (2H, s) , 5.47 (IH, s) , 6.60 (IK, s) , 6.80- 7.08 (4H, m) , 7.35-7.50 (4H, ) APCI-MASS (m/z) : 600, 602 (M+H + ) (5) l-Benzyl-l-[4- (4-bromophenoxy)benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3200-3700 (br) , 2922, 1662, 1564, 1481, 1236 cm "1 NMR (CDCI3, δ) : 2.39 (3H, s) , 2.47 (3H, s), 2.49 (3H, s), 4.61 (2H, s), 4.63 (2H, s), 5.68 (IK, s), 6.62 (IH, s), 6.82-7.05 (4H, ml , 7.25-7.50 (9H, m) APCI-MASS (m/z) : 594, 596 (M+H + ) (6) l-Cycloheptyl-l- [4- ( -bromophenoxy) benzyl] -3- [2, 4- dimethoxy-6-methylpyridin-3-yl]urea IR (KBr) : 3100-3700 (br) , 2926, 2856, 1668, 1597, 1504, 1481, 1240 cm "1 NMR (CDC1 3 , δ) : 1.40-2.10 (12H, m) , 2.38 (3H, s), 3.79 (3H, s), 3.83 (3H, s), 4.25-4.40 (IH, m) , 4.52 (2H, s), 5.43 (IH, s), 6.36 (IH, s), 6.82- 7.06 (4H, m) , 7.32-7.50 (4H, m) APCI-MASS (m/z) : 568, 570 (M+H + ) (7) 1-Benzyl-l- [4- (4-bromophenoxy) benzyl] -3- [2, 4- dimethoxy-6-methylpyridin-3-yl]urea IR (KBr) : 3200-3400 (br) , 2997, 1637, 1595, 1506, 1365 cm "1 NMR (CDCI3, δ) : 2.39 (3H, s), 3.80 (3H, s), 3.85 (3H, s) , 4.60 (4H, s), 5.64 (IH, s), 6.38 (IH, s), 6.80-7.05 (4H, m) , 7.22-7.50 (8K, m) APCI-MASS (m/z) : 562, 564 (M+H + ) Example 12 To a mixture of 1-cycloheptyl-l- [3- (l-tritylpyrazol-3- yl)benzyl] -3- (2, 4, 6-trifluorophenyl) urea (17.6 g) and anisole (35 ml) was added trifluoroacetic acid (70 ml) . The mixture was stirred at 60°C for 3 hours and cooled to room temperature. The excess trifluoroacetic acid was removed in vacuo. To the residue was added water and ethyl acetate. The mixture was basified with 5N-sodium hydroxide under ice cooling and extracted with ethyl acetate. The organic layer was washed with water, and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel (530 g, eluting with n-hexane - ethyl acetate (2:1 to 1:2)) to give 1-cycloheptyl-l- [3- (pyrazol-3-yl)benzyl] -3- (2, 4, 6- trifluorophenyl) urea (10.71 g) . IR (KBr) : 3500-2600 (br) , 2927, 2858, 1635, 1520, 1448, 1248, 1120 cm "1 NMR (CDC1 3 , δ) : 1.30-2.10 (12H, m) , 4.26-4.46 (IK, m) , 4.59 (2H, s), 5.63 (IH, s), 6.53-6.73 (3H, m) , 7.30-7.50 (2H, m) , 7.63 (IH, d, J=2.3Hz), 7.65-7.80 (2H, m) APCI-MASS (m/z) : 443 (M-*-H ÷ ) Exaπ e 13 To a solution of N-cycloheptyl-4- (4-fluorophenoxy) - benzylamine (1.57 g) in toluene (100 ml) were added 3- phenoxycarbonylamino-2, 4, 6-trimethylpyridine (2.56 g) and triethylamine (1.52 g) , and the mixture was refluxed for 3 hours under nitrogen. The mixture was cooled and poured into a mixture of ethyl acetate and water. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- cycloheptyl-1- [4- (4-fluorophenoxy)benzyl] -3- (2, 4, 6- trimethylpyridin-3-yl) urea (1.83 g) . IR (KBr) : 3313, 2924, 2856, 1630, 1603, 1497 cm "1 NMR (DMSO-d 6 , δ) : 1.4-1.9 (12H, m) , 2.06 (3K, s), 2.24 (3H, s), 4.05-4.25 (IH, m) , 4.48 (2K, s), 6.98 (IH, s), 6.9-7.1 (4H, m) , 7.2-7.4 (4K, m) , 7.66 (IH, s) APCI-MASS (m/z) : 476 (M+H + ) Example 14 To a solution of N-cycloheptyl-4- (4-fluorophenoxy) - benzylamine (2.51 g) in toluene (120 ml) were added 4- chloro-6-methyl-2-methylthio-3-phenoxycarbonylaminopyridine (2.47 g) and triethylamine (2.43 g) at room temperature and the mixture was refluxed for 2.5 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-l- [4- (4-fluorophenoxy) - benzyl] -3- (2-chloro-6-methyl-4-methylthiopyridin-3-yl) urea (2.76 g) . IR (KBr) : 3371, 3299, 2924, 2852, 1655, 1576, 1500 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.8 (12H, m) , 2.43 (6H, s), 4.0-4.2 (IH, m) , 4.46 (2H, s), 6.9-7.5 (9H, m) , 8.07 (IH, br s) Example 15 To a solution of N-benzyl-3- (pyrazol-3-yl)benzylamine (54.0 g) and triethylamine (143 ml) in toluene (1.35 f) was added 2, 4-bis (methylthio) -3-phenoxycarbonylamino-6- methylpyridine (62.4 g) at room temperature and stirred for 24 hours. The resulting precipitate was collected by filtration and recrystallized from dichloromethane - methanol - n-hexane to give 1-benzyl-l- [3- (pyrazol-3- yl) benzyl] -3- [2, 4-bis (methylthio) -6-methylpyridin-3-yi] urea (51.0 g) . mp : 209-210°C IR (KBr) : 3392, 3246, 2918, 1649, 1489, 1228, 1093 cm "1 NMR (DMSO-d 6 , δ) : 2.42 (6H, s), 2.47 (3K, s) , 4.49 (4H, s), 6.66 (IH, br s), 6.90 (IH, s), 7.18-7.90 (10H, m) , 8.30 (IH, s) , 12.89, 13.30 (total IH, each br) APCI-MASS (m/z) : 490 (M+rX) Example 16 To a solution of N-benzyl- [4- ( -bromophenoxy) benzyl] - 5 - 171 - amine (1.84 g) and 2,4, 6-trimethylphenyl-3- phenoxycarbonylaminopyridine (2.20 g) in N,N- dimethylformamide (50 ml) was added triethylamine (2.53 g) , and the mixture was stirred at 150°C for 3 hours under nitrogen. The mixture was cooled and ethyl acetate (150 ml) was added thereto. The insoluble materials were filtered off, and the filtrate was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-benzyl-l-[4- (4-bromophenoxy)- benzyl]-3- (2,4, 6-trimethylpyridin-3-yl)urea (2.51 g) . IR (KBr) : 3406, 3313, 2929, 2856, 1714, 1632, 1572, 1495 cm "1 NMR (DMSO-d 6 , δ) : 2.08 (3H, s), 2.26 (3H, s) , 2.35 (3H, s), 4.53 (2H, s), 4.57 (2H, s), 6.95-7.15 (5H, m) , 7.3-7.6 (9H, m) , 8.05 (IH, br s) APCI-MASS (m/z) : 531 (M+H + ) Sxample 17 To a solution of N-cycloheptyl-4- (4-fluorophenoxy)- benzylamine (1.25 g) in toluene (80 ml) were added 4,6- biε (methylthio) -2-methyl-5-phenoxycarbonylaminopyrimidine (1.29 g) and triethylamine (1.21 g) , and the mixture was refluxed for 2 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-l-[4- (4-fluorophenoxy)benzyl]-3-[4, 6- is (methylthio) -2-methylpyrimidin-5-yl]urea (1.33 g) . IR (KBr) : 3255, 2926, 2856, 1653, 1522, 1497 cm "1 NMR (DMSO-d β , δ) : 1.4-1.9 (12H, m) , 2.43 (6H, s), 2.56 (3H, s), 3.95-4.1 (IH, m) , 4.46 (2H, s), 6.9-7.4 (8H, m) , 8.00 (IK, br s) APCI-MASS (m/z) : 529 (M+H + ) Example 18 To a solution of 1-cycloheptyl-l- [4- (3, 5-di-tert- butyl-4-methoxymethoxyphenoxy) ]benzyl-3- (2, 4, 6- tri ethylphenyl) urea (860 mg) in methanol (8.6 ml) was added cone, hydrochloric acid (0.91 ml), and the mixture was stirred at room temperature for 2 hours and at 40°C for 3.5 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and neutralized by addition of saturated sodium bicarbonate aqueous solution. The separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-l- [4- (3, 5-di-tert-butyl-4- hydroxyphenoxy) benzyl] -3- (2,4, 6-trimethylphenyl) urea (495 mg) . IR (KBr) : 3639, 3404, 3323, 2956, 2923, 2860, 1651, 1593, 1504 cm "1 NMR (CDC1 3 , δ) : 1.41 (18K, s), 1.5-2.1 (12H, m) , 1.98 (6H, s), 2.22 (3H, s), 4.25-4.4 (IH, m) , 4.45 (2H, s) , 5.03 (IH, s), 6.80 (2K, s), 6.86 (2H, s), 6.93 (2H, d, J=8.5Hz), 7.35 (2K, d, J=8.5Hz) APCI-MASS (m/z) : 585 (M+H + ) Example 19 To a solution of 1-cycloheptyl-l- [4- ( - fluorophenoxy)benzyl] -3- [2, 4-bis (methylthio) -6- methylpyridin-3-yl] urea (22.11 g) in dichloromethane (150 ml) was added dropwise a solution of m-chloroperbenzoic acid (26.51 g) in dichloromethane (600 mg) at room temperature over 2 hours. The mixture was stirred at room temperature for 23 hours. The precipitates were removed by filtration and the filtrate was washed with dilute sodium bicarbonate aqueous solution and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- cycloheptyl-1- [4- (4-fluorophenoxy)benzyl]-3- [2, 4- bis (methylsulfonyl) -6-methylpyridin-3-yl]urea (20.42 g) . IR (KBr) : 3361, 3074, 3041, 3016, 2927, 2860, 1740, 1664, 1500, 1325, 1159, 1128 cm "1 NMR (CDC1 3 , δ) : 1.5-2.2 (12H, m; , 2.66 (3H, s), 3.19 (3H, s), 3.30 (3H, s), 4.55 (2H, s), 6.95-7.05 (6H, m) , 7.34 (2H, d, J=8.6Hz) 7.26 (IH, s), 7.85 (IH, s) APCI-MASS (m/z) : 604 (M+H + ) Example 20 To a solution of 1-cycloheptyl-l- [4- (4- fluorophenoxy)benzyl] -3- [2, 4-bis (methylthio) -6- methylpyridin-3-yl]urea (4.75 g) in dichloromethane (50 ml) was added dropwise a solution of m-chloroperbenzoic acid (3.96 g) in dichloromethane (80 ml) at room temperature. The mixture was stirred at room temperature for 20 hours. The mixture was washed with dilute sodium bicarbonate aqueous solution and brme, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give I-cycloneptyl- 1- [4- (4-fluorophenoxy)benzyl]-3- [2, 4-bis (methylsulfmyi; -6- methylpyridin-3-yl]urea (2.15 g) . IR (KBr) : 3251, 2927, 2858, 1738, 1651, 1496, 1055, 1036 cm "1 NMR (CDCI3, δ) : 1.4-2.0 (12H, m) , 2.59 (3K, s), 2.82 and 2.94 (total 3H, s), 2.98 (3H, s), 4.0-4.2 (2H, m) , 4.51 (2H, br s), 6.9-7.1 (7H, m) , 7.25- 7.35 (2H, m) , 7.77-7.79 (total IK, s) APCI-MASS (m/z) : 572 (M-i-H " " " ) Example 21 To a suspension of 1-cycloheptyl- l- [ 3- ( 1- tπ tylpyrazol-4 -yl ) benzyl ] -3- (2 , 4 , 6-trιmethylphenyI ) urea - 174 - (800 mg) in anisole (2 ml) was added trifluoroacetic acid (6 ml) and the mixture was stirred at 100°C for 2 hours. The mixture was evaporated in vacuo and poured into a mixture of ethyl acetate and water and adjusted to pH ca. 9 by addition of sodium hydroxide aqueous solution. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- cycloheptyl-1- [3- (pyrazol-4-yl)benzyl] -3- (2, 4, 6- trimethylphenyl) urea (102 mg) . IR (KBr) : 3400, 3207, 2926, 2856, 1635, 1608, 1510 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.08 (6H, s), 2.20 (3H, s), 4.1-4.3 (IH, ml, 4.51 (2H, s), 6.83 (2H, s), 7.1-7.5 (5H, m) , 7.84 (IH, s) , 8.11 (IH, s) , 12.95 (IH, br s) APCI-MASS (m/z) : 431 (M+H + ) Example 22 The following compounds were obtained according to a similar manner to that of Example 1, 2, 3 or . (1) l-Cycloheptyl-l- [4- (4-chlorophenoxy) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3410, 2920, 2850, 1660, 1590, 1505, 1485 cm "1 NMR (CDC1 3 , δ) : 1.5-2.1 (12H, m) , 2.00 (6H, s) , 2.22 (3H, s), 4.3-4.45 (IH, m) , 4.48 (2H, ε) , 5.6-5.8 (IH, br), 6.81 (2H, ε) , 6.92 (2H, d, J=8.5Hz) , 7.00 (2H, d, J=8.5Hz) , 7.28 (2H, d, J=8.4Hz) , 7.38 (2H, d, J=8.4Hz) (2) l-Cycloheptyl-l- [4- (3-fluorophenoxy) benzyl] -3- (2, 4, 6- trimethylphenyl) urea mp : 127-128°C IR (KBr) : 2924, 2856, 1624, 1605, 1506, 1485 cm "1 NMR (CDC1 3 , δ) : 1.35-2.10 (12H, m) , 2.01 (6H, s), 2.22 (3H, s), 4.30-4.50 (IH, m) , 4.50 (2H, s) , 5.46 (IH, s), 6.60-6.88 (3H, m) , 6.79 (2H, s), 7.00-7.10 (2H, m) , 7.20-7.35 (IH, m) , 7.36-7.47 (2H, m) APCI-MASS (m/z) : 475 (M J -H ÷ ) (3) l-Cycloheptyl-l- [4- (4-trifluoromethylphenoxy)benzyl] - 3- (2, 4, 6-trimethylphenyl) urea mp : 146-147°C IR (KBr) : 2924, 2856, 1628, 1504, 1327, 1246 cm "1 NMR (CDC1 3 , δ) : 1.40-2.10 (12H, m) , 2.03 (6H, s), 2.23 (3H, s), 4.30-4.50 (IH, m) , 4.51 (2H, s) , 5.47 (IH, s), 6.83 (2H, s) , 6.95-7.13 (4H, m) , 7.35-7.50 (2H, m) , 7.53-7.65 (2H, m) APCI-MASS (m/z) : 525 (M+H + ) (4) l-Cycloheptyl-l- [4- (3, 4-methylenedioxyphenoxy)benzyl] 3- (2, 4, 6-trimethylphenyl)urea mp : 125-126°C IR (KBr) : 3323, 2922, 2854, 1628, 1506, 1481 cm "1 NMR (CDC1 3 , δ) : 1.38-2.10 (12H, m) , 1.99 (6H, s), 2.22 (3H, s), 4.33-4.50 (IH, m) , 4.46 (2K, s), 5.46 (IH, s), 5.98 (2K, s), 6.47 (IH, dd, J=8.3, 2.4Hz), 6.56 (IH, d, J=2.4Hz), 6.76 (IH, d, J=8.3Hz), 6.81 (2H, s), 6.90-7.00 (2H, m) , 7.26- 7.38 (2H, ) APCI-MASS (m/z) : 501 (M+H + ) (5) l-Cycloheptyl-l- [4- (3, 5-di-tert-butyI-4- methoxymethoxyphenoxy) ]benzyl-3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3406, 3323, 2956, 2924, 2862, 1641, 1589, 1504 cm "1 NMR (CDCI3, δ) : 1.41 (18H, s) , 1.4-2.2 (14H, m) , 1.99 (6H, s), 2.22 (3H, s), 3.62 and 3.65 (total 3H, s), 4.3-4.5 (IH, m) , 4.46 (2H, s), 4.86 and 4.92 (total 2H, s), 6.80 (2H, s), 6.95-7.1 (4K, m) , 7.4-7.5 (2H, m) (6) l-Cycloheptyl-l- [4- (4-fluorophenoxy)phenyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3425, 2925, 2860, 1670, 1610, 1500 cm "1 NMR (CDCI3, δ) : 1.3-1.7 and 1.9-2.1 (12H, m) , 2.12 (6H, s), 2.22 (3H, s) , 4.45-4.65 (IK, m) , 5.30 (IH, br s), 6.82 (2H, s), 7.0-7.3 (8H, m) APCI-MASS (m/z) : 461 (M+H + ) (7) 1-Benzyl-l- [4- (4-fluorophenoxy) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3307, 3062, 3030, 2918, 1633, 1608, 1510, 1497 cm "1 NMR (CDCI3, δ) : 2.00 (6H, s), 2.22 (3H, s), 4.62 (4H, s), 5.68 (IH, s), 6.82 (2H, s), 6.9-7.1 (6H, m) , 7.3-7.45 (7H, m) APCI-MASS (m/z) : 469 (M+H + ) (8) 1-Pentyl-l- [4- (4-fluorophenoxy) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3292, 2958, 2920, 2856, 1632, 1608, 1498 cm "1 NMR (CDCI3, δ) : 0.90 (3H, t, J=6.3Hz) , 1.25-1.45 (4H, m) , 1.6-1.8 (2H, m) , 2.09 (6H, s) , 2.30 (3H, s), 3.39 (2H, t, J=7.4Hz), 4.55 (2H, s) , 5.74 (IK, br s), 6.84 (2H, s), 6.9-7.1 (6H, m) , 7.30 (2H, d, J=8.4Hz) APCI-MASS (m/z) : 449 (M+H + ) (9) 1-Cyclohexyl-l- [4- (4-fluorophenoxy) benzyl] -3- (2, 4, 6- - 177 - trimethylphenyl) urea IR (KBr) : 3296, 2958, 2922, 2890, 1624, 1520, 1487 cm "1 NMR (CDCi 3 , δ) : 1.3-2.0 (10H, m) , 1.99 (6H, s) , 2.22 (3H, s), 4.25-4.45 (IH, m) , 4.47 (2H, s) , 5.54 (IH, br s), 6.81 (2H, s), 6.9-7.1 (6H, m) , 7.35 (2H, d, J=8.5Hz) APCI-MASS (m/z) : 461 (M+H + ) (10) 1-Cyclopentyl-l- [4- (4-fluorophenoxy)benzyl] -3- (2, 4, 6- tri ethylphenyl) urea IR (KBr) : 3400, 3304, 3074, 2933, 2850, 1657, 1608, 1495 cm "1 NMR (CDC1 3 , δ) : 1.5-1.8 and 2.0-2.15 (8H, m) , 2.00 (6H, s), 2.22 (3H, s), 4.47 (2H, s), 4.7-4.9 (IH, m) , 5.35 (IH, br s), 6.82 (2H, s), 6.9-7.1 (6H, m) , 7.33 (2H, d, J=8.5Hz) APCI-MASS (m/z) : 447 (M+H + ) (11) l-Cycloheptyl-l- [4- (4-fluorophenoxy)benzyl] -3- (2, , 6- tπfluorophenyl) urea IR (KBr) : 3284, 2929, 2858, 1633, 1612, 1516, 1497 cm "1 NMR (CDC1 3 , δ) : 1.4-2.1 (12H, m) , 4.25-4.45 (IH, m) , 4.50 (2H, s), 5.58 (IH, s), 6.55-6.7 (2K, m) , 6.9-7.1 (6H, m), 7.25-7.4 (2H, m) APCI-MASS (m/z) : 487 (M+H + ) (12) l-Benzyl-l-[3- (pyrazol-3-yl)benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3404, 3207, 3060, 3029, 2967, 2918, 2858, 1635, 1608, 1510 cm "1 NMR (DMSO-d 6 , δ) : 2.09 (6H, s), 2.21 (3H, s;, 4.57 (2K, s), 6.0-6.05 (IH, m) , 6.84 (2H, s), 7.2-7.5 (7H, m) , 7.65-7.8 (3H, m) , 7.87 (iκ, s) , 12.89 - 178 - (IH, br) APCI-MASS (m/z) : 425 (M+H + ) (13) l-Benzyl-l-[3- (pyrazol-3-yl)benzyl] -3- (2,4,6- trifluorophenyl) urea IR (KBr) : 3246, 1637, 1522 cm "1 NMR (DMSO-d 6 , δ) : 4.54 (4H, s), 6.65 (IH, br s) , 7.2-7.5 (4H, m) , 7.7-7.9 (3H, m) , 8.47 (IH, br s), 12.90 and 13.34 (total IH, br s) APCI-MASS (m/z) : 437 (M+H + ) (14) l-Cycloheptyl-l- [3- (pyrazol-3-yl)benzyl] -3- (2,4,6- trifluorophenyl) urea IR (KBr) : 3226, 3062, 2927, 2858, 1635, 1612, 1518 cm "1 NMR (DMSO-d 6 , δ) : 1.4-1.9 (12H, m) , 4.0-4.2 (IH, m) , 4.55 (2H, s), 6.63 (IH, d, J=1.9Hz), 7.15-7.5 (4H, m) , 7.6-7.8 (3H, m) , 8.10 (IH, br s) APCI-MASS (m/z) : 444 (M+H ÷ ) (15) l-Cyclohexyl-l-[3- (pyrazol-3-yl) benzyl ] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3226, 2929, 2856, 1635, 1608, 1510 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.8 (10H, m) , 2.08 (6K, ε), 2.20 (3H, ε), 4.0-4.2 (IH, m) , 4.57 (2H, s) , 6.62 (IH, br s), 6.83 (2H, s), 7.2-7.45 (2H, m) , 7.55- 7.85 (3H, m) , 12.86 (IH, br s) APCI-MASS (m/z) : 417 (M+H + ) (16) 1-Cyclopentyl-l- [3- (pyrazol-3-yl) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3188, 2956, 2870, 1635, 1608, 1510 cm "1 NMR (DMSO-d 6 , δ) : 1.4-1.9 (12H, m) , 2.08 (6H, s), 2.20 (3H, s), 4.45-4.6 (IH, m) , 4.56 (2H, s), 6.63 (IH, br s), 6.83 (2H, s), 7.15-7.45 (2K, m) , - 179 - 7.55-7.85 (5H, m) , 12.87 (IH, br sϊ APCI-MASS (m/z) : 403 (M+H" 1 " ) ( 17 ) l-Cycloheptyl-l-[3- (l-tritylpyrazol-4-yl ) benzyl] -3- ( 2, 4, 6-trimethylphenyl) urea IR ( KBr ) : 3408, 3323, 3059, 3030, 2924, 2856, 1645, 1608, 1562 cm" 1 NMR ( DMSO-dg, δ ) : 1.4-1.9 (12H, m ) , 2.00 ( 6H, s ) , 2.20 ( 3H, s ) , 4.0-4.2 (IH, m) , 4.48 ( 2H, s ) , 6.80 ( 2H, s ) , 7.1-7.5 (19H, m) , 7.70 ( IK, s ) , 8.02 (IH, s) APCI-MASS (m/z) : 673 (M+H + ) ( 18 ) l-Cycloheptyl-l- [4- (l-tritylpyrazol-4-yl ) benzyl] -3- ( 2,4, 6-trimethylphenyl) unrea IR (KBr) 3406, 3323, 3057, 3030, 2924, 2854, 1640, 1568 cm "1 NMR ( DMSO-d 6 , δ ) : 1.40-2.0 (12H, m ) , 2.08 ( 6H, s;, 2.20 ( 3H, s ) , 4.05-4.25 (IH, ) , 4.47 ( 2H, s ) , 6.83 ( 2H, ε ) , 7.05-7.15 (5H, m)-, 7.25 ( 2K, d, J=8.2Kz ) , 7.3-7.4 (11H, m) , 7.49 ( 2K, d, J=8.2Hz ) , 7.78 (IH, s), 8.07 ( IK, s ) APCI-MASS (m/z) : 673 (M- r H + ) 19; l-Cycloheptyl-l- [3- ( l-methylpyrazol-4-yl ) benzyl] -3- ( 2,4, 6-trimethylphenyl) urea IR ( KBr ) : 3408, 2924, 2856, 1637, 1610, 1497, 1234 cm "1 NMR ( CDC1 3 , δ ) : 1.38-2.10 (12H, m) , 1.98 ( 6H, s ) , 2.20 ( 3 ή' f s ) , 3.95 (3H, s), 4.36-4.56 ( IH, ) , 4.52 ( 2H, s ) , 5.48 (IH, s), 6.73 ( 2K, s ) , 7.20- 7.52 ( 4H, m ) , 7.62 (IK, s), 7.75 ( IK, s> APCI-MASS (m/z) : 445 (M τ K + ) (20! l-Cycloheptyl-l- [3- (l-methylpyrazoi-3-yl ) benzyl] -3- (2,4, 6-trimethylphenyl) urea p : 142-143°C IR (KBr) : 3346, 2924, 2854, 1630, 1502, 1246 cm "1 NMR (CDC1 3 , δ) : 1.35-2.10 (12H, m) , 1.9" (6H, s) , 2.19 (3H, s) , 3.95 (3H, s) , 4.38-4.58 (IH, m) , 4.55 (2H, s) , 5.49 (IH, s) , 6.53 (IH, d, J=2.2Hz), 6.77 (2H, s), 7.30-7.50 (3K, m) , 7.65- 7.88 (2H, ) APCI-MASS (m/z) : 445 (M+H + ) (21) l-Cycloheptyl-l- [3- (l-methylpyrazol-5-yl) benzyl] -3- (2,4, 6-trimethylphenyl) urea mp : 171-172 β C IR (KBr) : 3307, 2924, 2856, 1626, 1506, 1254 cm "1 NMR (CDCI3, δ) : 1.38-2.10 (12H, m) , 2.00 (6H, s) , 2.21 (3H, s) , 3.89 (3H, s), 4.30-4.50 (IH, m) , 4.57 (2H, s) , 5.46 (IH, s) , 6.29 (IH, d, J=1.9Hz), 6.80 (2H, s), 7.25-7.56 (5H, m) APCI-MASS (m/z! 445 (M÷H + ; (22) l-Cycloheptyl-l- [3- (imidazol-4-yl) benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3140 (br) , 2924, 2S56, 1635, 1608, 1497 cm "1 NMR (DMS0-d 6 , δ) : 1.25-1.90 (12K, ) , 2.07 (6K, s) , 2.20 (3H, s) , 4.07-4.27 (IH, m) , 4.52 (2H, s) , 6.82 (2K, s) , 7.08-7.80 (7K, m) , 12.13, 12.53 (total IK, each br) APCI-MASS (m/z) : 431 (M+H + ) (23) l-Cycloheptyl-l- [4- (5-methyl-l, 3, 4-oxadiazol-2- yl) benzyl] -3- (2, 4, 6-trimethylphenyl) urea mp : 123-124°C IR (KBr) : 3319, 2924, 2856, 1622, 1500, 1243 cm "1 NMR (CDC1 3 , δ) : 1.35-2.10 (12H, m) , 2.04 (6H, s) , 2.22 (3H, s), 2.62 (3K, s), 4.20-4.40 (IK, m) , 559 - 181 - 4.58 (2H, s), 5.58 (IH, s), 6.81 (2H, s) , 7.49- 7.59 (2H, m) , 7.98-8.08 (2H, m) APCI-MASS (m/z) : 447 (M÷H + ) (24) l-Cycloheptyl-l- [4- (5-methyl-4H-l, 2, -triazol-3- yl)benzyl] -3- (2, 4, 6-trimethylphenyl) urea mp : 142-145°C IR (KBr) : 2600-3700 (br) , 2924, 2856, 1633, 1608, 1558, 1504, 1238 cm "1 NMR (CDC1 3 , δ) : 1.38-2.15 (12H, m) , 1.90 (6H, s), 2.27 (3H, s), 2.16 (3H, s), 4.37-4.57 (IK, m) , 4.58 (2H, s), 5.59 (IH, s), 6.71 (2H, s), 7.45- 7.57 (2H, m) , 8.05-8.17 (2H, m) APCI-MASS (m/z) : 446 (M+H + ) (25) l-Cycloheptyl-l- [4- (4-benzyl-5-methyl-4H-l, 2, 4- triazol-3-yl)benzyl] -3- (2, 4, 6-trimethylphenyl) urea mp : 193-194°C IR (KBr) : 3296, 2924, 2856, 1626, 1506, 1252, 847 cm "1 NMR (CDCI3, δ) : 1.35-2.05 (12H, m) , 2.00 (6K, s), 2.21 (3H, s), 2.39 (3H, s), 4.20-4.40 (IK, m) , 4.55 (2H, s), 5.15 (2H, s), 5.43 (IH, s), 6.80 (2H, s), 6.90-7.05 (2H, ) , 7.30-7.60 (7K, m) APCI-MASS (m/z) : 536 (M+H + ) (26) l-Cycloheptyl-l- [3- (2-methyI-2H-tetrazol-5-yl)benzyl] - 3- (2, 4, 6-trimethylphenyl) urea p : 175-176°C IR (KBr) : 3327, 2922, 2856, 1628, 1500, 1255 cm "1 NMR (DMSO-d β , δ) : 1.30-1.90 (12H, m) , 2.09 (6H, ε), 2.20 (3H, ε), 4.12-4.30 (IH, m) , 4.42 (3H, s), 4.59 (2H, s), 6.83 (2H, s), 7.40-7.65 (3K, m) , 7.85-7.95 (IH, m) , 8.06 (IH, ε) APCI-MASS (m/z) : 447 (M+H + ) [27) l-Cycloheptyl-l- [3- (l-methyl-lH-tetrazol-5-yl) benzyl] 3- (2, 4, 6-trimethylphenyl) urea mp : 171-173°C IR (KBr) : 3323, 2924, 2854, 1626, 1502, 1444, 1254 cm "1 NMR (DMS0-d 6 , δ) : 1.40-1.90 (12H, m) , 2.06 (6H, s), 2.20 (3H, s), 4.16 (3H, s), 4.10-4.28 (IH, m) , 4.59 (2H, s), 6.83 (2H, s), 7.54-7.80 (5H, m) APCI-MASS (m/zI 447 (M+H " (28) l-Cycloheptyl-l- [4- (1,2, 4-lH-triazol-l-yl) benzyl] -3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3310, 2924, 2856, 1639, 1518, 1277, 1147 cm "1 NMR (CDC1 3 , δ) : 1.40-2.10 (12H, m) , 2.07 (6H, ε), 2.22 (3H, s), 4.20-4.40 (IH, m) , 4.58 (2H, s), 5.49 (IH, s), 6.82 (2H, s), 7.50-7.60 (2H, m) , 7.64-7.74 (2H, ) , 8.11 (IH, s), 8.55 (IH, s) APCI-MASS (m/z) : 432 (M+H + ) (29) l-Cycloheptyl-l- [4- (1,2, 3-lH-triazol-l-yl) benzyl] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3331, 2924, 2856, 1637, 1498, 1319, 1234, 1034 cm "1 NMR (CDCI3, δ) : 1.40-2.10 (12H, m) , 2.07 (6H, s), 2.22 (3H, ε), 4.20-4.38 (IH, m) , 4.60 (2H, ε) , 5.55 (IH, s), 6.83 (2H, s), 7.52-7.61 (2H, m) , 7.70-7.80 (2H, m) , 7.86 (IH, s) , 8.00 (IK, s) APCI-MASS (m/z) : 432 (M+H + ) (30) l-Cycloheptyl-l- [4- (2H-1,2, 3-triazol-2-yl) benzyl] -3- (2,4, 6-trimethylphenyl) urea p : 157-158°C IR (KBr) : 3311, 2924, 2856, 1626, 1512, 1255, 955, 847 cm "1 - 183 - NMR (CDCI3, δ) : 1.40-2.10 (12H, m) , 2.04 (6H, s), 2.21 (3H, s), 4.25-4.45 (IH, m) , 4.57 (2H, s) , 5.51 (IH, s), 6.81 (2H, s), 7.48-7.58 (2H, m) , 7.82 (2H, ε), 8.04-8.14 (2H, m) APCI-MASS (m/z) : 432 (M+H + ) (31) l-Cycloheptyl-l- [4- (4-methylpiperazin-l-yl)benzylJ -3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3390, 3335, 2925, 2855, 2795, 2360, 1645, 1610, 1515 cm "1 NMR (DMS0-d 6 , δ) : 1.3-1.9 (12H, m) , 2.05 (6H, s), 2.20 (6H, s), 2.4-2.5 (4H, m) , 3.05-3.15 (4H, m) , 4.0-4.2 (IH, ) , 4.39 (2H, s) , 6.82 (2H, s) , 6.88 (2H, d, J=8.5Hz), 7.16 (2H, d, J=8.5Hz), 7.34 (IH, br s) APCI-MASS (m/z) : 463 (M+H + ) (32) l-Cycloheptyl-l- [4- (4-methylsulfonylaminophenyl) - benzyl]-3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3400, 3340, 2975, 2925, 2860, 1640, 1500 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.9 (12H, m) , 2.08 (6H, s), 2.20 (3H, s), 3.01 (3H, s), 4.1-4.3 (IH, m) , 4.53 (2H, ε), 6.83 (2H, s), 7.27 (2H, d, J=8.4Hz), 7.37 (2H, d, J=8.4Hz), 7.53 (IH, br s), 7.55-7.7 (4H, m) , 9.82 (IH, s) APCI-MASS (m/z) : 534 (M+H + ) (33) l-Cycloheptyl-l- [4- [2- (l-trityl-lH-tetrazol-5- yl)phenyl]benzyl] -3- (2, 4, 6- rimethylphenyl) urea IR (KBr) : 3407, 3058, 3026, 2924, 2856, 1647, 1608, 1493 cm "1 NMR (DMS0-d 6 , δ) : 1.4-1.8 (12H, m) , 2.04 (6H, ε), 2.20 (3H, ε), 4.05-4.25 (IH, m) , 4.48 (2H, s), 6.83 (2H, s), 7.04 (2K, d, J=7.9Hz), 7.23 (2H, d, - 184 - J=7.9Hz) , 7.5-7.8 (5H, m) FAB-MASS (m/z) : 751 (M+H + ) (34) l-Cycloheptyl-l- [4- (N-benzoylεulfamoyl)benzyl] -3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3415, 3361, 2924, 2858, 1632, 1593, 1549 cm "1 NMR (DMSO-d 6 , δ) : 1.4-2.0 (12H, m) , 2.07 (6H, s), 2.20 (3H, s), 4.1-4.3 (IH, m) , 4.51 (2H, s), 6.81 (2H, s), 7.2-7.4 (5H, m) , 7.53 (IH, br s) , 7.76 (2H, d, J=8.0Hz), 7.88 (2H, d, J=8.0Hz) APCI-MASS (m/z) : 548 (M+H + ) (35) l-Cycloheptyl-l- [4- (N-phenylsulfonylcarbamoyl)benzyl] - 3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3380, 3290, 3055, 2920, 2855*, 1690, 1625, 1610, 1505 cm "1 NMR (DMSO-d 6 , δ) : 1.3-1.8 (12H, m) , 2.07 (6H, s), 2.21 (3H, ε), 4.1-4.25 (IH, m) , 4.53 (2H, ε), 6.83 (2H, ε), 7.38 (2H, d, J=8.2Hz), 7.65-7.8 (4H, m) , 7.82 (2H, d, J=8.2Hz) , 8.00 (2H, d, J=6.7Hz) APCI-MASS (m/z) : 548 (M+H + ) (36) l-Cycloheptyl-l- [4- (3-pyridylmethyl)benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3412, 3304, 3028, 2920, 2854, 1626, 1502 cm "1 NMR (CDC1 3 , δ) : 1.4-2.1 (12H, m) , 1.95 (6H, s), 2.21 (3H, s), 3.98 (2H, ε) , 4.35-4.55 (IH, m) , 4.48 (2H, s), 5.42 (IH, s), 6.79 (2H, ε), 7.19 (2K, d, J=7.7Hz), 7.15-7.25 (IH, m) , 7.35 (2K, d, J=7.7Hz), 7.4-7.5 (IH, m) , 8.4-8.5 (2H, m) APCI-MASS (m/z) : 456 (M+H + ) (37) l-Cycloheptyl-l- [4- (4-pyridylmethyl) enzyl] -3- (2,4, 6- trimethylphenyl) urea IR (KBr) : 3408, 3304, 3024, 2922, 2856, 1632, 1605, 1512 cm "1 5 NMR (CDC1 3 , δ) : 1.4-2.1 (12H, ) , 1.95 (6K, s), 2.21 (3H, s), 3.96 (2H, s), 4.35-4.5 (IH, m) , 4.48 (2H, s), 5.42 (IH, s ] , 6X9 (2H, s), 7.09 (2H, dd, J=6.0, 1.6Hz), 7.20 (2H, d, J=8.1Hz), 7.37 (2H, d, J=8.1Kz), 8.49 (2H, dd, J=6.0, 1.6Hz) 10 APCI-MASS (m/z) : 456 (M-H + ) (38) l-Cycloheptyl-l- (3-benzyIbenzyl) -3- (2, , 6- trimethylphenyl) urea IR (KBr) : 3223, 3025, 2922, 2854, 1626, 1506 cm "1 ■15 NMR (CDCI3, δ) : 1.4-2.C (12H, ) , 1.95 (6K, s), 2.21 (3H, s), 3.97 (2K, s), 4.46 (2H, s), 4.3-4.5 (IK, m) , 5.42 (IH, s), 6.79 (2H, s), 7.1-7.35 (9H, m) APCI-MASS (m/z) : 455 (M+H + ) 20 (39) l-Cycloheptyl-l- [4- (pyrazol-1-ylmethyl)benzyl]-3- (2,4, 6-trimethylphenyl)urea p : 150-151°C IR (KBr) : 3307, 2922, 2856, 1628, 1508, 1250, 750 cm "1 25 NMR (CDCI3, δ) : 1.38-2.05 (12H, m) , 1.97 (6H, s), 2.21 (3H, s), 4.30-4.45 (IH, m) , 4.49 (2H, s), 5.32 (2H, s), 5.39 (IH, s), 6.28 (IH, dd, J=2.0, 2.0Hz), 6.79 (2H, s), 7.15-7.28 (2H, m) , 7.32- 7.42 (3H, m) , 7.55 (IH, d, J=2.0Hz) 30 APCI-MASS (m/z) : 445 (M+K + ) (40) l-Cycloheptyl-l- [4- (imidazol-1-ylmethyl)benzyl] -3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3329 (br) , 2924, 2856, 1637, 1504, 1234, 35 849, 735 cm "1 - 186 - NMR (CDCI3, δ) : 1.35-2.05 (12H, m) , 1.99 (6H, s) , 2.21 (3H, s), 4.25-4.45 (IH, m) , 4.51 (2H, ε) , 5.12 (2H, s), 5.40 (IH, s), 6.80 (2K, s), 6.89 (IH, s), 7.10 (IH, s), 7.13-7.23 (2H, m) , 7.35- 7.45 (2H, m) , 7.61 (IH, s) APCI-MASS (m/z) : 445 (M+H + ) (41) l-Cycloheptyl-l- [ (6-hydroxy-2, 5, 7, 8-tetramethyl- chroman-2-yl)methyl] -3- (2, , 6-trimethylphenyl) urea IR (KBr) : 3313, 2924, 2858, 1740, 1643, 1610, 1510 cm "1 NMR (DMSO-dg, δ) : 1.15 (3H, s) , 1.3-2.1 (16H, m) , 2.55-2.65 (IH, m) , 1.92 (3H, s) , 1.99 (3H, s), 2.02 (6H, s), 2.03 (3H, s), 2.21 (3H, s), 3.53 (2H, br ε), 6.83 (2H, ε), 7.44 (IH, br s) APCI-MASS (m/z) : 493 (M+H + ) (42) l-Cycloheptyl-l- [4- [N- (3, 5-di-tert-butyl-4- hydroxyphenyl) carbamoyl]benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3639, 3417, 3321, 2951, 2924, 2860, 1643, 1610, 1502 cm "1 NMR (DMSO-dg, δ) : 1.39 (18H, s) , 1.4-1.9 (12H, m) , 2.10 (6H, s) , 2.21 (3H, s), 4.1-4.3 (IH, ) , 4.57 (2H, s), 6.78 (IH, s), 6.85 (2H, s), 7.41 (2H, d, J=8.3Hz), 7.90 (2H, d, J=8.3Hz), 7.44 (2H, ε) , 7.59 (IH, br s), 9.87 (IH, br ε) APCI-MASS (m/z) : 612 (M+H + ) (43) l-Cycloheptyl-l- [4- [N- (4-fluorophenyl) carbamoyl] - benzyl] -3- (2, 4, 6-trimethylphenyl) urea IR (KBr) : 3280, 2926, 2856, 1643, 1610, 1549, 1508 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (12H, m) , 2.11 (6H, ε), 2.21 (3H, ε), 4.1-4.3 (IH, m) , 4.57 (2H, S ) , 6.85 - 187 - (2H, s), 7.15-7.3 (2H, m) , 7.43 (2H, d, J=8.2Hz), 7.64 (IH, br s) , 7.75-7.85 (2H, m) , 7.90 (2H, d, J=8.2Hz), 10.22 (IH, s) APCI-MASS (m/z) : 502 (M+H + ) (44) l-Cycloheptyl-l- [4- [N- (4-fluorophenyl) -N- methylcarbamoyl]benzyl] -3- (2, 4, 6-trιmethylphenyl) urea IR (KBr) : 3321, 2951, 2923, 2860, 1638, 1606 cm "1 NMR (DMSO-dg, δ) : 1.4-1.8 (12H, m) , 2.01 (6H, s), 2.20 (3H, s), 3.30 (3H, ε), 4.0-4.2 (IH, m) , 4.42 (2H, s), 6.82 (2H, s), 7.05-7.3 (8H, m) , 7.47 (IH, br s) APCI-MASS (m/z) : 516 (M+H + ) (45) l-Cycloheptyl-l- [4- [ (2, 4-dioxothiazolidin-5- yl)methyl]benzyl] -3- (2, , 6-trimethylphenyl) urea IR (KBr) : 2931, 2858, 2765, 1753, 1709, 1689, 1606, 1632, 1564, 1535, 1502, 1481 cm "1 NMR (DMSO-dg, δ) : 1.4-2.1 (12H, m),2.05 (6H, s), 2.20 (3H, s), 3.0-3.2 (IH, m) , 3.3-3.45 (IH, m) , 4.0-4.2 (IH, m) , 4.47 (2K, s) , 4.85-5.0 (IH, m) , 6.82 (2H, s), 7.19 (2H, d, J=8.2Hz), 7.25 (2H, d, J=8.2Hz), 7.44 (IH, br ε), 12.3 (IH, br) APCI-MASS (m/z) : 494 (M+H + ) (46) l-Cycloheptyl-l- [4- [ (2, -dιoxothiazolidin-5- ylidene)methyl]benzyl]-3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3410, 3122, 2924, 2958, 2758, 1743, 1707, 1603, 1504 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (12H, m) , 2.08 (6H, ε), 2.21 (3H, s), 4.1-4.3 (IH, m) , 4.54 (2H, s), 6.84 (2H, s), 7.44 (2H, d, J=8.3Hz), 7.56 (2H, d, J=8.3Hz), 7.61 (IH, br s), 7.77 (IH, s), 12.60 (IH, br) APCI-MASS (m/z) : 492 (M+H + ) - 1 3 8 - (47) l-Cycloheptyl-l- [4- (2-cyanophenyl) benzyl] -3- (2, 4, 6- trimethylphenyl) urea IR (KBr) : 3410, 3330, 2925, 2855, 2225, 1640, 1610, 1500 cm "1 NMR (CDC1 3 , δ) : 1.5-1.8 (12H, m) , 2.02 (6H, sj , 2.21 (3H, ε), 4.35-4.55 (IH, ) , 4.58 (2K, ε), 5.49 (IH, s), 6.80 (2H, ε), 7.4-7.3 (8H, ) APCI-MASS (m/z) : 466 (M+rX) Example 23 The following compounds were obtained according to a similar manner to that of Example 7, 8, 9, 10, 13, 14, 15, 16 or 17. (1) l-Cycloheptyl-l- [4- (4 '-chlorophenoxy)benzyl] -3- [2, 4- biε (methylthio) -6-methylpyridin-3-yl]urea IR (KBr) : 3371, 2924, 2856, 1662, 1589, 1564, 1506, 1485 cm "1 NMR (DMSO-d 6 , δ) : 1.35-1.9 (12H, m) , 2.39 (6K, s) , 2.44 (3H, s), 4.0-4.2 (IH, m) , 4.46 (2H, ε), 6.86 (IK, s), 6.95-7.1 (4H, m) , 7.35-7.5 (4K, m) , 7.84 (IH, br s) APCI-MASS (m/z) : 556 (M-rH + ) (2) l-Cycloheptyl-l- [4- (4-fluorophenoxy) benzyl] -3- [2, - bis (methylthio) -6-methylpyridin-3-yi] urea IR (KBr) : 3313, 2955, 2924, 2872, 1655, 1564, 1497 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (8H, m) , 2.39 (6H, s), 2.44 (3H, s), 4.3-4.5 (IH, m) , 4.47 (2K, s) , 6.86 (IH, ε) , 6.9-7.1 (4H, m) , 7.15-7.35 (4H, π) , 7.87 (IH, ε) APCI-MASS (m/z) : 512 (MX~T) (3) i-Cycloheptyl-1- (3-phenoxybenzyl) -3- [ 2 , 4- bis (methylthio) -6-methylpyridin-3-yl]urea IR (KBr) : 3294, 2924, 2854, 1740, 1635, 1562, 1483 cm "1 NMR (DMSO-dg, δ) : 1.3-2.0 (12H, m) , 2.32 (6H, s), 2.43 (3H, s) , 4.0-4.2 (IH, m) , 4.47 (2H, s), 6.83 (IK, s), 6.9-7.45 (9H, m) , 7.84 (IH, br s; APCI-MASS (m/z) : 522 (M+H + ) (4) l-Cycloheptyl-l- [3- (4-fluorophenoxy)benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3332, 3066, 2926, 2856, 1664, 1608, 1564, 1497 cm "1 NMR (CDC1 3 , δ) : 1.45-2.05 (12H, m) , 2.34 (3H, s) , 2.45 (6H, s), 4.15-4.4 (IH, m) , 4.54 (2H, s), 5.46 (IH, s) , 6.58 (IH, s), 6.85-7.4 (8H, ) (5) 1- (4-Dimethylaminobenzyl) -1- [3- (pyrazol-3-yl) benzyl] - 3- (2, 4, 6-trifluorophenyl) urea IR (KBr) : 2600-3650 (br) , 1635, 1614, 1522, 1448, 1352 cm "1 NMR (DMSO-dg, δ) : 2.83 (6H, s) , 4.38 (2H, ε), 4.47 (2H, s), 6.55-6.77 (3H, m) , 7.08-7.83 (9K, ) , 8.39 (IH, s), 12.89, 13.33 (total IH, each br) APCI-MASS (m/z) : 480 (M+H + ) (6) 1- (2, 3, 5, 6-Tetrahydro-4H-pyran-4-yl) -1- [4- (4- fluorophenoxy) benzyl] -3- [2, -bis (methylthio) -6- methylpyridin-3-yl]urea IR (KBr) : 3294, 3064, 2956, 2926, 2848, 1655, 1562, 1497 cm "1 NMR (DMSO-dg, δ) : 1.55-1.85 (4H, m) , 2.40 (6H, s) , 2.45 (3K, s), 3.3-3.5 (2H, ) , 3.8-3.9 (2H, ) , 4.1-4.3 (IH, m) , 4.51 (2H, s), 6.87 (IH, Sj , 6.9- 7.4 (8H, m) , 7.98 (IH, br s) - 190 - (7) 1- (2-Phenylethyl) -l-[4- (4-fluorophenoxy) benzyl] -3- [2, 4-bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3294, 3062, 3026, 2924, 1655, 1562, 1497 cm "1 NMR (CDC1 3 , δ) : 2.40 (3H, s), 2.48 (3H, s) , 2.51 (3H, s), 3.01 (2H, t, J=7.8Hz) , 3.61 (2H, t, J=7.8Hz) , 4.43 (2H, s) , 5.65 (IH, br s) , 6.64 (IH, s), 6.9-7.1 (6H, m) , 7.2-7.35 (7H, m) APCI-MASS (m/z) : 548 (M+H + ) (8) 1- (2-Ethoxyethyl) -1- [4- (4-fluorophenoxy) benzyl] -3- [2, 4-bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3298, 3063, 2976, 2926, 2881, 2856, 1664, 1562, 1495 cm "1 NMR (DMSO-dg, δ) : 1.12 (3H, t, J=6.9Hz), 2.40 (6H, s), 2.45 (3H, s), 3.46 (2H, q, J=6.9Hz) , 3.4-3.65 (4H, m) , 4.54 (2H, s) , 6.87 (IH, ε), 6.93-7.4 (8H, m) , 7.9 (IH, br s) APCI-MASS (m/z) : 516 (M+H + ) (9) 1-Benzyl-l- (3-phenoxybenzyl) -3- [2, 4-bis (methylthio) -6- methylpyridin-3-yl] urea IR (KBr) : 3404, 3032, 2997, 2922, 1668, 1610, 1562, 1500, 1452 cm "1 NMR (DMSO-dg, δ) : 2.35 (6H, s), 2.43 (3H, s), 4.44 (2H, s) , 4.47 (2H, s) , 6.86 (IH, ε) , 6.9-7.45 (14H, m) , 8.24 (IH, br ε) APCI-MASS (m/z) : 516 (M+H + ) (10) 1-Benzyl-l- [3- (4-fluorophenoxy) benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3298, 3062, 3028, 2922, 1662, 1564, 1498 cm "1 NMR (CDCI3, δ) : 2.36 (3H, s) , 2.46 (6H, s) , 4.61 (2H, ε) , 4.62 (2H, s) , 5.66 (IH, s) , 6.85-7.4 - 191 - (13H, m) APCI-MASS (m/z) : 534 (M+H + ) (11) l-Cycloheptyl-l- [3- (pyrazol-3-yl)benzyl]-3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl]urea IR (KBr) : 3211, 3061, 2924, 2856, 1643, 1564, 1531, 1485 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (12H, m) , 2.39 (6H, s), 2.45 (3H, s), 4.0-4.2 (IH, m) , 4.52 (2H, s), 6.6- 6.7 (IH, m) , 6.86 (IH, s), 7.2-7.9 (6H, m) , 12.85 (IH, br s) APCI-MASS (m/z) : 496 (M+H + ) (12) 1-Benzyl-l- [3- (l-methylpyrazol-3-yl)benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl]urea mp : 165-166°C IR (KBr) : 3280, 2922, 1643, 1562, 1500, 1435 cm "1 NMR (CDC1 3 , δ) : 2.36 (3H, s), 2.46 (6H, s), 3.95 (3H, s), 4.66 (4H, s), 5.70 (IH, ε), 6.57 (IH, d, J=2.3Hz), 6.61 (IH, s), 7.22-7.45 (8H, m) , 7.72- 7.80 (2H, m) FAB-MASS (m/z) : 504 (M+H + ) (13) 1-Benzyl-l- [3- (l-methylpyrazol-5-yl)benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl]urea IR (KBr) : 3280, 2922, 1649, 1562, 1500, 1431, 1390 cm "1 NMR (CDCI3, δ) : 2.35 (3H, s), 2.45 (3H, ε), 2.46 (3H, s), 3.88 (3H, s), 4.64 (2H, s), 4.71 (2H, s), 5.70 (IH, s), 6.32 (IH, d, J=1.9Hz), 6.61 (IH, s) , 7.20-7.55 (10H, m) FAB-MASS (m/z) : 504 (M+H + ) (14) 1-Benzyl-l- [4- (l-methylpyrazol-3-yl)benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl]urea IR (KBr) : 3305, 2922, 1659, 1564, 1489, 1338, 1227 cm "1 NMR (CDC1 3 , δ) : 2.38 (3H, s), 2.47 (3H, s) , 2.49 (3H, s), 3.96 (3H, s), 4.63 (4H, s), 5.71 (IH, s), 6.54 (IH, d, J=2.3Hz), 6.62 (IH, s), 7.25- 7.47 (8H, m) , 7.75-7.85 (2H, m) APCI-MASS (m/z) : 504 (M+H + ) (15) 1-Benzyl-l- [4- (l-methylpyrazol-5-yl)benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-ylj urea IR (KBr) : 3286, 2922, 1657, 1562, 1495, 1389 cm "1 NMR (CDCI3, δ) : 2.40 (3H, s), 2.47 (3H, s), 2.49 (3H, s), 3.90 (3H, s), 4.66 (2H, s), 4.69 (2K, s), 5.71 (IH, s), 6.31 (IH, d, J=1.9Hz), 6.63 (IH, s), 7.25-7.51 (9H, m) , 7.52 (IH, d, J=1.9Hz) APCI-MASS (m/z) : 504 (M+H + ) (16) 1-Benzyl-l- [4- (pyrazol-3-yl)benzyl] -3- [2,4- biε (methylthio) -6-methylpyridin-3-yl]urea mp : 150-152°C IR (KBr) : 3400, 3215, 2922, 1649, 1560, 1487, 1228 cm "1 NMR (DMSO-dg, δ) : 2.44 (6H, ε), 2.47 (3H, ε) , 4.46 (4H, ε), 6.72 (IH, s), 6.90 (IH, s) , 7.22-7.90 (10H, m) , 8.30 (IH, s), 12.87, 13.27 (total IH, each br) APCI-MASS (m/z) : 490 (M+H + ) (17) l-Cycloheptyl-l- [4- (pyrazoi-3-yl) benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea mp : 174-175°C IR (KBr) : 2690-3700 (br) , 2924, 2856, 1637, 1564, 1484, 1340, 1207, 804 err "1 NMR (DMSO-dg, δ) : 1.30-1.90 (12H, m) , 2.41 ( 6K r s) , 2.45 (3H, ε), 3.95-4.15 (IK, m) , 4.49 (2H, s) , 59 - 193 - 6.67 (IH, br s) , 6.86 (IH, s), 7.32-7.93 (6H, m) , 12.80, 13.19 (total IH, each br) APCI-MASS (m/z) : 496 (M-"-H + ) (18) 1- (4-Methoxybenzyl)-l-[3- (pyrazol-3-yl)benzyl] -3- [2, - bis (methylthio) -6-methylpyridin-3-yl]urea mp : 170-173°C IR (KBr) : 3394, 3250, 3101, 2920, 1664, 1562, 1483, 1223 cm "1 NMR (DMSO-dg, δ) : 2.42 (6H, s), .2.47 (3H, s) , 3.75 (3H, s), 4.41 (2H, s) , 4.45 (2H, s), 6.67 (IH, br s), 6.88-7.03 (3H, m) , 7.13-7.90 (7H, m) , 8.27 (IH, s), 12.89, 13.30 (total IH, each br) APCI-MASS (m/z) : 520 (M-H + ) (19) 1- (4-Fluorobenzyl)-l-[3- (pyrazol-3-yl)benzylJ -3- [2 , 4 - bis (methylthio) -6-methylpyridin-3-yl]urea mp : 166-168°C IR (KBr) : 3390, 3257, 2920, 1653, 1562, 1489, 1227 cm "1 NMR (DMSO-dg, δ) : 2.42 (6H, s), 2.46 (3H, s), 4.47 (2H, s), 4.49 (2H, s), 6.66 (IH, d, J=2.0Hz), 6.90 (IH, s), 7.12-7.45 (6H, m) , 7.60-7.90 (3K, m) , 8.30 (IH, s), 12.89, 13.30 (total IH, each br) APCI-MASS (m/z) : 508 (M+H + ) (20) 1- (4-Dimethylaminobenzyl) -1- [3- (pyrazol-3-yl)benzyl] - 3- [2, 4-bis (methylthio) -6-methylpyridin-3-yl] urea mp : 185-188°C IR (KBr) : 3236, 2922, 1633, 1612, 1524, 1487, 1338, 1219 cm "1 NMR (DMSO-dg, δ) : 2.42 (6H, S), 2.47 (3H, s), 2.89 (6H, s), 4.35 (2H, br s), 4.42 (2H, br s), 6.60- 6.76 (3H, m) , 6.90 (IH, s), 7.10-7.90 (7H, m) , - 194 - 8.23 (IH, s), 12.89, 13.30 (total IH, each br) APCI-MASS (m/z) : 533 (M+H + ) (21) l-Benzyl-l-[4- (l-methylpyrazol-4-yl) benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea mp : 224-225°C IR (KBr) : 3217, 2922, 1655, 1566, 1498, 1456, 1228, 806 cm "1 NMR (DMSO-dg, δ) : 2.43 (6H, s), 2.47 (3H, ε), 3.86 (3H, s), 4.30-4.50 (4H, m) , 6.90 (IH, s), 7.20- 7.40 (7H, m) , 7.50-7.60 (2H, m) , 7.86 (IH, s), 8.13 (IH, s), 8.28 (IH, s) APCI-MASS (m/z) : 504 (M+H + ) (22) l-Cycloheptyl-l- [4- (l-methylpyrazol-4-yl) benzyl] -3- [2, 4-bis (methylthio) -6-methylpyridin-3-yl]urea mp : 247-248°C IR (KBr) : 3188, 2922, 2854, 1641, 1564, 1491, 1213 cm "1 NMR (DMSO-dg, δ) : 1.30-1.90 (12H, m) , 2.40 (6H, s), 2.45 (3H, s), 3.85 (3H, s), 3.90-4.15 (IH, m) , 4.45 (2H, s), 6.86 (IH, s), 7.28-7.38 (2H, m) , 7.43-7.54 (2H, m) , 7.83 (IH, s) , 7.85 (IH, br s), 8.10 (IH, s) APCI-MASS (m/z) : 510 (M+H + ) (23) 1-Benzyl-1- [3- (imidazol-4-yl) benzylj -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea mp : 134-136°C IR (KBr) : 2690-3700 (br) , 1637, 1562, 1490, 1228 cm "1 NMR (DMSO-dg, δ) : 2.43 (6H, s), 2.47 (3H, ε), 4.47 (4H, ε), 6.90 (IH, ε) , 7.10-7.75 (11H, m) , 8.28 (IH, ε), 12.17, 12.55 (total IH, each br) APCI-MASS (m/z) : 490 (M+H + ) (24) l-Benzyl-l-[3- (2-methyl-2H-tetrazol-5-yl)benzyl] -3- [2, 4-bis (methylthio) -6-methylpyridin-3-yl]urea IR (KBr) : 3290, 2922, 1655, 1562, 1493, 1227, 970, 806 cm "1 NMR (CDC1 3 , δ) : 2.39 (3H, s) , 2.47 (3H, s), 2.48 (3H, s), 4.40 (3H, s), 4.67 (2H, s), 4.72 (2H, s), 5.72 (IH, s), 6.62 (IH, s), 7.25-7.58 (7H, m) , 8.01-8.18 (2H, m) APCI-MASS (m/z) : 506 (M+H + ) (25) l-Cycloheptyl-l- [4- [ (2, 4-dioxothiazolidin-5- yl)methyl]benzyl] -3- [2, 4-bis (methylthio) -6- methylpyridin-3-yl]urea IR (KBr) : 2924, 2860, 2769, 1753, 1701, 1603, 1506 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (12H, m) , 2.40 (6H, s), 2.45 (3H, s), 3.07 (IH, dd, J=14.0, 9.4Hz), 3.35 (IH, dd, J=14.0, 4.3Hz), 3.95-4.15 (IH, m) , 4.45 (2H, s), 4.90 (IH, dd, J=9.4, 4.3Hz), 6.86 (IH, s), 7.17 (2H, d, J=8.1Hz), 7.30 (2H, d, J=8.1Kz), 7.86 (IH, br s), 12.04 (IK, br) APCI-MASS (m/z) : 559 (M+H + ) (26) l-Cycloheptyl-l- [4- [ (2, 4-dioxothiazolidin-5- ylidene)methyl]benzyl] -3- [2, 4-bis (methylthio) -6- methylpyridin-3-yl]urea IR (KBr) : 3406, 3124, 2926, 2856, 2765, 1757, 1711, 1635, 1599, 1487 cm "1 NMR (DMSO-dg, δ) : 1.3-1.9 (12H, m) , 2.40 (6H, s), 2.45 (3H, s), 4.0-4.2 (IH, m) , 4.52 (2H, br s), 6.86 (IH, s), 7.48 (2H, d, J=8.6Hz), 7.54 (2H, d, J=8.6Hz), 7.77 (IH, s), 7.96 (IH, br s), 12.59 (IH, br) APCI-MASS (m/z) : 557 (M+H + ) (27; l-3enzyl-l- [4- (4-fluorophenoxy)benzyl] -3- (2, 4, 6- trimethylpyridin-3-yl) urea IR (KBr) : 3294, 3030, 2922, 1632, 1605, 1498 cm "1 NMR (DMSO-dg, δ) : 2.08 (3H, ε) , 2.26 (3H, ε), 2.35 (3H, ε), 4.52 (2H, ε), 4.56 (2H, s) , 6.95-7.45 (14H, m) , 8.02 (IH, br s) APCI-MASS (m/z) : 476 (M+H T ) (28) 1-Cyclohexyl-l- [4- ( -fluorophenoxy)benzyl] -3- (2, 4, 6- trimethylpyridin-3-yl) urea IR (KBr) : 3406, 3313, 2929, 2856, 1714, 1632, 1605, 1572, 1495 cm "1 NMR (DMSO-dg, δ) : 1.0-1.9 (10H, m) , 2.07 (3H, ε) , 2.24 (3H, s), 2.34 (3H, s), 3.95-4.15 (IH, m) , 4.51 (2H, s), 6.95-7.4 (6H, m) , 7.70 (IK, s) APCI-MASS (m/z) : 462 (M+H^) (29) l-Cycloheptyl-l- [4- (4-bromophenoxy) benzyl] -3- (2, 4, 6- trimethylpyridin-3-yl) urea IR (KBr) : 3310, 1632, 1504, 1483, 1238 cm "1 NMR (CDC1 3 , δ) : 1.38-2.05 (12H, m) , 2.04 (3H, ε) , 2.20 (3H, ε), 2.42 (3H, s), 4.30-4.50 (IH, ) , 4.50 (2H, s), 5.49 (IH, s), 6.82 (IH, s) , 6.83- 6.93 (2H, m) , 6.98-7.08 (2H, m) , 7.32-7.46 (4K, m) APCI-MASS (m/z) : 536, 538 (M+H + ) (30) 1-Benzyl-1- [3- (pyrazol-3-yl) benzyl1 -3- (2, 4, 6- trimethylpyridin-3-yl) urea IR (KBr) : 3236, 2924, 1645, 1564, 1493 cm "1 NMR (DMSO-dg, δ) : 2.10 (3H, s) , 2.28 (3H, s), 2.35 (3H, s), 4.59 (4H, sj , 6.6-6.7 (IH, m; , 6.94 (IK, s) , 7.2-7.8 (10H, m) , 3.0 " (IH, br s), 12.89 (IK, br) APCI-MASS (m/z) : 426 (M+H + ) - 197 - (31) l-Cycloheptyl-l- [3- (l-tritylpyrazol-3-yl)benzyl] -3- (2, , 6-trimethylpyridin-3-yl) urea IR (KBr) : 3404, 3313, 3059, 3028, 2924, 2856, 1720, 1650, 1605, 1500, 1481 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (12H, m) , 1.96 (3H, s), 2.19 (3H, s), 2.33 (3H, s) , 4.1-4.3 (IH, m) , 4.54 (2H, s), 6.71 (IH, d, J=2.5Hz), 6.85 (IH, s), 7.1-7.8 (20H, m) FAB-MASS (m/z) : 674 (M+H + ) (32) 1-Benzyl-1- [4- (4-fluorophenoxy)benzyl] -3- [4, 6- bis (methylthio) -2-methylpyridin-5-yl]urea IR (KBr) : 3275, 3062, 3030, 2926, 1637, 1535, 1479 cm "1 NMR (DMSO-dg, δ) : 2.46 (6H, s), 2.58 (3H, s) , 4.44 (2H, s), 4.48 (2H, s), 6.95-7.4 (13H, ) , 8.39 (IH, br s) APCI-MASS (m/z) : 535 (M+H + ) (33) l-Cycloheptyl-l- [4- (4-bromophenoxy)benzyl] -3- [4, 6- biε (methylthio) -2-methylpyrimidin-5-yl] urea mp : 173-175°C IR (KBr) : 3375, 2926, 2852, 1668, 1583, 1479, 1238, 810 cm "1 NMR (CDC1 3 , δ) : 1.38-2.10 (12H, m) , 2.48 ( 6 ' ή, ε), 2.59 (3H, s), 4.20-4.42 (IH, m) , 4.54 (2H, s), 5.40 (IH, s), 6.85-6.93 (2H, m) , 7.00-7.10 (2H, m) , 7.34-7.50 (4H, m) APCI-MASS (m/z) : 601, 603 (M+H + ) (34) 1-Benzyl-1- [3- (4-fluorophenoxy)benzyl] -3- [4, 6- biε (methylthio) -2-methylpyrimidin-5-yl] urea IR (KBr) : 3271, 3059, 3030, 2926, 2789, 2735, 2605, 1639, 1585, 1533, 1508 cm "1 NMR (CDCI3, δ) : 2.46 (6H, s), 2.58 (3H, s), 4.61 (4H, br s), 5.58 (IH, s), 6.8-7.4 (13H, m) APCI-MASS (m/z) : 535 (M+H + ) (35) l-Cycloheptyl-l- [3- (pyrazol-3-yl) benzyl] -3- [4, 6- bis (methylthio) -2-methylpyrimidin-5-yl]urea mp : 164-165°C IR (KBr) : 3194, 2926, 2856, 1633, 1518, 1419, 1296, 812 cm "1 NMR (DMSO-dg, δ) : 1.30-1.90 (12H, m) , 2.43 (6H, s), 2.57 (3H, s), 3.95-4.15 (IH, m) , 4.53 (2H, s), 6.65 (IH, s), 7.15-7.90 (5H, m) , 8.07 (IH, s), 12.86, 13.30 (total IH, each br) APCI-MASS (m/z) : 497 (M+H + ) (36) l-Benzyl-l-[3- (pyrazol-3-yl)benzyl] -3- [4, 6- bis (methylthio) -2-methylpyrimidin-5-yl] urea mp : 212-213°C IR (KBr) : 3388, 3265, 2924, 1653, 1524, 1487, 1390, 1356, 1298, 1228 cm "1 NMR (DMSO-dg, δ) : 2.46 (6H, s), 2.58 (3H, ε) , 4.50 (4H, s), 6.60-6.70 (IH, m) , 7.15-7.85 (10H, m) , 8.45 (IH, s), 12.89, 13.32 (total IH, each br s) APCI-MASS (m/z) : 491 (M+H + ) (37) l-Benzyl-l-[4- (4 ' -fluorophenoxy) benzyl] -3- [2,4- dimethoxy-6-methylpyridm-3-yl] urea IR (KBr) : 3394, 3315, 3062, 2945, 2858, 1660, 1597, 1497 cm "1 NMR (DMSO-dg, δ) : 1.99 (3H, s), 3.80 (3H, s), 3.81 (3H, s), 4.41 (2H, s), 4.45 (2H, ε), 6.67 (IH, s) , 6.95-7.45 (13H, m) APCI-MASS (m/z) : 502 (M+H + ) (38) l-Cycloheptyl-l- [3- (pyrazol-3-yl) benzyl] -3- [2, 4- dιmethoxy-6-methylpyridin-3-yl]urea IR (KBr) : 3379, 3207, 3055, 2926, 2856, 1651, 1597, 1502 c "1 NMR (DMSO-dg, δ) : 1.3-1.9 (12H, ) , 2.35 (3H, s), 3.75 (3H, s,, 3.76 (6H, s), 4.0-4.2 (IH, m) , -,.50 (2H, s) , 6.55 (IH, s;, 6 . 6- 6 . 65 (IK, ) , 7.1-7.8 (5H, m) , 12.85 (IH, br ≤) APCI-MASS (m/z) : 464 (M+H " ) (39) 1-Benzyl-l- [3- (l-trityipyrazoI-3-yi) enzyl] -3- (2, - dimethoxy-6-methylpyridin-3-yI) urea IR (KBr) : 3990, 3066, 3032, 293C, 2923, 1678, 1637, 1512, 1497 cm "1 NMR (DMSO-dg, δ) : 2.36 (3H, s), 3.72 (3H, sj , 3.74 (3H, s) , 4.46 (4H, br ε), 6.64 (IH, s) , 6.73 (IH, d, J=2.5Hz), 7.1-7.7 (24K, m) (40) 1- (4-Fluorobenzyi) -1- [3- (l-tritylpyrazol-3-yi)benzyl] - 3- (2, 4, 6-trifluorophenyl; urea IR (KBr) : 3294, 1637, 1608, 1518, 1446, 1225 cm "1 NMR (CDC1 3 , δ) : 4.58 (2H, s), 4.60 (2H, s), 5.75 (IH, s) , 6.54 (IH, d, J=2.5Kz; , 6.57-7.10 (6H, ) , 7.13-7.43 (18K, ml, 7.65-7.80 (2H, m) (41) l-Cycloheptyl-l- (4-phenylbenzyl) -3- (2, 4, 6- trimethylpyridin-3-yI) urea IR (KBr) : 3402, 3023, 2924, 2854, 1728, I66C, 1602, 1566, 1493 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (12H, m) , 2.09 (3K, s) , 2.27 (3H, s), 2.34 (3H, s) , 4.05-4.25 (IK, m) , 4.55 (2H, s), 6.93 (IH, s), 7.3-7.8 (9H, m) APCI-MASS (m/z) : 442 (M+H + ) Example 24 The following compounds were obtaineα according to a similar manner to that of Example 6, 12 or 21. (1) l-Cycloheptyl-l- [4- (pyrazol-4-yl)benzyl] -3- (2,4,6- trimethylphenyl) urea IR (KBr) : 3184, 2926, 2856, 1630, 1650, 1510 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (12H, m) , 2.09 (6H, s), 2.21 (3H, s), 4.05-4.25 (IH, m) , 4.48 (2H, s), 6.83 (2H, s), 7.28 (2H, d, J=8.2Hz), 7.50 (IH, br S), 7.56 (2H, d, J=8.2Hz), 7.87 (2H, s) (2) l-Cycloheptyl-l- [3- (pyrazol-3-yl)benzyl] -3- [2, 4- dimethoxy-6-methylpyridin-3-yl) urea IR (KBr) : 3406, 3228, 3062, 3026, 2974, 1676, 1653, 1597, 1508 cm "1 NMR (DMSO-dg, δ) : 2.37 (3H, s), 3.79 (3H, s), 3.80 (3H, s), 4.47 (4H, s) , 6.65 (IH, d, J=2.7Hz), 6.66 (IH, s), 7.2-7.5 (7H, m) , 7.65-7.8 (4H, m) APCI-MASS (m/z) : 458 (M+H + ) (3) l-Cycloheptyl-l- [3- (pyrazol-3-yl)benzyl] -3- (2,4, 6- trimethylpyridin-3-yl) urea IR (KBr) : 3400, 3224, 3055, 2929, 2856, 1714, 1633, 1568, 1500 cm "1 NMR (DMSO-dg, δ) : 1.4-1.9 (12H, m) , 2.09 (3K, s) , 2.26 (3H, s) , 2.34 (3H, s), 4.05-4.25 (IH, m) , 4.56 (2H, s), 6.6-6.7 (IH, m) , 6.91 (IH, s), 7.2- 7.5 (2H, m) , 7.6-7.9 (3H, m) , 12.85 (IH, br ε) APCI-MASS (m/z) : 432 (M+H + ) (4) 1- (4-Fluorobenzyl)-l-[3- (pyrazol-3-yl)benzyl] -3- (2,4, 6-trifluorophenyl) urea mp : 204-206°C IR (KBr) : 3413, 3066, 1664, 1610, 1520, 1223 cm -1 NMR (DMSO-dg, δ) : 4.51 (2H, s), 4.55 (2H, s), 6.65 (IH, d, J=2.3Hz), 7.10-7.50 (9H, m) , 7.55-7.90 (2H, m) , 8.46 (IH, s), 12.89, 13.30 (total IH, each br) APCI-MASS (m/z) : 455 (M+H + ) (5) l-Cycloheptyl-l- [4- [2- (lH-tetrazol-5- yl)phenyl]benzyl]-3- (2,4, 6-trimethylphenyl) urea IR (KBr) : 3408, 3310, 2924, 2856, 1620, 1605, 1506 c "1 NMR (DMSO-dg, δ) : 1.4-1.8 (12H, m) , 2.04 (6H, s) , 2.20 (3H, s), 4.05-4.25 (IH, m) , 4.48 (2H, ε) , 6.83 (2H, s), 7.04 (2H, d, J=7.9Hz), 7.23 (2H, d, J=7.9Hz), 7.5-7.8 (5H, m) F.AB-MASS (m/z) : 509 (M+H + ) Example 25 To a solution of 1-cycloheptyl-l- [4- (4- fluorophenoxy)benzyl] -3- [2, 4-bis (methylsulfonyl) -6- methylpyridin-3-yl]urea (3.04 g) in methanol (100 ml) was added sodium methanethiolate (315 mg) and the mixture was stirred at 50°C for an hour under nitrogen. The mixture was cooled to 5°C and the precipitates were collected by filtration, washed with methanol and diisopropyl ether and dried in vacuo to give 1-cycloheptyl-l- [4- (4- fluorophenoxy)benzyl] -3- (2-methylεulfonyl-4-methylthio-6- methylpyridin-3-yl) urea (1.35 g) as a crystal. IR (KBr) : 3377, 3072, 2926, 2858, 1657, 1572, 1498, 1473 cm "1 NMR (CDC1 3 , δ) : 1.5-2.1 (12H, m) , 2.44 (3H, s), 2.54 (3H, ε), 3.23 (3H, s), 4.1-4.3 (IH, ) , 4.55 (2H, ε), 6.98 (IH, ε), 6.9-7.1 (6H, m) , 7.35 (IH, d, J=8.6Hz) Example 26 To a stirred εolution of 1-benzyl-l- [3- (pyrazol-3- yl)benzyl]-3- [2, 4-bis (methylthio) -6-methylpyridin-3-yl] urea (1 g) in dichloromethane (8 ml) was added a solution of m- chloroperbenzoic acid (1.32 g) in dichloromethane (26 ml) at 0-5°C. After stirring for one hour at room temperature, the mixture was washed with saturated sodium bicarbonate aqueouε solution, water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel to give 1-benzyl-l- [3- (pyrazol-3-yl) benzyl] -3- [2, 4-bis (methylsulfonyl) -6- methylpyridin-3-yl]urea (183.0 mg) and 1-benzyl-l- [3- (pyrazol-3-yl)benzyl] -3- [2, 4-bis (methylεulfinyl) -6- methylpyridin-3-yl]urea (235.6 mg) . 1-Benzyl-1- [3- (pyrazol-3-yl)benzyl] -3- [2, 4- bis (methylsulfonyl) -6-methylpyridin-3-yl] urea IR (KBr) : 3344, 2924, 1655, 1493, 1313, 1238, 1136 cm "1 NMR (DMSO-dg, δ) : 2.70 (3H, s), 3.32 (6H, s), 4.52 (4H, br ε), 6.75 (IH, br ε), 7.20-7.85 (10H, ) , 8.13 (IH, s), 8.66 (IH, ε), 12.87, 13.22 (total IH, each br) APCI-MASS (m/z) : 554 (M+H + ) l-Benzyl-l-[3- (pyrazol-3-yl)benzyl] -3- [2,4- biε (methylsulfinyl) -6-methylρyridin-3-yl] urea IR (KBr) : 3217, 2922, 1651, 1495, 1236, 1038, 960 cm "1 NMR (DMSO-dg, δ) : 2.60-2.80 (9H, m) , 4.42-4X5 (4H, m) , 6.71 (IH, br s), 7.15-7.85 (UK, m) , 8.84, 8.96 (total IH, each s) , 12.93, 13.35 (total IK, each br) APCI-MASS (m/z) : 522 (M+H + ) Example 27 To a solution of N-cycloheptyl-4- (4- fluorophenoxy)benzylamine (1.57 g) in toluene (40 mi) were added 2, 4-dichloro-6-methyl-3-phenoxycarbonylaminopyridine (1.49 g) and triethylamine (1.52 g) , and the mixture was stirred at 100°C for 3.5 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- cycloheptyl-1- [4- (4-fluorophenoxy)benzyl]-3- (2, 4-dichloro- 6-methylpyridin-3-yl) urea (916 mg) . IR (KBr) : 3365, 3275, 3062, 2927, 2858, 1653, 1581, 1543, 1497 cm "1 NMR (CDC1 3 , δ) : 1.5-2.1 (12H, m) , 2.47 (3H, ε) , 4.2- 4.4 (IH, ) , 4.53 (2H, s) , 5.89 (IH, ε), 6.9-7.1 (6H, m) , 7.14 (IH, s), 7.36 (2H, d, J=8.7Hz) APCI-MASS (m/z) : 520, 518, 517 (M+H + ) Example 28 The following compounds were obtained according to a similar manner to that of Example 7, 8, 9, 10, 13, 14, 15, 16, 17 or 27. (1) l-Cycloheptyl-l- [4- (4-fluorophenoxy) benzyl] -3- [ (2- methoxy-4-methylthio-6-methyl)pyridin-3-yl] urea IR (KBr) : 3371, 3064, 2926, 2856, 1666, 1585, 1498 cm "1 NMR (CDCI3, δ) : 1.5-2.1 (12H, m) , 2.38 (6K, s) , 3.79 (3H, s), 4.2-4.4 (IH, m) , 4.52 (2K, ε), 5.66 (IH, br s), 6.53 (IH, s), 6.9-7.1 (6H, m) , 7.35 (IH, d, J=8.7Hz) APCI-MASS (m/z) : 524 (M+H + ) (2) 1-Benzyl-l- [4- (4-fluorophenoxy) benzyl] -3- (2-chloro-4- methylthio-6-methylpyridin-3-yl) urea IR (KBr) : 3294, 3061, 3030, 2924, 1651, 1576, 1497 cm "1 - 204 - NMR (CDCI3, δ) : 2.42 (3H, s) , 2.47 (3H, s), 4.61 (2H, s), 4.63 (2H, s), 5.96 (IH, s) , 6.82 (IH, s), 6.9-7.1 (6H, m) , 7.25-7.45 (7H, m) (3) l-Benzyl-l-[3- ( l-methylpyrazol-4-yl ) benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea mp : 137-138°C IR (KBr) : 3255, 2922, 1651, 1562, 1493, 1228, 982 cm "1 NMR (DMSO-dg, δ) : 2.42 (6H, s) , 2.47 (3H, s), 3.87 (3H, s) , 4.66 (2H, br s), 4.48 (2H, br ε), 6.90 (IH, s), 7.13 (IH, d, J=7.4Hz), 7.20-7.56 (8H, m) , 7.81 (IH, s), 8.06 (IH, s), 8.29 (IH, s) APCI-MASS (m/z) : 504 (M+H + ) (4) l-Cycloheptyl-l- [3- (l-methylpyrazol-4-yl) benzyl] -3- [2, 4-bis (methylthio) -6-methylpyridm-3-yl] urea mp : 197-198°C IR (KBr) : 3290, 2924, 2854, 1653, 1485, 1227 cm "1 NMR (DMSO-dg, δ) : 1.25-1.90 (12H, m) , 2.40 (6H, s), 2.45 (3H, ε), 3.87 (3H, s), 3.98-4.17 (IH, m) , 4.48 (2H, br s), 6.87 (IH, s), 7.15 (IH, d, J=7.5Hz), 7.27 (IH, dd, J=7.5, 7.5Hz), 7.38 (IH, d, J=7.5Hz), 7.52 (IH, s), 7.80 (IH, ε), 7.90 (IH, br s) , 8.04 (IH, s) APCI-MASS (m/z) : 510 (M-rH + ) (5) 1- (2-Methoxybenzyl) -1- [3- (pyrazol-3-yl) benzyl] -3- [2, 4- biε (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3220, 2922, 1649, 1562, 1491, 1240 cm "1 NMR (DMSO-dg, δ) : 2.41 (6H, s) , 2.46 (3H, ε) , 3.73 (3H, ε) , 4.44 (2H, br s), 4.53 (2H, br s) , 6.67 (IH, br s), 6.88 (IH, s), 6.90-7.05 (2H, m 7.15-7.90 (7H, m) , 8.19 (IH, br s), 12.89, 13.30 (total IH, each br) - 205 - APCI-MASS (m/z) : 520 (M+H + ) (6) l-(3-Methoxyben∑yl)-l-[3- (pyrazol-3-yl)benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl]urea mp : 165-166°C IR (KBr) : 3400, 3248, 3099, 2926, 1664, 1483, 1225, 1049 cm "1 NMR (DMSO-dg, δ) : 2.41 (6H, s), 2.46 (3H, ε) , 3.75 (3H, s), 4.46 (2H, br s), 4.50 (2H, br s), 6.58- 6.72 (IH, m) , 6.74-6.95 (4H, m) , 7.15-7.85 (6H, m) , 8.28 (IH, s) , 12.87, 13.29 (total IK, each br) APCI-MASS (m/z) : 520 (M+H + ) (7) l-Benzyl-I-[3- (pyrazol-3-yl)benzyl] -3- [2-chloro-4- methylthio-6-methylpyridin-3-yl]urea IR (KBr) : 3230, 2922, 1647, 1576, 1497, 1338, 1279, 1232 cm "1 NMR (DMSO-dg, δ) : 2.45 (6K, ε), 4.51 (4H, br s), 6.57-6.70 (IH, m) , 7.16 (IH, s), 7.17-7.85 (10H, m) , 8.52 (IK, ε), 12.89, 13.31 (total IK, each br) APCI-MASS (m/z) : 478, 480 (M+H + ) (8) 1- (4-Methoxybenzyl) -1- [4- (4-fluorophenoxy)benzyl]-3- [2, 4-bis (methylthio) -6-methylpyridm-3-yl] urea mp : 130-131°C IR (KBr) : 3404, 2995, 2924, 2833, 1674, 1610, 1562, 1493, 1250, 1211 cm "1 NMR (CDC1 3 , δ) : 2.39 (3K, s), 2.49 (3H, s), 2.51 (3H, ε), 3.81 (3H, ε), 4.56 (2H, ε), 4.58 (2K, s), 5.72 (IH, s), 6.64 (IH, s), 6.85-7.12 (8H, m) , 7.20-7.38 (4H, m) APCI-MASS (m/z) 564 (M+H + ; (9) 1-Benzyl-I- [4- (4-fluorophenoxy) benzyl] -3- (2, 4- dichloro-6-methylpyridin-3-yl) urea IR (KBr) : 3302, 3066, 3032, 2924, 1639, 1581, 154 1497 cm "1 NMR (CDC1 3 , δ) : 2.48 (3H, s), 4.63 (2H, ε) , 4.64 (2H, s), 6.05 (IH, br ε), 6.9-7.4 (I4H, ) , APCI-MASS (m/z) : 514, 512, 510 (M+H~; (10) 1- (3-Phenylpropyl) -1- [4- (4-fluorophenoxy) benzyl] -3- [2, 4-bis (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3290, 2922, 1649, 1562, 1497, 1211, 1093 cm "1 NMR (CDCI3, δ) : 1.92-2.13 (2H, m) , 2.38 (3K, s), 2.48 (3H, s), 2.49 (3H, s) , 2.68 (2H, t, J=7.7Hz), 3.39 (2H, t, J=7.6Hz), 4.57 (2H, s), 5.57 (IH, s), 6.63 (IH, s), 6.87-7.10 (6H, m) , 7.10-7.37 (7H, m) APCI-MASS (m/z) : 562 (MXH + ) (11) 1- (2-Phenylethyl)-l-[3- (pyrazol-3-yl) benzyl] -2- [2, - biε (methylthio) -6-methylpyridin-3-yl] urea IR (KBr) : 3209 (br), 2922, 1647, 1562, 1491, 1338, 1238 cm "1 NMR (DMSO-dg, δ) : 2.42 (6H, ε), 2.47 (3K, ε; , 2.80 2.98 (2H, m) , 3.35-3.54 (2K, m) , 4.44 (2H, ε), 6.65 (IH, br ε) , 6.90 (IH, s) , 7.10-7.45 (7K, m 7.45-7.83 (3H, m) , 8.13 (IH, s) , 12.87, 13.30 (total IH, each br) APCI-MASS (m/z; 504 (M+H" (12) 1- [ (S) -1-Phenylethyl] -1- [4- (4-fluorophenoxy) benzyl] - [2, 4-bis (methylthio) -ό-methylpyridin-3-yi] urea IR (KBr) : 3373, 3310, 297S, 2924, 1660, 1562, 1497 1246, 1211 cm "1 NMR (CDCI3, δ) : 1.63 (3H, d, J=7.1Hz), 2.37 (3K, s 2.46 ;3H, s), 2.4 7 (3 , s) / Δ _ 2 1 (IH, c, J=l7.2Hz), 4.50 (IH, d, J=17.2Hz), 5.53 (IH, si, 5.75-5.92 (IK, m, , 6.50 (IK, s , 6.83- 7 .10 '£H, m) , 7 .22-7.5C (7K, ) APCI-MASS (m/z) : 546 ( -H " [α]^ 0 : -61.0° (C =1.02, CHCi 3 ) (13) I- [ >,R) -1-Phenylethyl] -1- [4- (4-fluorophenoxy) benzyl] -3- [ 2, -bis (methylthio) -6-methylpyri in-3-ylj urea IR (KBr) : 3369, 3309, 2978, 2924, 1659, 1562, 1497, 1246, 1211 cm "1 NMR (CDC1 3 , δ) : 1.63 (3K, C, J=7.1HzX 2.3 " " ;3K, s>, 2.46 (3H, si, 2.47 (3H, s), 4.27 (IH, d, J=17.2Hz), 4.50 (IH, d, J=17.2Hz), 5.52 (IK, s), 5.75-5.92 (IH, ) , 6.60 (IH, s] , 6.88-7.10 (6H, m) , 7.22-7.50 (7E, m) APCI-MASS (m/z) : 548 (K+H ~ ) ]α]§ 9 : -r62.2° .'C =1.02, CHCI3) (14) l-Cycloheptyl-l- [ 4 - (4-fluorophenoxy)benzyl] -3- 4- chioro-2-metnylthic-6-methyIpyrιdir.-3-yl) urea IR (KBr) : 3371, 3275, 3062, 2926, 2856, 1653, 1560, 1498 cm ~ - NMR (CDCI3, δ) : 1.4-2.1 (I2H, ) , 2.44 (3K, s), 2.47 (3H, ε) , 4.25-4.45 (IH, r.) , 5.61 (2K, s , 6.89 (IH, s) , 6.9-7.1 (6H, m) , 7.37 (2H, d, J=S.6Hzl APCI-MASS (m/z) : 530, 528 (M+H " ) (15) l-3e zyl-i- [ 4- (4-fluorophenoxy) benzyl] -3- X-chioro-2- me t hylthio-6-methylpyridin-3-yl) rea IR (KBr) : 3275, 3062, 3030, 2924, 1645, 1560, 1497 cm "1 NMR (CDCI3, δ) : 2.46 (3H, s), 2.49 (3H, s), 4.61 (2H, s), 4.63 (2K, s) , 5.80 (IK, br s), 6.9-7.1 (7K, m) , 7.25-7.4 (7H, m) APCI-MASS (m/z) : 524, 522 (M+H + ) (16) l-Cycloheptyl-l- [4- (4-bromophenoxy) benzyl] -3- [2- chloro-4-methylthio-6-methylpyridin-3-yl] urea mp : 105-107°C IR (KBr) : 3379, 2926, 2854, 1668, 1579, 1483, 1238 cm "1 NMR (CDC1 3 , δ) : 1.38-2.08 (12H, m) , 2.41 (3H, s) , 2.48 (3H, s), 4.20-4.40 (IH, ) , 4.54 (2H, s), 5.76 (IH, s), 6.82 (IH, s), 6.82-6.93 (2H, m) , 6.95-7.08 (2H, m) , 7.32-7.50 (4H, m) APCI-MASS (m/z) : 588, 590, 592 (M+K + ) (17) l-3enzyl-l- [4- (4-bromophenoxy) benzyl] -3- [2-chloro-4- methylthio-ό-methylpyridin-3-yl]urea IR (KBr) : 3280, 3030, 2920, 1651, 1578, 1504, 1435, 1236, 804 cm "1 NMR (CDCI3, δ) : 2.43 (3K, s) , 2.49 (3H, s), 4.63 (2H, s), 4.64 (2H, s), 5.93 (IH, ε), 6.84 (IH, s), 6.84-6.94 (2H, m) , 6.94-7.07 (2H, m) , 7.22- 7.50 (9K, m) APCI-MASS (m/z) : 582, 584, 566 (M+K + ) (18) l-Cycloheptyl-l- [3- (pyrazol-3-yl) benzyl] -3- [2-chloro- 4-methylthio-6-methylpyridin-3-yl] urea mp : 165-166°C IR (KBr) : 3205, 2926, 2856, 1624, 1572, 1491, 804 cm "1 NMR (DMSO-dg, δ) : 1.30-1.90 (12H, m) , 2.43 (6K, s), 4.00-4.18 (IH, ) , 4.53 (2H, br ε), 6.55-6.67 (IH, m) , 7.12 (IH, ε), 7.20-7.83 (5H, m) , 8.11 (IH, br s), 12.85, 13.28 (total IH, each br s) APCI-MASS (m/z) : 484, 486 (M+H + ) Examp e 29 The following compound can be obtained by treating 1- benzyl-1- [3- (pyrazol-3-yl) benzyl] -3- [2, 4-biε (methylthio) -6- methylpyridin-3-yl]urea with hydrochloric acid or hydrochloride in a conventional manner. 1-Benzyl-1- [3- (pyrazol-3-yl) benzyl] -3- [2, 4- biε (methylthio) -6-methylpyridin-3-yl]urea-hydrochloride Example 30 The following compound can be obtained by treating 1- benzyl-1- [3- (pyrazol-3-yl)benzylj -3- [2, 4-bis (methylthio) -6- methylpyridin-3-yl]urea with sulfuric acid in a conventional manner. 1-Benzyl-l- [3- (pyrazol-3-yl) benzyl] -3- [2, 4- bis (methylthio) -6-methylpyridin-3-yl] urea-sulfate Example 31 The following compound was obtained according to a similar manner to that of Example 19. 1-Benzyl-l- [4- (4-fluorophenoxy)benzyl] -3- [2, 4- biε (methylsulfonyl) -6-methylpyridin-3-yl] urea IR (KBr) : 3348, 3066, 3030, 2927, 1734, 1668, 1610, 1583, 1497 cm "1 NMR (CDCI3, δ) : 2.67 (3H, s) , 3.20 (3K, ε), 3.32 (3H, s), 4.6-4.7 (4H, m) , 6.9-7.1 (6H, m) , 7.3- 7.5 (2H, m) , 7.62 (IH, br s), 7.88 (IH, s) APCI-MASS (m/z) : 598 (M+H + ) Example 32 The following compound was obtained according to a similar manner to that of Example 29. l-Cycloheptyl-l- [4- (4-fluorophenoxy)benzyl] -3- (2, 4, 6- trimethylpyridin-3-yl) urea hydrochloride mp: 176-178°C NMR (DMSO-dg, δ) : 1.35-1.9 (12H, m) , 2.32 (3H, s), 2.52(3H, s), 2.65 (3H, s), 4.1-4.3 (IH, m; , 4.53 (2H, s), 6.95-7.4 (8H, m) , 7.61 (IH, s), 8.30(1H, br s)

Claims: C L I S A compound of the formula wnere R 1 is a group of the formula (in which R * is aryl which may have suitable substituent (s) , or heterocyclic group which may have suitable substituent (s) , and C I! Y is bond, lower alkylene, -S-, -0-, -C-, =CH-, -CONH-, -N-CO-, (in which R 7 iε lower R7 alkyl), -NHS0 2 -, -S0 2 NH-, -S0 2 NHCO- or -CONHSO* ? -) ; or thiazolyi, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent (s) ; R^ is lower alkyl, lower alkoxy(lower) alkyl, cycloalkyl, ar (lower) alkyl which may have suitable substituent(s) , heterocyclic group or heterocyclic (lower) alkyl, R 3 is aryl which may have suitable substituent(ε) or heterocyclic group which may have suitable substituent(s) , and n is 0 or 1, and a pharmaceutically acceptable salt thereof A compound of claim 1, wherein R 1 is a group of the formula : (in which R is phenyl which may have 1 to 3 substituent (s) selected from the group consisting of halogen, lower alkyl, di (lower)alkylamino, protected amino, cyano, heterocyclic group which may have mono(or di or tri)- ar(lower)alkyl, hydroxy, protected hydroxy and mono (or di or tri)halo(lower)alkyl; or thienyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrrolyl, tetrazolyl, oxazolyl, thiazolyi, oxadiazolyl, piperazinyl, thiazolidinyl or methylenedioxyphenyl, each of which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, mono(or di or tri) ar(lower)alkyl and oxo; O Ii Y is bond, lower alkylene, -S-, -0-, -C-, =CH-, -CONH-, -N-CO- (in which R 7 is lower alkvl), R' -NHS0 2 -, -S0 9 NH-, -S0 2 NHC0- or -CONHSO ? -); or thiazolyi, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have 1 to 5 substituent (s) selected from the group consisting of lower alkyl, hydroxy, protected hydroxy, phenyl, halophenyl, phenylthio and pyrrolyl; R ~~ is lower alkyl; lower alkox (lower) alkyl; cyclo (C 3 -C 7 ) alkyl; phenyl (lower) alkyl which may have 1 to 3 substituent (s) selected from the group consisting of halogen, lower alkoxy and di (lower alkyDamino; tetrahydropyranyi; or furyl (lower)alkyl; R 3 is. phenyl which may have 1 to 3 substituent (s) selected from the group consisting of lower alkyl and halogen; pyridyl or pyrimidinyl, each of which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, lower alkylthio, halogen, lower alkoxy, lower alkylsulfinyl and lower alkylsulfonyl. A compound of claim 2, wherein R 1 is a group of the formula : (in which R 4 is phenyl which may have 1 to 3 substituent ( s ] selected from the group consiεting of halogen, lower alkyl, di (lower) alkylamino, acylamino, cyano, tetrazolyl which may have mono (or di or tri)phenyl (lower) alkyl, hydroxy, lower alkoxy(lower) alkoxy and mono (or di or tri)halo (lower) alkyl; or thienyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrrolyl, tetrazo-lyl, oxazolyl, thiazolyi, oxadiazolyl, piperazinyl, thiazolidinyl or methylenedioxyphenyl, each of which may have one or two substituent (s) selected from the group consisting of lower alkyl, phenyl (lower) alkyl, triphenyl (lower) - alkyl and oxo; 0 II Y is bond, lower alkylene, -S-, -0-, -C-, =CH-, -C0NH-, -N-CO- (in which R 7 is lower alkyl), R 7 -NHS0 2 -, -S0 2 NH-, -S0 2 NHCO- or -CONHS0 2 -) ; or thiazolyi, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have 1 to 5 substituent (s) selected from the group consisting of lower alkyl, hydroxy, acyloxy, phenyl, halophenyl, phenylthio and pyrrolyl; R- ~ is lower alkyl; lower alkoxy(lower) alkyl; cyclo (C3-C7) alkyl; phenyl (lower) alkyl which may have one or two substituent (s) selected from the group consisting of halogen, lower alkoxy and di (lower alkyl) amino; tetrahydropyranyl; or furyl (lower) alkyl; and R 3 is phenyl which may have two or three substituents selected from the group consisting of lower alkyl and halogen; pyridyl or pyrimidinyl, each of which may have two or three substituents selected from the group consisting of lower alkyl, lower alkylthio, halogen, lower alkoxy, lower alkylsulfinyl and lower alkylsulfonyl . 4. A. compound of claim 3, wherein R 1 is a group of the formula : (in which R 4 is phenyl; halopheny; lower alkylphenyl; di (lower) alkylaminophenyl; lower alkylsulfonylaminophenyl; cyanophenyl; tetrazolylphenyl; (triphenyl (lower) - alkyltetrazolyl)phenyl; trihalo (lower) - alkylphenyl; phenyl having two lower alkyl and hydroxy; phenyl having two lower alkyl and lower alkoxy(lower) alkoxy; thienyl; pyrazolyl which may have lower alkyl or triphenyl (lower) alkyl; imidazolyl; triazolyl which may have one or two substituent (s) selected from the group consisting of lower alkyl and phenyl (lower) alkyl; pyridyl; pyrrolyl; tetrazolyl which may have lower alkyl or triphenyl (lower) alkyl; oxazolyl; lower alkylthiazolyl; lower alkyioxa- diazolyl; lower alkylpiperazinyi; dioxothiazolidinyl; or methylenedioxyphenyl]; and O II Y is bond, lower alkylene, -S-, -0-, -C-, =CH-, -CONH-, -N-CO- (in which R 7 is lower alkyl), R 7 -NHS0 2 -, -S0 2 NH-, -S0 2 NHCO- or -CONHS0 2 ~) ; halophenylthiazolyl; phenylimidazolyl; phenylpyrazolyl; phenylpyridyl; phenylthiopyridyl; pyrrolylpyridyl; phenylthienyl; phenylfuryl; phenylisoxazolyl; or chromanyl having 4 lower alkyl and hydroxy; R 2 is lower alkyl, lower alkoxy(lower) alkyl, cyclo ( ^- η ) lkyl, phenyl (lower) alkyl, halophenyl (lower)alkyl, lower alkoxyphenyl (lower)alkyl, di.dower alkyl)a inophenyl (lower)alkyl, tetrahydropyranyl or furyl (lower) alkyl, and R 3 is pyridyl having two lower alkylthio and lower alkyl; pyridyl having halogen, lower alkyl and lower alkylthio; tri (lower alkyl)pyridyl; pyridyl having two lower alkoxy and lower alkyl; pyridyl having lower alkoxy, lower alkylthio and lower alkyl; pyridyl having two lower alkyl¬ sulfinyl and lower alkyl; pyridyl having two lower alkylsulfonyl and lower alkyl; pyridyl having lower alkylthio, lower alkoxy and lower alkyl; pyridyl having lower alkylsulfinyl, lower alkylsulfonyl and lower alkyl; pyridyl having lower alkylthio, lower alkylsulfonyl and lower alkyl; pyridyl having two halogen and lower alkyl; di (lower) lkoxypyrimidinyl; or pyrimidinyl having two lower alkylthio and lower alkyl. A compound of claim 4, wherein R 1 is a group of the formula : ;in which R- is phenyl or halophenyl, and Y is -0-) , - 216 - R 2 is cyclo{C3-C7) alkyl or phenyl (lower) alkyl, R 3 is phenyl having two lower alkylthio and lower alkyl; tri (lower alkyl)pyridyl; pyridyl having two halogen and lower alkyl; pyridyl having 5 halogen, lower alkyl and lower alkylthio; pyridyl having lower alkylthio, lower alkoxy and lower alkyl; pyridyl having lower alkylthio, lower alkylsulfonyl and lower alkyl; pyridyl having two lower alkylsulfonyl and lower alkyl; or 10 pyrimidinyl having two lower alkylthio and lower alkyl; and n is 1. 6. A compound of claim 5, wherein 15 R is a group of the formula : 20 (in which R 4 is halophenyl, and Y is -0-) , R 2 is cyclo (C3-C7) alkyl, and R 3 is tri (lower alkyl)pyridyl; or ? , pyridyl having two lower alkylsulfonyl and lower alkyl. 7. A compound of claim 4, wherein P. 1 is a group of the formula : 30 (in which R 4 is pyrazolyl and 35 Y is bond) , - 217 - R 2 is phenyl (lower)alkyl, lower alkoxyphenyl ( lower ) alkyl, halophenyl ( lower ) alkyl, di ( lower ) alkylaminophenyl (lower ) alkyl or cyclo (C3-C7) lkyl, R J i s p yridyl having two lower alkylthio and lower alkyl ; pyridyl having halogen, lower alkyl and lower alkylthio ; or p yrimidinyl having two lower alkylthio and lower alkyl ; and n is 1. 8. A compound of claim 7, wherein ι R- i s a group of the formula : '-O ( in which R 4 is pyrazolyl, and Y is bond) , R 2 is phenyl (lower) alkyl, and R 3 is pyridyl having two lower alkylthio and lower alkyl. - A p rocess for preparing a compound of t he formul, wherein R is a group of the formula : R 4 ( in which 4 substituent (s) , or heterocyclic group which mav have suitable substituent ( s ) , and !ι Y is bond, lower alkylene, -S-, -0-, -C-, =CH-, -C0NH-, -N-CO-, (in which R 7 is lower R7 alkyl), -NHS0 2 -, -S0 2 NH-, -S0 2 NHCO- or -C0NHS0 2 X; or thiazolyi, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent (s) ; R ~~ is lower alkyl, lower alkoxy(lower) alkyl, cycloalkyl, ar(lower) alkyl which may have suitable substituent (ε) , heterocyclic group or heterocyclic (lower) alkyl, " is aryl which may have suitable substituent (s) or heterocyclic group which may have suitable substituent (s) , and n is 0 or I, or a salt thereof, which comprises (1) reacting a compound of the formula : R 1 - (CH 2 ) n -NH -> R-- wherein R 1 , R 2 and n are each as defined .above, or a salt thereof with a compound of the formula 0=C=N-R- wherein R 3 is as defined above, or a salt thereof to give a compound of the formula R l 1- (CH 2 ) n -N-CI'-NH-R J 3 wherein R , R 2 , R 3 and n are each as defined above, or a salt thereof, or ) subjecting a compound of the formula - wherein R , R^ and n are each as defined above, or a salt thereof and a compound of the formula : H 2 N-R wherein R J is as defined above, or a salt thereof to formation of ureido group to give a compound of the formula : - 220 r- . 5 1 wherein R , R ~~ , R J and n are each as defined above, or a sal t thereof , 10 . or (3) subjecting a compound of the formula : 0 1 wherein R , R^ and n are each as defined above, and R 3 is pyridyl having two lower alkylthio and lower alkyl, or a salt thereof to oxidation reaction to give a 5 compound of the formula : 0 R 1 (CH 2 } n -N-CI'-NH-Rg3 < ? 0 R^ wherein R , R 2 and n are each as defined above, and R -x is pyridyl having two lower alkylsulfonyl - 221 - and lower alkyl; pyridyl having two lower alkylsulfinyl and lower alkyl; or pyridyl having lower alkylsulfonyl, lower alkylsulfinyl and lower alkyl; or a salt thereof. 10. A pharmaceutical composition comprising a compound of claim 1, as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient. 11. A compound of claim 1 for use as a medicament. 12. A method of therapeutic treatment and/or prevention of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby which comprises administering an effective amount of a compound of claim 1 to human beings or animals. 13. Use of a compound of claim 1 for the manufacture of a medicament for treating and/or preventing hypercholesterolemia, hyperlipidemia, atherosclerosis of diseases caused thereby in human beings or animals.

Inventors: CHIBA TOSHIYUKI, TAKASUGI HISASHI, TANAKA AKIRA, TERASAWA TAKESHI, CHIBA, TOSHIYUKI, TAKASUGI, HISASHI, TANAKA, AKIRA, TERASAWA, TAKESHI
Applicants: CHIBA TOSHIYUKI, FUJISAWA PHARMACEUTICAL CO, TAKASUGI HISASHI, TANAKA AKIRA, TERASAWA TAKESHI, CHIBA, TOSHIYUKI, FUJISAWA PHARMACEUTICAL CO., LTD., TAKASUGI, HISASHI, TANAKA, AKIRA, TERASAWA, TAKESHI
Application year: 1995
Main classification: C07C275
IPC codes: A61K31, A61P3, A61P9, C07C275, C07C311, C07C323, C07D207, C07D211, C07D213, C07D231, C07D233, C07D239, C07D249, C07D257, C07D261, C07D263, C07D271, C07D277, C07D295, C07D307, C07D311, C07D317, C07D333, C07D401, C07D403, C07D405, C07D417, C07D521